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Cover illustration:
Re-refined structure model Paracoccus denitrificans cytochrome c550, the oldest 
structure model with experimental data in the Protein Data Bank [155c; Timkovich & 
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coloured by atomic displacement - warm er colours show greater displacement.
4
Contents
Chapter 1
Introduction
Chapter 2
Validation o f  pro tein  stru ctu re  m odels  
Chapter 3
PDB im provem en t s ta r ts  w ith  d a ta  deposition  
Chapter 4
PDB_REDO: au to m a ted  re-refinem en t o f  X -ray structure m odels 
in the PDB
Chapter 4.A
N ew  protein  stru ctu res replace the old 
Chapter 5
R e-refinem ent fro m  deposited  X -ray da ta  can deliver im proved  
m odels fo r  m o st PDB entries
Chapter 6
H om ology m odelling and spectroscopy, a never-ending love s to ry
Samenvatting 
Dankwoord 
Curriculum Vitae 
List of publications
Scope and summary of this thesis
9
27
67
71
95
99
121
147
150
152
153
7
5
6
Scope and summary of this thesis
Nearly all processes in living organisms are governed by proteins. They are 
the tiny cogs that make the machine of life work. With this in mind, research 
questions in molecular biology, genetics, and medical science can often be 
reduced to a series of questions about the chemistry of a particular protein. A 
timely question would for example be: “why does Oseltamivir (Tamiflu) not 
work against a novel influenza mutant and how should the drug be adapted 
to become effective again?”. Answering such questions requires an accurate 
description of the structure of the protein under investigation. Protein 
structure is described at different levels, from the sequence of amino acids 
(the protein building blocks) to a description in which each individual 
protein atom has three-dimensional (3D) coordinates. These different levels 
of protein structure and the experimental means of determining them are 
described in the introductory Chapter 1.
The 3D structures of proteins, typically determined using X-ray 
crystallography, are usually much more informative than the sequence. 
Unfortunately, they are also much more difficult to obtain. As a result, we 
know more than 100 times more sequences than 3D structures. Despite of 
the best efforts of the crystallographic community, this lack of 3D structures 
will not be solved quickly. So to advance our knowledge of proteins we have 
to make do with the 3D structures that are available to the scientific 
community via the Protein Data Bank (PDB). Bioinformatics, the use of 
computers to solve biological problems, can help to get the most out of our 
current collection of 3D protein structures. In this thesis three approaches to 
this end are explored.
Chapter 2 extensively covers the first approach to get the best results 
with our current 3D structure knowledge: structure validation. Protein 
structures are determined experimentally and every experiment leaves room 
for random noise and experimental (human) error. Structure validation uses 
scientific knowledge of molecules, chemical interactions, and statistical 
knowledge of proteins to detect good, bad, and ugly parts of protein 
structures. This helps us to select the optimal protein structure to answer 
our research questions. It also helps us to estimate the reliability of the 
scientific conclusions drawn from (certain parts of) protein structures.
Structure validation gives us a way to measure the quality of a 
protein structure. An obvious next step is to try to improve this quality. This 
second bioinformatics approach to getting the most out of protein structures 
is based on this reasoning: A 3D protein structure is an (indirect) model of an 
X-ray crystallography experiment and the methods to make such models
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improve continuously. It is therefore likely that we can make better 3D 
protein structures now than, say, ten years ago. Completely repeating the X- 
ray crystallography experiments for all current protein structures (the result 
of tens of years of hard work from a huge scientific community) is of course 
impossible. Fortunately, the crystallographic community has had the 
foresight to store the original experimental data for majority of 3D protein 
structures. As a result we can start "Combining old data with new methods" to 
get better protein structures. Chapter 3 discusses a proof of concept of this 
approach. In this PDB_REDO experiment we re-refined (i.e. repeated the last 
steps of the X-ray experiment; see Chapter 1) a limited test set of nearly 1200 
protein structures and their original experimental data using a completely 
automated computational method.
Chapter 4 covers the re-refinement of a much larger set: all protein 
structures for which the complete experimental data (including the so-called 
R-free set) were available. Because of the scale of this experiment (nearly 
17000 structures) a new computing platform 'the GRID' was used. By 
applying the validation methods discussed in Chapter 2 we showed that 
existing protein structures can be improved fully automatically using the 
original experimental X-ray data. The appendix, Chapter 4.A, shows some 
reactions of 3d protein structure users on the re-refinement results and the 
overall PDB_REDO project.
The re-refinement is a means of model improvement via parameter 
optimisation; in Chapter 5 we raised the bar and explored the possibility of 
extending the PDB_REDO method towards error fixing (i.e. adding another 
step of the X-ray experiment to the procedure). Five protein structures were 
optimised manually to see which of the occurring errors were candidates for 
automated error fixing.
With structure validation and structure improvement we have made 
a solid basis for the most constructive bioinformatics approach to dealing 
with a limited amount of protein structures: making new 3D protein 
structures via homology modelling. The final chapter discusses the 
importance of combining protein science in the computer and protein 
science in the lab. Here we show that homology modelling depends on high- 
quality protein structures as a starting point, which stresses the importance 
of the re-refinement studies in this thesis: "Combining old data with new 
methods fo r  b e tte r  stru ctu ra l bioinformatics."
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Chapter 1
Introduction
9
1.1. Understanding life through proteins
Philosophy, religion, and science can be seen as separate end very different 
endeavours of mind, hart and body, but they share a common goal: obtaining 
a better understanding of (the meaning of) life and, hopefully, finding 
enlightenment in this understanding. What better way is there to combine 
the aforementioned endeavours than to study science at an institute with a 
religious heritage to obtain the degree of doctor of philosophy?
Biology, literally the study of life, looks at life's many facets on several 
different levels. On one hand, we can look outward and go from the study a 
single organism to a population of organisms, to symbiosis with other 
species, or even to the study of several species and their lifeless 
surroundings. On the other hand, we can look inward, going from the 
organism to an organ, to a cell, to organelles, or to the tiny cogs that make the 
whole mechanism work: the proteins.
Proteins govern all the key processes in the body. They help to break 
down nutrients to provide energy and they help to make small molecules so 
these can do all the things they are supposed to do. They recognise signals 
from inside or outside the body (think of the light that hits your eyes or of 
recreational drugs in the brain) or they are the signals themselves (like the 
protein-hormone insulin). They protect us from harm via the immune system 
and help us to harm our prey (that is, if you use your protein-based nails to 
catch prey). Proteins are also transporters of small molecules inside the 
body: they can move water, salts, sugars, and oxygen to the right place at the 
right time. Proteins even govern the expression, i.e. the production, of (other) 
proteins trough an intricate mechanism of feedback loops that reaches to the 
very basis of the protein system. This brings us to the one thing not done by 
proteins; the information about which proteins can be made in an organism 
is not stored in a protein, but encoded in a different type of molecule: the 
DNA. This DNA holds all the necessary information about the proteins. That 
is also the only thing the DNA does, hold information. The DNA molecule 
itself is securely packed in protein and reading and duplication (and the 
prevention thereof) is done by proteins.
With all these important functions of proteins, it is no wonder that 
they are a major subject of biological study. Understanding proteins, will lead 
to understanding the mechanisms in the cell, which will lead to 
understanding of the workings of organs, etc. More importantly, 
understanding proteins will help us explain why something does not work. 
Diseases, afflictions, conditions even normal variation like different hair 
colours, can be traced to (a set of) proteins or the parts of the DNA that 
describe them. It is therefore not surprising that we want to know as much as
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we can about proteins. We can then try to apply our knowledge to 'solve' 
some of the problems connected to proteins. Drugs, both medicinal and 
recreational, are aimed at changing the way proteins work. The same can be 
said for genetic modification although this does not work on proteins 
directly, but rather on the DNA.
1.2. Protein structure
Understanding proteins and, more so, trying to manipulate them requires 
in-depth knowledge of the workings of said proteins. This knowledge can be 
gained from biological or biochemical experiments in which a protein is 
made to do something under controlled circumstances. A simple example 
would be adding an amount of amylase (a protein from saliva) to starch in 
solution. After a while we can measure that the starch is gone and instead we 
have a sugar known as maltose. We now conclude that amylase turns starch 
into maltose. In other words: amylase is the enzyme that converts starch into 
maltose. Unfortunately, by doing this experiment, we know w hat amylase 
does, but not how it does it. So if someone's amylase does not convert starch, 
we do not know what the underlying problem is.
An alternative approach to finding out more about a protein is 
inferring knowledge from a similar protein. But what constitutes 'similar'? 
What measure should we use?
The solution to the problems above is not treating a protein as black 
box, but rather looking at its structure. In this more chemical or molecular 
perspective we acknowledge that the protein is made up of smaller subunits, 
twenty different amino acid residues (short: residues), each with specific 
properties. In a protein, the residues have chemical bonds and non-bonded 
interactions with each other. The interactions of these residues with the 
outside world are instrumental in the protein function. For instance, not all 
residues in amylase interact directly with starch. Some help in the 
recognition of starch molecules whereas others perform the specific task of 
breaking the chemical bond between the maltose subunits of starch, but the 
majority provides structural integrity to the protein; these residues keep the 
other residues at the right place. Removing or changing amino acid residues 
in the protein can have serious detrimental effects, but not in equal amounts. 
The residues that do the actual bond breaking cannot be missed, but 
changing a residue that is used solely for keeping the other amino acids at 
the right spot may be changed without serious consequences. This holds not 
only for amylase, but for all proteins: one change, a so-called mutation, in the 
structure can cause an enormous problem (as happens in many genetic
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disorders), another does not seem to do anything. We must bear in mind that 
when it comes to genetic disorders we are always presented with a 'filtered 
view' of the severity of mutations. The most devastating genetic disorders 
are the ones that keep an embryo from developing properly. People with 
such disorders are never born which means that these genetic problems are 
typically not investigated. For (nearly) all other mutations we can tell which 
mutation is problematic and which is not by studying the structures of the 
involved proteins (e.g. Swinkels et al., 2008).
The term 'protein structure' may sound informative, but is actually 
used in different context by different people. In order to avoid confusion, four 
levels of proteins structure are defined (Figure 1.1). The primary structure of 
proteins describes the number and sort order of the amino acid residues in a 
protein. This is usually referred to as the sequence. Although the residues are 
chemically linked, the primary structure is normally not used in a molecular 
or chemical sense. Instead, it is used as a description of a protein in text form. 
For instance, the primary structure in Figure 1.1 is expressed as the sequence 
AEMLHDILQ. Sequences are used to find the 'similar' proteins described 
above, in order to transfer information about one protein to the other. This 
similarity and thus the ensuing information transfer is not limited to the 
primary structure, but can be extrapolated to higher structure levels in a 
process called homology modelling. Such an extrapolation may sound risky, 
but is warranted because the higher structure levels are encoded in the 
primary structure. After all, in the cell a protein is produced by linking amino 
acids together. From this primary structure, the protein forms increasingly 
higher levels of structure by folding and the formation of complexes. This 
folding process is driven by thermodynamics that we are slowly learning to 
understand. With enough computer power we can even simulate this folding 
process (admittedly, with limited success), in what is called ab initio folding, 
starting with only the primary structure. Both homology modelling and ab 
initio folding will be covered in more detail in Chapter 6.
The secondary structure of a protein describes the torsion angles 
between certain atoms, the backbone atoms, of the amino acid residues. The 
two main types, a-helix and ß-strand, are formed by atomic interactions in 
the protein called hydrogen bonds. For a-helices, these hydrogen bonds occur 
within the helix, whereas ß-strands form hydrogen bonds between each other 
forming so-called ß-sheets (Figure 1.1 shows a ß-sheet consisting of three 
arrows, the ß-strands). Like the primary structure, the secondary structure is 
frequently expressed in text-form with 'H' for a-helical residues, 'S' for ß- 
strands, and several other letters for other types of secondary structure such 
as turms, ß-bridges, 310-helices, etc.
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P r im a ry  S e c o n d a ry  T e r t ia ry  Q u a te r n a r y
Figure 1.1: The four levels of protein structure. The primary structure describes how amino 
acid residues are linked, the amino acid sequence. The secondary structure describes the 
backbone torsion angles in the amino acid residues. The tertiary structure describes the 
coordinates of all the atoms in the protein. The quaternary structure describes the position 
and orientation of all proteins in a complex.
The tertiary structure of a protein describes the position (or coordinates) of 
all the atoms in a protein molecule in three dimensions. When the terms 
'protein structure' or 'protein structure model' are used, they usually refer to 
this level of structure (which also holds for this work). A protein folds into its 
tertiary structure through the combined effect of several atomic interactions: 
hydrogen bonds, sulphur bridges (chemical bonds between cysteine 
residues), ionic/electro-static interactions (salt bridges), and hydrophobic 
(or water-exclusion) interactions. Tertiary structures are the most sought- 
after of all protein structures because they can be used to really understand 
what is going on in a protein. They are used in many aspects of protein 
science: to explain how an enzyme works, to explain the nature of a disease, 
to design drugs, etc. The tertiary structure of proteins is so important that a 
broad science journal like Nature featured these types of structures on its 
cover three times in 2008.
Finally, the quaternary structure of proteins describes complexes of 
several protein chains held together by hydrophobic, ionic, and hydrogen 
bond interactions. A typical example of a quaternary structure is found in the 
oxygen transport protein haemoglobin (which is also the example in Figure
1.1). It consists of four separate protein chains, two of the a-type and two of 
the ß-type, which are different in primary structure. Like the tertiary 
structures, quaternary structures are used to gather insight about how 
proteins perform their function.
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1.3. Experimental methods
Because protein structures are so informative, we want to be able to 
determine them. Unfortunately, single proteins cannot be seen with the 
naked eye and, barring a few exceptions, neither can they be seen through a 
microscope. We need more elaborate experimental techniques to determine 
the structure of a protein.
1.3.1. Determining the primary structure
Over the years, many different methods of determining the primary 
structure, the sequence, of a protein have been developed. There are two 
different approaches, one starts with an isolated protein and the other starts 
with DNA.
Say, we find an unknown protein on the body of a murder victim (see 
www.bioinformatics-at-school.eu) and we want to know more about it. We 
should probably start by determining the sequence. In the old days of protein 
study, this had to be done by the slow and very laborious Edman degradation 
(Edman, 1950), a method in which the first amino acid residue is removed 
from the protein chain and identified. This process is then repeated with the 
remaining protein chain over and over again. Nowadays, mass spectroscopy 
(e.g. Pappin et al., 1993) is a much more user friendly technique. Here the 
protein is cleaved into small, charged fragments that are then separated 
based on charge and mass. The fragments, consisting of several residues, 
have unique mass/charge ratios which are used for identifying them. 
Through clever sorting and pasting the fragments can be put together again 
to form the whole protein sequence.
Working from the DNA to identify protein sequences is much quicker, 
but it cannot be used to identify a specific protein. Instead (part of) the DNA 
sequence of an organism is determined and parts that describe proteins are 
than translated to protein sequences. This method works well because 
sequencing DNA can be done with the use of robots at an enormous pace. 
Entire genomes (i.e. all the DNA of an organism, including man) are now 
readily available and new ones are added to our collective scientific 
knowledge frequently. As a result, thousands of protein sequences are made 
available every day. But these primary structures of proteins are not all that 
informative unless we can transfer information from similar proteins or 
obtain a higher structure level.
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1.3.2. Determining the secondary structure
Normally, the secondary structure of a protein is either predicted from the 
primary structure or measured in the tertiary structure. This does not make 
secondary structure unimportant: there are for example some proteins that 
can change their secondary structure from, for instance, a-helix to ß-strand 
and cause havoc in the brains (and many other tissues) of sheep, cows, 
humans, and other species. They are called prions (Prusiner, 1998), cause 
diseases like scrapie, mad-cow disease, and Creutzfeldt-Jakob disease, and 
their discovery and study earned Stanley Prusiner the 1997 Nobel Prize in 
Physiology or Medicine.
1.3.3. Determining the tertiary structure
There are a number of methods to determine the tertiary structure of a 
protein, but two methods deliver the majority of known tertiary structures: 
Nuclear Magnetic Resonance (e.g. Kaptein et al., 1985; Williamson et al.,
1985), and X-ray crystallography (Kendrew et al., 1958). Of the two methods, 
X-ray crystallography is the oldest (over 50 years old) and most successful: 
six out of seven known structures are determined by this method. We 
therefore focus on this method.
1.3.3.1. Diffraction. When looking at a Compact Disc (CD) in the sun we 
can see the pretty rainbow reflections caused by the diffraction of light on 
the disc's surface. The white light that hits the CD is broken down to its 
multicoloured components because the tracks on the disc, which are spaced 
very regularly, diffract each wavelength (that is, each colour) in the white 
light in a slightly different direction.
When we shine light of a single colour (a single wavelength) on a CD, 
for instance with a laser pointer, and let the reflected light hit a wall, we can 
see another phenomenon: the single ingoing (laser) beam is split into several 
outgoing beams. Try it; you will see one bright spot on the wall at the place 
where you (probably) expect it and several less bright spots at other places, 
all on the same line. The spacing between the spots seems to be regular 
which can be explained by a phenomenon called interference. Without getting 
into too much detail, imagine this: a track on the CD diffracts the light in all 
directions, the track next to that does the same thing, the next track as well, 
and so on. This means that the light diffracted from each track crosses the 
light from the other tracks. As it turns out, in most cases the rays of light that
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cross each other cancel each other out (destructive interference). Only in 
very specific directions, the rays amplify each other (constructive 
interference). The final result is the extra spots on the wall.
When we repeat the same experiment with a DVD, we also get several 
spots on the wall, only at different positions. The tracks on the DVD cause 
similar diffraction, but because the tracks are spaced differently the 
destructive and constructive interference occur at different places. This is an 
important finding: we can tell something about the inner structure of the CD 
and DVD by looking at the way they diffract light. More specifically, we can 
tell something about the repetitive elements on the discs (the tracks) from 
the way they diffract light.
The organisation of the tracks on a CD can be described as a
1-dimensional array of repetitive elements. I.e. if we look from the centre of 
the CD toward the edge we see the same thing over and over again. A
2-dimensional array of repetitive elements, for instance a finely woven mesh 
of wires, also shows diffraction. However, this time the diffracted rays of light 
do not give spots on a single line, but on a 2-dimensional plane. Again the 
spots tell something about the structure of the repetitive elements in the 
array.
This concept can be extended to three dimensions. If we let a
3-dimensional array diffract light, we get spots in three dimensions that hold 
information about the individual elements of the array. So if the elements are 
proteins, we can tell something about them (their structure) if we get them 
organised into a regular 3-dimensional array and let that array diffract light. 
A protein crystal is exactly what we need (Figure 1.2A). It consists of blocks 
of proteins (unit cells) that are stacked neatly into a 3D array (Figure 1.2B).
The previous paragraph explains the 'crystallography' in the term X- 
ray crystallography. The 'X-ray' part can be explained another feature of 
diffraction: optimal diffraction occurs when the wavelength of the light (i.e. 
electromagnetic radiation) is of the same order of magnitude as the size of 
the repetitive elements of the array. Because we are looking at molecules, 
visible light is just 'too big'; the wavelength is too long. We need 'light' of the 
right wavelength and X-rays happen to be just right.
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Figure 1.2: The process of tertiary structure determination consists of an X-ray diffraction 
experiment on a protein crystal (A) which is a 3-dimensional grid of stacked proteins. The X- 
ray beam is diffracted in to smaller X-rays of varying intensity which are recorded as spots on 
an X-ray film or a digital sensor (C). The spots (reflections) are processed to a computer file 
with indices and intensities for each reflection (D). Together with phases from an outside 
source (either another diffraction experiment or a molecular replacement calculation) this 
data is converted to an electron density map (ED map; E) which is a 3-dimension 
representation of the content of the protein crystal. A tertiary structure model (F) is built 
inside this ED map. The initial model is usually suboptimal so the model has to be refined. The 
cycle of ED map generation, model building, and refinement is iterated until the model is 
complete and the tertiary structure can be considered 'solved'. See text for details.
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1.3.3.2. X-ray crystallography in the lab. Knowing we need protein 
crystals and X-rays, we can now look at the typical X-ray experiment (Figure
1.2). Our 3-dimensional array, our crystal, is illuminated with a narrow beam 
of X-rays coming from either a 'home source' (typically a sort of TV-tube that 
sends out X-rays instead of visible light) or a particle accelerator called a 
synchrotron. The crystal diffracts the X-ray beam which registers as spots on 
our recording device. This device used to be X-ray sensitive film, but 
nowadays is a CCD (charge-coupled device; a type of sensor that can be found 
in a digital camera).
In the previous section we have already established that a 
1-dimensional array gives a 1-dimensional set of spots and a 2-dimensional 
array a 2-dimensional set. Extrapolating this we expect a 3-dimensional set 
of spots caused by our diffracting crystals. Because we can only measure the 
spots in two dimensions (the X-ray film or CCD is flat), we cannot measure 
everything at once. The crystal has to be rotated step by step in order to have 
all spots (called reflections by crystallographers) appear on our recording 
device. We now leave the lab with a set of X-ray images with reflections, one 
for each orientation of the crystal. From this point onwards things are done 
in the computer.
1.3.3.3. X-ray crystallography in the computer. First of all, the 
reflections have to be correlated to the orientation of the crystal. Each 
reflection is given 'coordinates' in the form of the Miller indices h, k, and l, and 
the relative intensity (i.e. the darkness of each spot in Figure 1.2C) is 
recorded. Because most reflections are recorded more than once, an 
estimated standard deviation can also be calculated for each intensity. This 
process is called indexing and integration.
The intensities and indices of the reflections describe 3-dimensional 
diffraction pattern of the crystal (Figure 1.2D). Via a nifty mathematical trick 
called Fourier transform this diffraction pattern can be changed into a 3D 
representation of the repetitive element of our crystal: the unit cell with the 
protein inside. This 3D representation is called an electron density map 
(Figure 1.2E) because it's the electrons of the protein atoms that cause the 
actual diffraction. Unfortunately there is a catch: the intensities and indices 
alone are not enough to do the Fourier transform. We also need something 
called phases which can be seen as the relative time differences between the 
diffracted X-rays. These phases cannot be measured directly so 
crystallographers are left with the so-called 'phase problem'.
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Over the years many solutions were found to alleviate the phase problem and 
get reasonable estimates for the phases. Some of these solutions are 
experimental (and some of them have names that seem to describe the 
frustration associated with the phase problem: MAD, SAD), while others are 
computational. Describing all the methods of finding the initial phases 
needed to create our first electron density is beyond the scope of this text. 
Below is just a very short introduction to a computational method that was 
implicitly used in the experiments described in the ensuing chapters: 
molecular replacement (MR).
Molecular replacement makes use of a concept that we have already 
covered in Section 1.2: similar proteins have similar properties. This also 
counts for phases in a diffraction experiment. So, if we already know the 
tertiary structure of a protein (the search model) that has a sequence similar 
to that of the protein we crystallised, and if we can position this protein in 
the 3-dimensional crystal array, we can assume that the phases generated by 
the X-ray diffraction by this protein are a reasonable estimate of the phases 
we need.
This is particularly true for the subset of reflections that describe the 
overall features of the protein structure. These low-resolution reflections 
describe for instance the position of a-helices and ß-sheets. We expect that 
the overall features of our search model are more like our crystallised 
protein than the details, so the high-resolution reflections that describe the 
atomic positions are not taken into account in molecular replacement.
The positioning of the protein is the difficult part of MR, but this is 
fortunately done by very useful computer programs. Getting the phases from 
that point onwards is not a big problem because we can simulate the 
diffraction of the protein by doing a backwards Fourier transform: based on 
the atom coordinates in the well-positioned protein we can calculate what 
the electron density should look like and from that density calculate 
reflections with Miller indices, intensities AND phases.
We now have our measured intensities and a reasonable estimate of 
the phases so we can finally make our first electron density map. If we used 
MR to get the phases we also have a first-approach model for the tertiary 
structure. We can start the iterative process of model building and 
refinement (Figure 1.2F). With the primary structure of our crystallised 
protein at hand we can fit amino acid residues into the electron density (or 
rebuild our MR model) to get an atomic model of the tertiary structure. Our 
first model is (probably) not good enough to send directly to the PDB so we 
have to refine this model by tweaking the atomic coordinates in such a way 
the intensities we calculate from our atomic model (again by doing a Fourier 
transform) are close to the measured intensities. After the refinement we can
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create a new electron density map (a Fourier transform will give us updated 
phases) and start building again. This process is repeated ad tedium and ends 
with a complete tertiary structure model. The tertiary protein structure is 
then 'solved'.
1.3.3.4. Further reading. The above introduction to X-ray crystallography 
just brushes the surface of this interesting scientific field. Many writings give 
a more in-depth description of crystallography. Two books that are 
commonly used by the starting crystallographer and hence can be found in 
many protein crystallography labs are: 1) Crystallography Made Crystal Clear 
(Rhodes, 2000) covers all the basics of X-ray crystallography and is a very 
good first step in the world of crystallography. 2) Principles o f Protein X-Ray 
Crystallography (Drenth, 1999) covers the nitty-gritty of X-ray 
crystallography for those who want to know all the details.
1.3.4. Determining the quaternary structure
High resolution quaternary structures are obtained with the same methods 
as tertiary structures. This can be done explicitly when the complete 
quaternary structure is the repetitive element of our crystal, or implicitly 
when a part of the quaternary structure is the repetitive element of the 
crystal. In the latter case several repetitive elements in the crystal make up 
one complete quaternary structure.
Even if we cannot measure the position of individual atoms in a 
quaternary structure, we can still get a description of the shape of a protein 
complex by means of methods like (cryo-)electron microscopy (McDowall et 
al., 1983). With this method we can make multiple low resolution images of 
the complex. These images can be combined to form a 3-dimensional shape, 
called a molecular envelope. This envelope can then be filled with high quality 
tertiary structures. In this indirect way we can get a model that describes the 
position of atoms in a protein complex. However, care must be taken when 
drawing conclusions from such a 'Frankenstein' model: the proteins may 
behave somewhat differently in the complex than in a solution or crystal 
without their complex partners.
This brings us to an important issue: how can we ensure the quality 
of a protein structure? But before we get to that, we have to find a sensible 
way to deal with all the protein structure data that we have.
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1.4. Bioinformatics
1.4.1. The biology part
All the knowledge about proteins, e.g. all the structures, has to be stored in an 
easily accessible way. Obviously, storing all our knowledge in books is rather 
inefficient. Instead we save everything in computer data banks that are freely 
accessible over the Internet. When it comes to protein structures, primary 
structures are stored in Uniprot (Apweiler et al., 2004), secondary structures 
(derived from tertiary structures) in DSSP (Dictionary of Secondary 
Structure of Proteins; Kabsch & Sander, 1983), tertiary structures in the PDB 
(Protein Data Bank, 1971). Simple quaternary structures with all the atoms 
in the repetitive elements of the crystal (see Section 1.3.4) are available 
directly from the PDB. The same applies to the 'Frankenstein' models. 
Quaternary structures that require an additional step of combining repetitive 
units in the protein crystal can be obtained from the PDB as 'biological units' 
or via the Protein Quaternary Structure (PQS) file server as complete 
assemblies (Henrick & Thornton, 1998). Molecular envelopes of quaternary 
protein structures are stored in the Electron Microscopy Databank (EMDB; 
Fuller, 2003).
Of course, storing data is probably one of the least exciting things one 
can do with a computer. We want to solve biological and biomedical 
problems. The research field that tries to do that with the help of computers 
is called bioinformatics (Hogeweg & Hesper, 1978). Bioinformatics is a broad 
scientific field, but protein structure and function play very important role in 
most bioinformatics studies. Structural bioinformatics is an obvious example: 
it deals with getting information out of protein tertiary (and quaternary) 
structures. This information can be specific, e.g. "Why does Oseltamivir 
(Tamiflu) not work against a novel N1 neuraminidase mutant and how 
should the drug be adapted to become effective again?”, or much broader, e.g. 
“How are protein structures affected by a sudden change in pH?”.
Whatever the question we want to answer, to do structural 
bioinformatics we obviously need protein structures. Unfortunately for us, 
determining the primary structure of a protein is much easier than 
determining the tertiary structure. To give an idea of the extent of the issue: 
Uniprot contains more than 8 million entries whereas the PDB has fewer 
than 60 thousand. The bioinformatics approach to this problem is discussed 
in Section 1.5.
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1.4.2. The informatics part
Apart from protein structures, (structural) bioinformatics also requires vast 
amounts of computer power that a regular desktop computer cannot deliver. 
A personal example: less than three months into the PhD studies described in 
this thesis, I ran a calculation that overheated my computer and caused my 
hard drive to crash. Not much work was lost because all important data was 
safely backed-up, but the warning was clear: if a calculation on a single 
protein structure can be so damaging to my computer, I cannot possibly do 
calculations on hundreds (and later tens of thousands) of protein structures 
on my machine. And even if my (newly repaired) computer would survive 
another assault, the work would take much too long.
A new computer resource had to be found and fortunately the 
national computer infrastructure at SARA (Stichting Academisch 
Rekencentrum Amsterdam; www.sara.nl) has a supercomputer well-suited 
for bioinformatics research. This computer, called Lisa, is a cluster consisting 
of 571 nodes with a total of 2054 CPU cores and more than 3 TeraBytes of 
memory. Each CPU core can do a single protein structure calculation in a 
matter of hours so more than 1000 structure calculations can be done in less 
than a day. Of course, Lisa has to be shared with many other scientists, but 
even so a calculation on Lisa is nearly 100 times faster than on a single 
desktop computer.
This speed-up was fine for the project described in Chapter 3, but the 
hunger for CPU time was even bigger for the project described in Chapter 4. 
This time a machine like Lisa was just not powerful enough to do the 
required calculations in a reasonable amount of time and an alternative was 
found in the form of the European computer Grid made available through the 
EMBRACE (European Model for Bioinformatics Research And Community 
Education; http://www.embracegrid.info) virtual organisation. This Grid 
consists of computation and data storage facilities spread over different 
locations throughout Europe. In other words: many Lisa-like computers that 
are linked together to form one gigantic cluster. The project on the European 
Grid was also a proof-of-concept of the Grid itself: a computationally 
intensive biology project was needed to show the benefits of Grid computing. 
This completed the circle for bioinformatics: biology needs computers and 
computers need biology.
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1.5. Getting tertiary structures the bioinformatics 
way
We are faced with a serious problem: we need protein tertiary structures to 
obtain a better understanding of the 'how and what' of all known proteins, 
but the experimental determination of tertiary structures cannot keep up 
with the fast growing number of known proteins. Labs all over the world are 
collaborating to step up the pace, but the gap is just too big to close at the 
moment.
We must do the best possible science with the structures that are 
available now and bioinformatics can help us to do so in several ways. First 
of all, we need to make sure that all the tertiary structures that we do know 
are of the best possible quality. Because the structures are determined 
experimentally, there are bound to be errors caused by experimental noise, 
experimental errors, and of course human errors. When these errors go 
undetected, they will affect the knowledge we derive from protein structures. 
If the errors are discovered and acknowledged, they can be taken into 
account which means that any knowledge derived from protein structures 
becomes more reliable. Or at any rate, we will know which parts of the 
derived knowledge may be better or worse than others. This process of 
structure quality assessment is called structure validation and is extensively 
covered in Chapter 2.
Protein X-ray crystallography has evolved a lot over its half-century 
existence. The experimental methods have improved drastically. This means 
that experiments done previously can now be repeated and are likely to have 
better results. However, completely re-determining the structure of proteins 
is slow and expensive especially because the crystallisation of proteins is still 
a bottleneck. And besides, lab experiments are outside the scope of 
bioinformatics. Fortunately, we still have the experimental data for many 
crystallographic studies. At the fiftieth birthday of protein crystallography, 
the PDB has even made the deposition of this experimental data mandatory. 
So even though we cannot go all the way back to the original crystallisation 
experiment, we can still use the original experimental data (the reflections 
and their intensities) that lie at the root of the protein structures in the PDB. 
This brings us to the second bioinformatics approach to the tertiary structure 
problem: using this original experimental data it is possible to recalculate, or 
rather re-refine, the known protein structures with the original data. 
Chapters 3 and 4 cover this re-refinement from an early proof of concept to a 
full blown re-refinement of all the structures in the PDB that have sufficient 
experimental data: the PDB_REDO project. The work described in these
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chapters shows that with the original data from then and the methods from 
now, we can make structures that fit the experimental data better than before 
and also have better results in the structure quality assessments described in 
Chapter 2.
In recognition of the success of the re-refinement work described in 
Chapter 4, Nature decided to dedicate a news article to the project. This 
article, based on telephone and e-mail interviews with my promoter, myself, 
and several key players in the protein structure world, was written by 
Katharine Sanderson. It is presented in Chapter 4.A. To us (that is, to my 
promoter and myself) the publication of the news article was an occasion to 
celebrate the completion of the PDB_REDO data bank 
(http://www.cmbi.ru.nl/pdb_redo): all 38,000 PDB entries with 
experimental data, even the previously problematic ones, had been added. 
New entries are added automatically once the new PDB files are available 
and entries are replaced when the PDB files or the associated experimental 
data are changed. The few PDB entries that cause crippling errors (for 
instance because the experimental data does not make any sense) are 
annotated in the WHY_NOT system (http://www.cmbi.ru.nl/WHY_NOT2). 
With the encouraging results of the PDB_REDO project it was time to look 
ahead and find possibilities for further improvement. Chapter 5 presents a 
follow-up study in which five re-refined protein structure models were 
optimised by hand to see what common problems occur in PDB entries and 
to what extent these problems can be resolved automatically. This chapter 
also stresses the importance of having enough information about the 
experiment to improve the structure model at hand. More data will also help 
improve refinement methods in general as it will provide software 
developers better test sets. It is put forward that at some point we will have 
to deposit the X-ray images themselves instead of just the derived reflection 
data so that methods at the 'indexing and integration' stage of the X-ray 
experiment (see sections 1.3.3.2 and 1.3.3.3) may also be improved.
The third bioinformatics approach to the tertiary structure problem 
is homology modelling. As explained in section 1.2, homology modelling is 
used to make a model of the tertiary structure of one protein, based on the 
tertiary structure of a similar (in primary structure) protein. So instead of 
checking the quality of a structure model or improving its quality, we are 
making new models altogether. This has a much greater impact on the 
tertiary structure problem than the other to approaches. So, why not spend 
more time modelling and less time validating and re-refining? Because 
validation, re-refinement, and homology modelling go hand in hand: a better 
original tertiary structure model, called a modelling template, leads to a 
better homology model. Also, better protein structures can be used to
24
improve the methods behind homology modelling. As such, the work 
presented in Chapters 2-5 provides improved infrastructure for homology 
modelling. Chapter 6 can therefore be seen as more than just a description of 
an application of re-refinement. It is the 'this is why we do it' chapter. And 
because it also describes the relation between homology modelling and 
experimental protein structure studies, it is the perfect ending of this thesis, 
it shows that bioinformatics belongs in the lab and the lab belongs in 
bioinformatics.
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Abstract
The wealth of structural information about proteins that is now available in 
the Protein Data Bank (PDB) comes at a price. When using protein structure 
models for modelling and drug design purposes, one must often choose 
between multiple seemingly equivalent coordinate sets. Protein validation is 
an important step in this selection process. It is the key to assessing the 
quality of protein structures and thereby to the quality of all subsequent 
computational steps.
In this chapter we shall explain the importance of structure validation 
for drug design and many other applications of protein structural data. 
Different types of validation are discussed; from the detection of simple 
administrative errors, to calculations of amino acid packing and hydrogen 
bond networks. We show that even seemingly unimportant errors can have 
serious implications when gone undetected.
Structure validation, and the large number of software tools that help 
in the process, has developed over time to keep up with the demands of 
structural biologists and drug designers. We discuss the development of the 
quality of protein structures since the beginning of the PDB based on a 
number of validation tests. Validation has a long future ahead of it because 
new classes of errors are still discovered frequently and many problems still 
await resolution. Generally, there is a trend towards better structures over 
time and that trend should continue. We therefore encourage the validation 
of protein structures before use for drug design and homology modelling, but 
also during the process of structure calculation and refinement in NMR 
spectroscopy and X-ray crystallography.
2.1. Introduction
The use of (experimental) 3-dimensional models of protein and nucleic acid 
structures is now commonplace in biochemistry, and medicine alike. These 
models give us more insight in the inner workings of the cell which is of 
paramount importance in the ongoing fight against disease. They form the 
basis of structure-based (or, rather audaciously: rational) drug design (Hol,
1986), which is one of many techniques used for the discovery and 
optimization of new medicines.
The total number of macromolecular structures publicly available in 
the Protein Data Bank (PDB; Bernstein et al., 1977) is increasing rapidly 
(Figure 2.1). Of the more than thirty thousand protein and nucleic acid
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structures currently in the PDB, only a relatively small number is unique 
(Table 2.1; Wang & Dunbrack, 2003). This redundancy introduces a problem 
of convenience for users of this structural data: which of the available 3D 
structure models should one use?
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Figure 2.1: The Protein Data Bank (PDB; Bernstein et al., 1977) has grown exponentially since 
its modest start in 1972. It currently (July 2005) holds 32545 structures determined using X- 
ray diffraction, Nuclear Magnetic Resonance, and several other methods. At the current rate of 
growth more than 100 structures are added every week. The black columns represent the 
total number of entries in the PDB for each single year, the grey columns show the number of 
structures added per year. Data from http://www.rcsb.org.
Table 2.1: Unique entries in the PDB
Sequence identity Number of entries3
< 25 % 3977
< 50 % 6957
< 75 % 8303
< 99 % 13970
< 100 % 29081
a Only entries with 40 to 10,000 amino acid residues are considered
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To help make this very important choice, a vast number of tools have been 
developed with a widely varying level of sophistication. These tools supply 
information about the quality of the experimental data, the correlation 
between the measured data and the resulting 3D model, the quality of the 
structure model with respect to our general knowledge of physics and 
chemistry, and the correlation between the model and our ever-increasing 
knowledge of the specific features of protein and nucleic acid structures. The 
goal of all these tests is the same: to provide insight into the quality of the 
final structure model so that the 'best' structure can be used for further 
research.
2.1.1. Why?
The conclusions drawn from a 3D structure model are, at best, as good as the 
model itself. Structure validation helps us to identify anomalies and errors in 
structure models. This enables 3D coordinate users to select the best 
structure models and to take into account any abnormalities in those 
structures. Some errors can even be fixed before the 3D coordinates are used.
A striking example of the importance of using the correct structure 
model occurred in 1989. Immediately after the coordinates of the human 
immunodeficiency virus protease (HIV-1 protease) became available, they 
were used to direct the search for inhibitors (Navia et al., 1989). Because the 
initial structure model included a mistake in the dimer interface region, 
understanding the molecular mechanisms of the release of HIV-1 protease 
became difficult (Blundell & Pearl, 1989). Based on a comparison with the 
homologous retroviral Rous sarcoma virus (RSV) protease, Blundell and 
Pearl (1989) suggested that there might be something wrong with the 
proposed HIV-1 protease structure. This idea was reinforced by a homology 
model of the HIV-1 protease, built using RSV as a template, which showed a 
small but important difference in structure (Weber et al., 1989). Finally, the 
discrepancy was solved by Wlodawer et al. (1989), who determined the 
structure of a synthetic HIV-1 protease, but now with the correct chain 
tracing of the amino-terminal strands at the dimer interface. The 
development of HIV protease inhibitors in the fight against the human 
immunodeficiency virus was a major breakthrough for structure-based drug 
design. It has shown the importance of validating protein models to extract 
the right structural information.
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2.1.2. Sources of errors
The processes of obtaining structure coordinates of macromolecules by 
means of X-ray crystallography, NMR or any other method consist of many 
complicated steps, each introducing uncertainties and errors. Crystallization 
and data recording introduce measurement errors and noise. Human 
interpretation of data is often required when no straightforward answer is 
available. This may result in a significant degree of subjectivity in the model 
building process (Brândén & Jones, 1990). The computer software used 
during refinement is not without weaknesses either. The cumulative effect of 
errors and human interpretation is almost impossible to assess, but 
Laskowski & Swaminathan (2007) give a very thorough description of the 
problems one can encounter.
To complicate matters even further, users of 3D structure 
coordinates are not necessarily trained in the methods that were used to 
obtain those coordinates. Fortunately for them, many tools have been 
developed to provide insight in the ambiguities, anomalies and errors of 
those coordinates.
2.1.3. The good, the bad and the ugly
Telling right from wrong is no black or white matter. First of all, we have to 
establish what is right, or better, what is normal. This is derived from sources 
like (a subset of) the PDB, that we assume to be representative for the 
proteins we study. Any 'normal' value has to be accompanied by a standard 
deviation ( g )  to give some perspective on the distribution of the values one 
could encounter. Using these two values to separate right from wrong 
requires a third value: the cut-off. Given an expected value, a standard 
deviation and a cut-off we can separate the good from the bad. However not 
every anomaly is bad, some are just ugly. For any large set with a Gaussian 
distribution a certain fraction of outliers is expected.
To minimize the risk of false positives (reported outliers that are in 
fact correct), a suitable deviation from the expected value has to be allowed. 
Table 2.2 shows the relation between the Z-score (the number of standard 
deviations an observed value differs from the expected value) and the 
probability that a flagged outlier may be a false positive (Nabuurs e t al., 
2003).
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Table 2.2: Relation between Z-score and the probability an outlier is a false positive
Z-score Probability (%)
1
2
3
4
31.74
4.54
0.26
0.01
So with a 4 g  cut-off, about 1 in 10,000 flagged outliers is a false positive. 
Therefore, the PDBREPORT (http://www.cmbi.ru.nl/gv/pdbreport; Hooft et 
al., 1996a) databank with its 11.6 million errors (July 2005) contains about 
1100 flagged errors that are actually correct. The errors in Figure 2.2 
however, are all definitely wrong.
2.1.4. Working with errors
When an error is identified in a structure model, the user must assess its 
impact on the overall quality of the work for which the structure model will 
be used. For instance, an unlikely short inter atomic distance between two 
atoms (a bump) at some uninteresting spot on the protein surface may be 
less problematic than a similar bump in the active site.
Critical errors must be fixed, preferably using experimental data. This 
however requires expert knowledge of the method used to solve the 
structure and is therefore not preferred by most structure users.
Alternatively, the structure can be improved by using standard 
conformation libraries (Jones et al., 1991). It is important to realise that by 
doing so, one is normalising the structure, fixing it to use the most reasonable 
conformations and as a consequence making it pass conformation tests, 
while not necessarily improving the correlation with the experimental data. 
There is a risk involved in using standard libraries: circularity. For instance, 
using side chain conformation libraries (Jones et al., 1991; Ponder & 
Richards, 1987; Kleywegt & Jones, 1998; Chinea et al., 1995; Lovell et al., 
2000) to reposition side chains to the preferred rotamer has a reinforcing 
effect on the database distribution of the preferred rotamer. In other words: 
the most popular rotamer becomes even more popular. Residue 
conformations purely based on conformational libraries should be flagged so 
that they can be excluded when generating new libraries. Often, this is done 
implicitly or explicitly by crystallographers. If a side chain cannot be properly 
seen in the experimental electron density, it will have a very high B-factor (if 
no B-factor restraints are used) or an atomic occupancy of (nearly) zero.
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Figure 2.2: Some examples of errors in the PDB. A) Histidine 211 that coordinates the zinc ion 
has a 23g  deviation from normal planarity whereas the other two histidines are planar (PDB 
entry 1biw). B) The Cß of threonine 5 has inversed chirality. The OYi and CV2 atoms are 
swapped; threonine 7 has correct chirality (PDB entry 5rxn). C) The two rings in tryptophan 
67 make an angle of 106 degrees. This is a 37g  deviation from the correct planar configuration 
(PDB entry 7gpb). D) Aspartate residue 168 in PDB entry 1dlp has a 64g  deviation from 
planarity. Its direct neighbour, aspartate 169 is 'normal'.
Some crystallographers prefer leaving out the ill-defined atoms completely, 
submitting structures with partial amino acid residues. In any of these cases, 
the user of the 3D coordinates has to be aware of the problem. Validation 
programs like WHAT_CHECK (Hooft et al., 1996a) warn the user if such 
residues are encountered.
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Some errors cannot be resolved either because the problem is too global of 
nature, such as bad Ramachandran statistics (Ramachandran et al., 1963), or 
no straightforward solution is at hand due to a lack of (experimental) data. In 
those cases one can either choose another structure, if such an alternative is 
available, or just 'learn to live with it'. The latter is not as bad as it sounds. A 
known error is much less of a problem than an error that goes undetected. If 
the drug designer or molecular biologist knows that certain residues are 
likely to be imprecise or wrong, he or she can take appropriate action in the 
design of experiments.
2.1.5. Correlation of the structure with experimental data
The best known quality score for X-ray structures is the so-called R-factor. It 
describes the correlation between the measured data and the final 
macromolecular structure. The lower the R-factor, the better. Or so it seemed 
until one of us showed that a purposely misthreaded structure can still have 
the perfectly acceptable R-factor of 21.4% (Kleywegt & Jones, 1995). This 
proved that the R-factor by itself is not reliable enough. The free R-factor, 
Rfree, is calculated from crystallographic reflection data that is not used 
during the building and refinement of the protein structure (Brunger, 1992). 
It is therefore an independent measure of the quality of the structure. Rfree, or 
better the difference between the R-factor and Rfree can also be used to 
recognise over-refinement of 3D structure (Kleywegt & Jones, 1995; 
Kleywegt & Brunger, 1996). Similar independent quality factors have been 
developed for NMR, also relying on experimental data that is not used during 
refinement (Clore & Garrett, 1999).
Apart from these global correlation tests, there are numerous local 
correlation validation tests. For X-ray structures, the Electron Density Server 
(EDS; http://eds.bmc.uu.se; Kleywegt et al., 2004) gives a summary of 
important validation values including the Real Space R-factor (RSR; Jones et 
al., 1991) and the real space correlation factor which give information of the 
fit to the data at a residue level. We shall discuss working with experimental 
X-ray data in more detail in section 2.2.7.
The number of distance or angular restraints per residue is a 
commonly used quality indication for NMR derived 3D coordinates. The 
QUEEN program (Nabuurs et al., 2003) supplies statistics on the actual 
information content of distance restraints, correcting for the redundancy that 
is usually encountered in sets of restraints. The correlation between data and 
structure on a per-residue basis is best described by the number of restraint 
violations, that is, the number of inter-atomic distances longer than
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prescribed by the restraint distance. The size of each violation has to be 
taken into account as well. For drug designers, a 1.0Â violation is worse than 
five 0.2Â violations.
2.1.6. The data problem
In order to validate the data used to derive the protein structure model, it has 
to be made available by the depositor of the 3D coordinates. At the moment 
(July 2005) only 55% of all NMR derived and 64% of all X-ray derived entries 
in the PDB have experimental data available and in both cases the spread in 
standards used upon data deposition makes it hard to use these 
experimental data in a fully automated way (Kleywegt et al., 2004; 
Doreleijers et al., 1998). Because ever more scientific journals require the 
submission of experimental data, and because deposition of experimental 
data is now an integral part of the deposition of PDB entries, these 
percentages are increasing rapidly (87% for this year's X-ray structures so 
far). This, however, does not solve the problem for the older PDB entries.
Fortunately, here are numerous validation tools that do not require 
experimental data. Instead, they use geometrical parameters like bond 
lengths, angles and planarity (Engh & Huber, 1991; Parkinson et al., 1996; 
Cremer & Pople, 1975; Hooft et al., 1996b), protein backbone torsion angles 
(Ramachandran et al., 1963) and the relative orientation of amino acids. 
These tools supply the user with a wealth of information about the protein 
structure but no details are given about the correlation with the 
experimental data. Therefore any anomalies or errors flagged during the 
validation of the model in question cannot be traced back to the original 
experiment or the interpretation of the experimental data. This also limits 
the ability of the user to correct the errors.
2.1.7. Overview
We shall discuss different types of errors that are of special interest to those 
who use the structures in the PDB to collect information about the workings 
of proteins and those who use 3D coordinates to design drugs. Where 
possible, we shall elaborate on the errors with examples of difficult 
structures or interesting errors. We shall pay special attention to the 
hydrogen bonding network that is thoroughly explored and validated in the 
WHAT_CHECK package. This package is available, free of charge, to both 
academic and commercial users (http://swift.cmbi.ru.nl/gv/whatcheck) and
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can be used for all types of protein structures, independent of the method by 
which they are derived. Apart from validating the entire PDB, we encourage 
the validation of protein (homology) models for drug design.
We will also give a historic overview of the quality of published 
structures. Have they improved or not? Which errors are less common and 
which are not? Finally, we will give a look at work to be done in the field of 
structure validation. Many more types of errors are still waiting to be 
discovered.
2.2. Different types of errors
A larger number of different classes of errors have been identified, some 
more important than others. Discussing all those classes is beyond the scope 
of this chapter. Instead, we shall focus on the types of errors that are of 
special significance to those who want to use 3D structural data of proteins 
and nucleic acids for biological and drug design purposes.
2.2.1. Administrative errors
Errors with the format of PDB files, for example missing atoms or wrong 
atomic occupancies, are easy to make, seem innocuous, but can have serious 
implications when gone undetected. A missing side chain can give 
unexpected results in electrostatics and hydrophobicity calculations. What 
does a drug docking program do with atoms with the wrong names?
The standard for PDB files is well-defined but not all programs that 
produce PDB files strictly adhere to this standard. Even simply reading in a 
file and writing it out again with the same software can cause many 
deviations from the standard that make a PDB file invalid.
CRYST1, MTRIX and SCALE records describe the crystal parameters 
and may be important when symmetry derived molecules are considered. 
For instance, in drug docking care must be taken that the target site is not 
influenced by symmetry related molecules. Some flexible residues may seem 
buried and relatively rigid due to crystal packing. This can only be checked if 
the molecular symmetry is properly described (Hooft et al., 1994).
We find an example in PDB entry 4dfr. The binding site for the hetero 
compound is influenced by side chains from a symmetry related molecule 
that is not found directly in the PDB file (Figure 2.3). This influences the way 
the compound is bound. This should be taken into account when structures
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like this are used to benchmark docking algorithms. Without proper 
administration of the crystal symmetry, such slight distortions of binding 
sites would go undetected.
Figure 2.3: The binding site of methorexate is strongly influenced by inter-symmetry 
interactions (PDB entry 4dfr). Lysine 32 and arginine 52, both positively charged, coordinate 
the charged group in methorexate (MTX, in space-filling representation). Their conformation 
is restricted by two residues from an adjacent copy of the same protein. It is not included in 
the PDB entry because this copy can be generated by applying crystal symmetry operators. 
Glutamate 17 forms a salt bridge with arginine 52. Lysine 32 is pulled towards glutamate 120 
forming a hydrogen bond. As a result, the binding of methorexate cannot be exactly the same 
as in the native protein.
The two glutamate residues that influence the binding site are produced by a symmetry 
operation and cannot be seen without applying this operation. Therefore their influence can 
only be assessed when this symmetry is properly administrated.
In PDB entries the MTRIX records describe non-crystallographic symmetry 
(NCS) transformations between related molecules. The determinant of this 
matrix should be exactly 1 or one molecule may be 'inflated' with respect to 
the other. This means that a molecule produced by application of this matrix 
will have systematically longer (or shorter) bonds than the original molecule.
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If this deviation from 1 is too large it may be wise to validate NCS related 
molecules separately and only use the best one.
Atoms with an occupancy < 1 should be inspected carefully. They can 
have an alternative position in which case all positions must be taken into 
account in calculations, or they can be flagged as 'not-there'. This means that 
there is no experimental data to support their position. Users must treat such 
atoms with caution. In PDB entry 4dfr, for example, we find many atoms with 
occupancy < 1. Especially water molecules have a wide variety of 
occupancies without any specified alternate positions.
Atomic occupancies > 1 are also encountered. Sometimes the reason 
for this is obvious: a few PDB entries (e.g. 4hhb) use the number of electrons 
instead of the occupancy. Some occupancies >1 are caused by occupancy 
refinement, in which the occupancy of atoms is adapted to ensure the 
optimal fit with the electron density. This is, again, encountered in the water 
molecules in PDB entry 4DFR. At any rate, occupancies > 1 should be treated 
with a healthy dose of suspicion.
An exceptionally complicated situation is found in PDB entry 1cbq 
(Figure 2.4). It has a phosphate group on a threefold symmetry axis with the 
P-O1 bond exactly on the axis. Only one of the other oxygen atoms, O2, is 
present in the file because O3 and O4 are symmetry related to O2. The 
phosphorous atom has its occupancy set to 0.33 which makes it a full atom 
when the three fold symmetry is applied. Unfortunately, oxygen atom O1 has 
occupancy 1.00 which makes it three full atoms on the same position after 
the symmetry operation. This in turn causes WHAT_CHECK to detect a very 
serious atomic bump. Upon closer inspection of the PDB file, the cause of the 
error is easily identified as a typo: O1 and O2 have their occupancies 
switched. This example shows that seemingly serious errors can be caused 
by simple administrative mistakes. We observe a form of error inheritance: 
one error can cause a number of anomalies that are flagged by validation 
programs. On the other hand, the atoms O2, O3 and O4 now have occupancy 
0.33, and as WHAT_CHECK does not issue warnings for atoms with 
occupancy < 0.5, any errors related to these three oxygen atoms will remain 
undetected.
Missing atoms, either purposely left out or just lost when switching 
from one program to the other, can also cause a lot of problems when using a 
protein structure. A missing surface side chain can make the difference 
between a docking calculation that works and a docking without a usable 
result. In such cases, a badly positioned side chain is often more realistic than 
no side chain at all. It does not work the other way around. Extra side chain 
atoms are not welcome. It is therefore an error that PDB entry 1vns has a Cß 
on glycine 126.
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Figure 2.4: The phosphate group on a three­
fold symmetry axis in PDB entry 1cbq has an 
occupancy problem. The atoms O3 and O4 are 
symmetry related to O2 and are formed after 
applying the proper symmetry. The phosphorus 
atom (in green) has occupancy = 0.33 so that 
one whole atom is formed after applying 
symmetry. O1 on the same symmetry axis has 
occupancy = 1.00. This means that, taking 
symmetry into account, there are three atoms 
at one site. This in turn causes error messages 
for close atomic contacts (bumps).
There are numerous things that can go wrong with naming schemes in the 
PDB. We shall only discuss a few relevant types of errors here. The PDB 
provides a very wide variety of nomenclature related errors, some 
insignificant to drug designers, many annoying, and some catastrophic.
It is important to realize that there might be discrepancies between 
the protein sequence in the SEQRES record in a PDB entry, the corresponding 
ATOM records, and the sequence in sequence databases like UNIPROT (Lesk 
et al., 1989; Apweiler et al., 2004). Residues for which the side chain cannot 
be identified in the electron density are sometimes renamed to alanine 
during the refinement process. We find an example of this in PDB entry 
1wcm in which a poly-alanine chain replaces the amino acid residues in the 
original sequence found in UNIPROT entry RPB4_YEAST. Discrepancies like 
this one should be intercepted upon deposition of the structure to the PDB. 
Before using the 3D coordinates, one has to assure that he or she is looking at 
the protein with the right sequence.
Chain identifiers in PDB records have to be unique. However, hetero 
compounds associated with a certain protein chain should have the same 
chain ID. This is useful for drug docking as the smallest unique unit (that is, 
the drug target) can be extracted with all ligands and ions included, merely 
by selecting a chain identifier. This is particularly true for hetero compounds 
that are covalently bound to the protein chain. PDB entry 1myp is an example
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of what can go wrong (Figure 2.5). The N-acetyl-D-glucosamine groups have 
a different chain ID than the asparagine residues to which they are bound.
Figure 2.5: Detail of PDB entry 1myp. Assigning the right chain ID can help when selecting a 
protein molecule with all the (covalently) bound hetero compounds. In this case the protein is 
designated chain D (in blue) and the N-acetyl-D-glucosamine groups (NAG, in red) have chain 
identifier B. This causes a single molecule with only covalent bonds to have two different chain 
identifiers.
ATOM records in PDB files have four positions reserved for atom 
names. The first two are reserved for the chemical (or Mendeleev) symbol, 
the third for a remoteness indicator (a, ß, y, ô, etc), and the fourth for a 
branch number. This means that CA-- (dashes denote spaces here) is a 
calcium atom whereas -CA- is a Ca atom. In that sense, the chlorine atom 
found in PDB record 1nde named 3CL3, should have been called CL33 to 
avoid it being recognized as a carbon atom (Figure 2.6).
Another fine example of badly chosen atom names can be found in 
entry 1e6y which has an atom named OXT in the middle of a hetero 
compound. This can cause errors in molecular graphics and dynamics 
programs because the atom name OXT is reserved for the 'second' C-terminal 
oxygen atom of amino acid chains.
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Figure 2.6: Choosing non-standard atom 
names can have serious consequences when 
working with hetero compounds. The atom 
3CL3 in the ligand of PDB entry 1nde is 
recognized as a carbon because the first two 
positions in its name, which denote the atom 
type, are a digit and the letter C. The right name 
would have been CL33. That way, the first two 
letters would be CL which stands for chloride, 
the right atom type.
The naming of hydrogen atoms is more complicated than usual. First of all, an 
exception to the atom naming scheme was necessary for protons as often 
two branch indicators are needed. In such cases, the second one is put in the 
first 'empty' space so 1H12 is a correct PDB name for the atom H121. 
Secondly, because NMR software is poorly standardized, many naming 
schemes are used. Fortunately, a much needed 'Rosetta stone' is available at 
the BioMagResBank (Seavey et al., 1991). Stereochemistry is an important 
factor in naming hydrogen atoms (Doreleijers et al., 1999). One example can 
be found in glycine. The two hydrogens connected to the Ca atom have 
unique names depending on their prochirality (Rectus or Sinister). The 
proper names for hydrogen atoms are important for calculation of bond and 
torsion angles in calculations like simulated annealing and drug docking.
2.2.3. Hetero compounds
The refinement and validation of hetero compounds is limited due to a lack 
of statistical data and probably also due to a lack of quantum chemical 
expertise of many crystallographers and NMR spectroscopists (Kleywegt et 
al., 2003). New compounds do not have a predefined naming scheme and 
many programs either crash because of unexpected input or ignore the 
compound completely. The geometry of new compounds can only be 
validated by adding its topology and target geometry as an extra library file. 
Generating such libraries used to be hard work but two web servers can now 
help. The PRODRG (van Aalten et al., 1996; Schuettelkopf & van Aalten, 2004) 
server can produce topology files for nine popular programs from various
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types of input. This input includes PDB coordinates and simple text drawings. 
Optional energy minimization can produce an ideal geometry.
The HIC-Up (Hetero-compound Information Centre - Uppsala; 
Kleywegt & Jones, 1998) database contains a collection of hetero compounds 
extracted from the PDB. It has both experimental and idealized coordinates 
for each molecule and a complete list of all the PDB entries that contain this 
molecule.
A nice example of problems that can occur with hetero compounds 
can be found in PDB entry 1jx6. The LuxP protein in this coordinate file 
contains an unknown compound named AI-2 (Figure 2.7). Because of the 
good electron density, the composition of this molecule could be derived by 
fitting atoms to the electron density and using potential hydrogen bonds to 
tell the difference between carbon and oxygen (Chen et al., 2002). An 
orthocarbonate moiety was found in AI-2. The proposed molecular structure, 
however, could not be stable enough to exist in a protein. This is not picked 
up by any protein validation tool because such complicated chemistry is not 
(yet) implemented. Software packages like LHASA (Corey et al., 1975) that 
are used for optimizing (the synthesis of) small compounds are able to detect 
such instable compounds. Careful study showed that the compound was in 
fact a borate diester: the number 2 atom in one of the rings (Figure 2.7) was a 
boron atom instead of carbon. Unfortunately, this solution introduces new 
problems as boron is not yet supported by many programs, including 
PRODRG, because it is seldom encountered in protein structures.
Extra complications occur when hetero compounds are covalently 
linked to each other. When two sugars are bound through a condensation 
reaction, one oxygen atom is lost. However, there are no strict rules 
prescribing which one. In a lot of cases we do not even know which one is 
lost in the actual chemical reaction. This can cause numerous missing atom 
errors, even when there is no real problem.
Another interesting problem occurs in mannose. a-D-mannose and ß- 
D-mannose have the same topology and covalent geometry apart from the 
oxygen atom connected to C1, which can be either above or below the plane. 
Their names (MAN and BMA respectively) should reflect this so that the 
proper stereochemistry can be used when validating the structure. 
Unfortunately, this does not happen all the time. In the PDB, a lot of mannose 
groups called MAN have the wrong name (e.g. PDB entry 1hgd). This is 
reflected by HIC-Up where the MAN record is used for both a-D-mannose and 
ß-D-mannose, whereas the BMA record only describes ß-D-mannose.
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Figure 2.7: Cartoon representation of PDB entry 1jx6. The previously unknown AI-2 
compound in space-filling representation contains one boron atom (in green). Because boron 
is very uncommon in protein structures, geometrical restraints cannot be produced 
automatically with tools like PRODRG (van Aalten et al., 1996; Schuettelkopf & van Aalten, 
2004).
From a crystallographic point of view it was hard to tell whether this atom should be a carbon 
or a boron atom. The (physico-)chemical knowledge that can be used to make that distinction 
is not yet implemented in protein validation software.
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2.2.4. Geometry
The geometry of amino acids is without doubt the most extensively validated 
set of parameters in protein structures. Root mean square deviations from 
standard bond lengths and angles (Engh & Huber, 1991; Parkinson e t al.,
1996) are typically reported when a structure is published. Even though 
these angles and bond lengths are usually restrained during refinement, and 
are therefore not independent values, they still provide interesting 
information about the structure model. Not just obvious outliers, like 1c0p 
(Figure 2.8), but also structures with too tightly restrained geometry should 
be flagged. The latter because tight restraints may inhibit maximal 
correlation with the experimental data, delivering models that suboptimally 
represent the biological structures. When enough experimental data is 
available, the restraints should be relaxed accordingly. A systematic 
deviation of bond lengths (i.e. all bonds are a bit too long or too short) may 
imply an error in the cell dimension or X-ray wavelength (EU 3-D Validation 
Network, 1998). This should have been intercepted in the early stages of 
structure determination (Vriend et al., 1986) and indeed modern X-ray 
reflection and indexing software does so. These systematic deviations can be 
resolved to a reasonable extent by refinement with improved crystal 
parameters but early validation of the crystal parameters is preferable (EU 3­
D Validation Network, 1998).
Figure 2.8: Detail of the C-terminus of PDB 
entry 1c0p. The terminal glycine residue has an 
extremely long bond between the carboxylate 
carbon and terminal oxygen OXT. The bond 
length is 3.32Ä.
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Proline puckering (Cremer & Pople, 1975) and the planarity of amino acid 
side chains (Hooft et al., 1996b) are validated by programs like 
WHAT_CHECK and PROCHECK (Laskowski et al., 1993). It is not just the 
position of the heavy atoms that should be planar; the hydrogen atoms 
should be planar in certain residues as well (Doreleijers et al., 1999). The 
NMR structure ensemble 1d3z has a number of arginine residues with 
strongly deviating He atoms (Figure 2.9). This error can be traced back to a 
refinement problem: the He atoms were not constrained to the guanidine 
plane. Because these atoms can make a hydrogen bond it is important to 
position them correctly. The calculation of pKa values can be greatly 
influenced by the local hydrogen bonding network (Nielsen & Vriend, 2001). 
Proper electrostatics and pKa values are of paramount importance for the
Figure 2.9: Detail of PDB entry 1d3z. 
Two arginine residues near the C- 
terminus have their HE-atoms sticking 
far out of the guanidine plane as a result 
of under-restrained geometry. Wrong 
hydrogen positions can have serious 
consequences for the calculation of 
hydrogen bonds, pKa-values, and 
electrostatic potentials.
Another aspect of protein geometry is the large number of torsion angles in 
the protein backbone and the residue side chains. These angles are not 
validated against a single value. Instead, they are compared against a 
distribution of values that is considered normal. This is done because there is 
no ideal value with a well-defined standard deviation. Many different 
conformations are possible, but some are more likely than others. If many 
unlikely conformations are found in a PDB entry, or a few unlikely rotamers 
are found close together, further inspection of the structure is necessary.
We describe two groups of torsion angles: on the one hand we have 
the ^- and ^ -angles which were initially described by theory (Ramachandran 
et al., 1963), on the other we have the side chain x-angles that are usually 
compared to a database distribution derived from high-quality PDB entries
design of protein inhibitors and activators.
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(Chinea et al., 1995; Lovell et al., 2000; MacArthur & Thornton, 1999). The 
well-known Ramachandran plot is a scatter plot of ^  and ^-angles against a 
background of expected angle combinations. Certain zones in the plot are 
typical for the secondary structure types, while other zones are deemed 
'forbidden'. Because backbone torsion angles are usually not restrained 
during refinement, the Ramachandran plot is seen as an independent 
validation tool. Unfortunately, there remains a problem with the 
interpretation of such plots: PROCHECK divides the plot in four sections 
(most favoured, allowed, generously allowed, and disallowed) but a binary 
approach was proposed later (Kleywegt & Jones, 1996). WHAT_CHECK uses a 
database approach in which the scoring system is not discrete but 
continuous (Hooft et al., 1997). This continuum of scores is separately 
defined for each residue type. Therefore, WHAT_CHECK can express the 
quality of the Ramachandran plot as a real Z-score, rather than a percentage 
in a certain region. MOLPROBITY uses a method described by Lovell et al. 
(2003) that takes into account the Cß positions of the residues.
Because of the global nature of the Ramachandran plot, large 
deviations from acceptable values imply that a structure is not very good as a 
whole and should preferably not be used for drug design or modelling. 
Individual outliers must be inspected because they may contain valuable 
information (Herzberg & Moult, 1991).
Side chain x-angles have a specific distribution which becomes more 
apparent at high resolution (MacArthur & Thornton, 1999). There is also 
some context specificity in this distribution (Dunbrack & Karplus, 1993): for 
instance, the rotamer distribution for histidine is different at the begin of an 
a-helix than at the end of a helix (Vriend et al., 1994). Deviating rotamers 
should be inspected because they may be at an interesting site for drug 
design. If experimental data is available, alternative rotamers can be built if 
sufficient evidence is found to allow it.
Omega angles in the peptide bond form a different kind of validation 
set because they can typically have just two values: 0° or 180°. This 
corresponds to the cis- and trans-conformation, respectively. An in-depth 
evaluation of œ-angles was performed by MacArthur & Thornton (1996), 
who describe the distribution of these angles based on small molecules as 
well as protein structures.
Cis-peptide bonds are relatively uncommon in protein structures 
because they are energetically unfavourable. However, about 5% of all 
peptide bonds between any residue X and a proline residue (X-Pro) are found 
in the cis-conformation. This fraction of observed cis-peptide bonds 
increases with improved resolution because a lot of cis-peptides are not 
recognized at low resolution (Jabs et al., 1999). An equal relation is observed
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for cis-peptides with no prolines involved. However, the cis-peptide fraction 
is only 0.03% for bonds without proline. WHAT_CHECK has a routine that 
flags potential cis-peptides. Because the refinement of the flagged peptides 
may have been performed with the wrong peptide conformation, the local 
backbone may be distorted. Therefore, this section has to be carefully 
inspected using the experimental data, so that the correct peptide 
conformation can be found. Additional refinement may be necessary.
2.2.5. Contact analysis
The simplest form of contact analysis is bump detection. No two atoms can 
fill the same space, so a minimum separation between all atoms must exist. 
This separation is usually chosen as the sum of the two Van der Waals radii 
minus some tolerated overlap. Because bumps are energetically 
unfavourable, they can have a profound impact on molecular dynamics and 
docking studies. It is therefore important that they are flagged and inspected 
during structure validation. Inter-symmetry bumps, i.e. bumps between 
symmetry related molecules, are a special case because they are easily 
missed when symmetry is not taken into account. Proper administration of 
crystal symmetry is therefore indispensable.
When we look at the type of inter-atomic contact, packing becomes 
less straightforward but also more valuable as a validation tool. It has been 
shown that the packing quality of proteins increases with decreasing R-factor 
(Vriend & Sander, 1993). This implies that better versions of a protein have 
better packing. It has also been shown that correctly folded proteins make 
twice as many hydrophobic contacts as misfolded proteins (Bryant & Amzel,
1987).
There are numerous approaches to packing analysis but the principle 
remains the same: is a certain atom (or group of atoms) likely to be found 
near another atom (or group)? A very comprehensive study was performed 
by Singh & Thornton (1992), resulting in the Atlas of protein side-chain 
interactions. This wealth of information can be used to create packing 
validation software.
There are many software tools that validate protein packing. PROSA- 
II expresses residues packing as an energy potential to give a packing score 
(Sippl, 1993). Profile3D applies the knowledge derived from the PDB (Luthy 
et al., 1992). This program uses the model's sequence, which is compared to a 
3D structure profile calculated from high-quality protein structures. The 
program ERRAT compares the distribution of atoms of a certain type (C, N or 
O) near the atom that is to be evaluated, to the expected number of atomic
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contacts from a database (Colovos & Yeates, 1993). It is based on the 
knowledge that the distribution of atoms at a given distance from a central 
atom is non-random. A similar but more sophisticated approach is the 
directional atomic contact analysis (DACA; Vriend & Sander, 1993). This is 
based on the interaction between a rigid group of atoms (e.g. three 
consecutive atoms in a lysine side chain or the phenyl group plus Cß of 
phenylalanine) and atoms of a certain type (e.g. alanine Cß or methionine Ss). 
The secondary structure of the fragment is taken into account as is the 
spatial orientation of the contacting atoms. This leads to a vast number of 
possible contacts, each with a specific score. Comparison of the environment 
of a fragment and the probability of such an environment, summed over all 
interactions, gives a correlation value that can be used for validation 
purposes. However, one must bear in mind that an improbable packing 
environment can be the result of more than just bad model building. A 
residue with an abnormal packing environment can in fact be very important 
for the function of a protein. Also, a badly packed residue can be an 
interesting target for mutation studies and protein design in both medical 
and industrial applications (Eijsink et al., 1992).
2.2.6. Hydrogen bonds & water
In X-ray crystallography, except in ultra high resolution structures, hydrogen 
atoms cannot be seen. In NMR it is completely the other way round: the 
protons dominate the structure calculation process. In any case, hydrogen 
atoms, especially those that form hydrogen bonds, are extremely important 
for drug design. Therefore, hydrogen related validation tests are 
indispensable.
The simplest tests entail the validation of hydrogen nomenclature. The PDB 
has a strict definition for hydrogen names. Unfortunately, structure 
calculation programs use different naming schemes, as we have mentioned in 
section 2.2.2. Many NMR ensembles do not even contain all the hydrogen 
atoms that are to be expected, but only the ones that can be seen in the 
experiment (Doreleijers et al., 1999). There are many geometrical 
considerations when validating hydrogen atoms. We have already discussed 
the planarity in section 2.2.4 but also dihedral angles are important as 
staggered conformations are energetically more favourable than eclipsed 
conformations.
It becomes much more complicated, but also a lot more interesting 
when hydrogen bonds are taken in to consideration. Individual hydrogen 
bonds are of course important for protein structure in general, but a lot more
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information can be derived from the hydrogen bond network (Hooft et al., 
1996c). First of all, the position of missing hydrogens can be ascertained, 
secondly the optimal orientation of histidine, glutamine, and asparagine can 
be found. This is of particular interest for X-ray structures because the 
difference between the NH2 group and the oxygen atom for asparagine and 
glutamine, and the nitrogen and carbon atoms in histidine is not visible at 
normal resolutions. The planar end of the side chains of these amino acids is 
therefore easily flipped into the wrong conformation (McDonald & Thornton, 
1995). Such errors can be very costly in electrostatics and pKa calculations. 
Deviations of up to 2 pKa units as a result of a single flip have been reported 
(Nielsen et al., 1999). This brings us to the third advantage of an optimized 
hydrogen bonding network: proper calculation of the ionization states of 
charged residues and histidine. The final advantage is the validation of water 
molecules. In crystallography, adding water molecules to the model has a 
significant lowering effect on the R-factor. It is therefore very tempting to fill 
peaks in the electron density with water. However, not all peaks are water; 
some may be ions like Na+ (Nayal & Di Cera, 1996; Shui et al., 1998). In this 
sense, water molecules without any hydrogen bonds are rather suspect. 
Clusters of water molecules that do not make any hydrogen bonds (directly 
or indirectly) to the protein or another compound may be something more 
interesting than water. On the other hand, they may also be islands of 
spurious density kept alive by 'feeding' it water during refinement.
An optimized hydrogen bond network has many merits for the design 
of potential drugs. Without it, a proper description of the binding site is not 
possible in terms of electro-statics, local pH, and pKa or hydrogen bonding 
potential. H-bonds are also important for validation purposes: we have 
already mentioned the histidine, asparagine, and glutamine flips as well as 
validation of crystal water, but hydrogen bonds are important for describing 
secondary structure too (Kabsch & Sander, 1983). The number of buried 
unsatisfied H-bond donors in a structure is also a validation criterion 
because good structures tend to have very few of them (McDonald & 
Thornton, 1994).
WHAT_CHECK uses an empirical hydrogen bond force field to 
perform a very thorough validation of the H-bond network. It considers the 
full hydrogen bond network at once, taking into account potential side chain 
flips, crystal symmetry and H-bonds geometry (also for bifurcated bonds). 
The main problem lies in the number of proton conformations that can be 
generated. For instance, using 10 degree steps, there are 36 options for 
hydroxyl groups in serine, threonine, and tyrosine, and there are 366 
orientations for each water molecule. This creates a mind-boggling number 
of possible networks which needs to be reduced significantly before
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calculation becomes feasible. First a list of all possible hydrogen bonds is 
made and any H-bond that can be unambiguously assigned is flagged. This 
way, the network is subdivided into independent clusters of ambiguous 
conformations. The problem is now greatly reduced and subnetworks that 
have fewer than a fixed number of possible structures can be fully assigned. 
We are left only with the larger subsections of the H-bond network for which 
a separate approach is used. A randomly selected ambiguous conformation is 
selected and set to a fixed value and the subnetwork is evaluated. Threshold 
acceptance (Dueck & Scheuer, 1990) is used to create an energy cut-off. This 
way, any change can be either accepted or rejected. After a series of 
permutations, the energy threshold is lowered. These steps are repeated 
until the threshold energy is reduced to zero. The whole procedure is 
repeated a few times and the best solution is used. Finally, a local 
optimization for each hydrogen bond is performed.
The calculation of the complete hydrogen bond network is very 
computer intensive but can be performed in a reasonable amount of time on 
a normal workstation. The optimization of the H-bond network can have 
such a large effect on drug docking experiments that it is worth every CPU 
cycle.
2.2.7. Using experimental X-ray data
Validation of the actual experimental data is typically the task of the 
crystallographer or NMR spectroscopist as this requires specialized software 
and expertise. Nevertheless, a few 'sanity checks' can sometimes be carried 
out by non-experts using either specialized software, e.g. SFCHECK (Vaguine 
et al., 1999) for X-ray data, or web-accessible databases like EDS (Kleywegt et 
al., 2004). For instance, one can obtain information about the resolution and 
completeness of the crystallographic data (higher resolution and 
completeness usually leads to better models), or about any problems with 
the crystals or the data that may have gone undetected by the 
crystallographers (e.g., twinning or anisotropic diffraction of the crystals). 
Finally, the Wilson B-factor that is calculated from the data can be compared 
to the average B-factor of the model and it should be of similar magnitude. If, 
for example, the average B-factor of the model is 20Ä2 and the Wilson B- 
factor is 60Ä2, then this suggests that the model's B-factors are unreliable.
However, a much more important advantage of the availability of 
experimental data is that it allows electron-density maps to be calculated. 
This, in turn, enables even non-experts to inspect the quality of the density 
on which the model is based, both overall and for parts of the model that are
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of specific interest, such as ligands, cofactors, catalytically active residues, 
etcetera. In addition, statistics that measure the fit of the model and the 
density can be derived.
A global statistic that measures the fit between model and data is the 
R-value (see section 2.1.5), but for most applications knowledge of the local 
quality of the fit between model and density is of greater interest. For this 
reason, Jones et al. (1991) introduced the real-space fit, which compares 
experimental electron density with the density distribution calculated 
directly from the structure model. If the model is a faithful representation of 
the data, these two densities should be very similar. The real-space fit is 
usually calculated for one amino-acid residue, nucleotide or small molecule 
at a time and thus provides a local quality score. The fit can be expressed as 
an R-value (lower values imply a better fit) or as a correlation coefficient 
(values closer to one imply a better fit). These real-space fit statistics are 
readily available from EDS for the large majority of crystal structures in the 
PDB for which the experimental data was deposited (about 15,000 entries in 
EDS in July 2005). In addition, since EDS contains real-space fit statistics for 
millions of amino-acid residues and nucleotides, typical values (average and 
sample standard deviation) for each type of residue or nucleotide at various 
resolutions are easy to compute. These values, in turn, can be used to flag 
residues that have unusually high real-space R-values (given their type and 
the resolution). A cut-off of two standard deviations above the mean is used 
in EDS, which tends to flag those residues that have very poor density indeed. 
An example of the importance of the use of electron-density maps to select 
between alternative, seemingly equivalent entries in the PDB is provided in 
Figure 2.10. PDB entries 268d and 1d63 are both complexes of a small 
fragment of DNA with the drug berenil. Both structures were determined at 
2.0Ä resolution, with similar R-factors (16% and 17%, respectively) and 
similar average B-factors (29 and 31Ä2, respectively). The overall 
completeness of the data for 1d63 was only 73%, whereas that for 268d was 
99%.
The latter statistic could be used to make a case for using 268d rather 
than 1d63 for subsequent modelling or design studies. However, this would 
be an unfortunate choice, as the density for the two berenil molecules 
reveals. The berenil molecule in 1d63 has excellent density as one would 
expect for a fully occupied site in a 2Ä electron-density map, and this is 
reflected in a real-space R-value of 0.11, close to the average value of 0.10 for 
the entire model (minus the waters). The berenil molecule in 268d, on the 
other hand, has a real-space R-value of no less than 0.44 (compared to an 
average of 0.12 for the entire model).
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Figure 2.10: Electron-density maps, taken from EDS (Kleywegt et al., 2004), for the drug 
berenil in complex with DNA from two different PDB entries, both determined at 2.0Ä 
resolution. A) Density for berenil in PDB entry 268d, and B) in PDB entry 1d63.
A similar trend is visible in the behaviour of the real-space correlation 
coefficient (1d63: 0.93 for berenil, 0.96 overall; 268d: only 0.82 for berenil, 
compared to 0.95 for the entire model) and the B-factors (1d63: 35Ä2 
compared to 31Ä2 overall; 268d: 56Ä2 for berenil, which is about twice the 
average of 29Ä2 for the entire model). In this particular case, the appearance 
of the density maps and the statistics suggest that the berenil site in 268d 
probably had a very low occupancy, making 1d63 the obvious model of 
choice for any further computational or experimental studies.
2.3. Time flies when you are validating structures
Structure validation is not new. Many years of research have led to the 
validation tools that are available today. But the development of structure 
validation and structure determination is not standing still; many new tools 
and methods are being developed. We therefore want to put validation in a 
temporal perspective. In this section we shall look at the past, present, and 
future of validation.
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2.3.1. The quick and the dead
We can categorize validation checks into two types: living and dead. Some 
validation methods are completely based on definitions or on solid 
experimental data. No one will dispute that 'P 1-' is a non-standard space 
group in protein crystallography and will therefore cause problems with 
many software packages. Nor will anyone say that a non-bonded inter-atomic 
distance can be as short as 1.281Ä in a protein. The typical bond lengths and 
angles as determined by Engh & Huber (1991) have been proven to be 
correct when extrapolated to macromolecules (EU 3-D Validation Network, 
1998). These undisputed values in validation need no further development 
and are therefore considered dead. Small updates have occurred (Engh & 
Huber, 2001), but the changes were small enough not to significantly modify 
the results of the validation of structures. The dead validation parameters 
are accepted and have found their way into a lot of refinement protocols.
However, not all validation parameters are as well-determined as the 
bond lengths and angles. There are no perfect side chain torsion angles or 
ideal residue packing environments. Our definition of right and wrong, or 
better normal and abnormal, is based on information extracted from the best 
entries in the PDB. But the protein data bank is continuously updated and 
our perception of what is 'the best' needs to be updated as well. The 
databases from which we extract validation parameters grow and/or change 
in composition. This makes tools that rely on these databases living tests.
This is not without consequences for the validation results of older 
structures. For certain validation tests, the average resolution of the database 
is an important factor. The average values of certain validation parameters 
are significantly resolution dependent (MacArthur & Thornton, 1999). This 
may result in bias towards structures that have the same resolution as the 
structures in the database even to the extent that higher resolution 
structures sometimes score worse than lower resolution structures if the 
latter have resolutions close to those of the files in the validation database. 
Furthermore, because the average quality of structures increases with date 
of deposition (Weissig & Bourne, 1999; Kleywegt & Jones, 2002), database 
derived tools become sterner (see Table 2.3). As a result of this, older 
structures have a disadvantage: they can look quite bad even though they 
had the best possible refinement at that time. This is unfortunately 
unavoidable. After all, drug designers and other users of protein 3D 
coordinates should use the best data available by our current standards.
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Table 2.3: Quality indicators for PDB entry 1crn based on databases for 2000, 2002 and 2005
Structure Z-scoresa 2000 2002 2005
First-generation packing quality 0.163 0.163 0.163
Second-generation packing quality -0.547 -1.509 -0.531
Ramachandran plot appearance -0.230 -0.244 0.754
Chi-1/chi-2 rotamer normality -0.195 -0.738 -1.079
Backbone conformation 0.470 1.089 0.841
a Positive is better than average. For more information see PDBREPORT.
2.3.2. Database generation
Many validation tools are based on the comparison of some parameter with 
the average value for that parameter in a set of 'good quality' PDB entries. 
There are many ways to generate such a set of PDB entries but they all follow 
a basic principle. Here we describe parameters that are common to most 
dataset generation protocols (Wang & Dunbrack, 2003; Hooft et al., 1996b; 
Hobohm et al., 1992; Noguchi et al., (1997; Heringa et al., 1992).
First of all, the method with which the structure models were derived is 
considered. Usually only crystal structures are used, but pure NMR databases 
may be useful for specific purposes. Provided that X-ray structures are used, 
the resolution becomes the second selection criterion. Low resolution 
structures are usually excluded. Even high resolution structures can be bad 
so the R-factor has to be taken into account. High R-factor structures have 
less correlation with the experimental data. In this sense, the difference 
between R-factor and Rfree should also be reasonable (less than 5%) because 
a large difference may imply over-interpretation of the experimental data.
Normally, the structure database contains only native proteins, no 
mutants. This is especially important for packing analysis as mutants may 
have distorted packing environments. The same holds for the amino acid 
sequence. No non-natural amino acids should be included. Incomplete 
residues (e.g. with missing side chain atoms) can distort many calculations so 
they must not be included in validation databases.
There are many other possible criteria like chain length, average B- 
factors, occupancy, and hetero compounds. Any database created with the 
parameters above may still be significantly biased. It is very important that 
the database is filtered resulting in minimal pairwise sequence identity. To 
ensure that data redundancy does not bias the statistics, individual proteins 
in the database should only have low levels of mutual sequence identity. 
WHAT_CHECK uses a cut-off of 30%. Table 2.4 shows the resolution cut-off 
that can be used to create a database of more than 500 non-redundant PDB
54
entries over the years. At the current rate (assuming exponential growth of 
the PDB) we can make a 1Ä database in 2011.
Table 2.4: Date at which a non-redundant, 500 entry database was available for different 
resolutions
Resolution cut-off (A) Date
1.8 October 2002
1.7 December 2003
1.6 March 2004
1.5 June 2005
1.0 2011a
a At current rate of growth of the number of 1.0Ä (or better) entries in the PDB
When updating a database to a new version, there is a final criterion that is 
as important as it is straightforward: any new structure in the database 
should have passed the validation based on the previous version of the 
database. Because of the steady growth of the PDB, databases can be updated 
at regular intervals resulting in a good representation of our current 
knowledge. This keeps the so-called living tests alive.
2.3.3. Errors over the years
In 1996 we reported that there were more than 1 million 'errors' in the PDB 
(Hooft et al., 1996a). This was received with scepticism at the time (Jones et 
al., 1996). Surely, those errors must have been caused by the old structures 
in the PDB? Apparently not, as we now see 11.6 million outliers in the 
protein data bank. The number of newly introduced tests does not account 
for that increase alone. Newly submitted structures still contain errors, even 
ones that are easy to detect (Badger & Hendle, 2002).
To see which errors have become less frequent and which errors are 
more common now than they used to be, we have selected a few dead tests 
that are independent of the development of the PDB in terms of average 
quality and resolution (Figure 2.11). From the beginning of the PDB until the 
early nineties the number of deposited structures per year was so small that 
the graphs are quite noisy. However, it is clear that most errors are as old as 
the PDB itself. An interesting exception is errors with non-unique chain 
identifiers which only started occurring in 1990 (Figure 2.11B). This is 
caused by the limitations of the PDB format that only allows a chain identifier 
of one character. The large structures that are now resolved can be so large 
that the number of chains exceeds the number of possible chain identifiers.
55
The advent of modern refinement software in the early nineties had a very 
clear effect when we look at geometrical parameters (Figure 2.11C through 
2.11G). The percentage of PDB entries with these geometry errors has 
declined significantly in the last ten years. Errors regarding parameters that 
are not refined (Figure 2.11A and 2.11B) have been reasonably steady in the 
same period. It is surprising that the number of PDB entries with non­
hydrogen-bonded water molecules is slowly increasing even though proper 
validation of hydrogen bonds has been available for many years (Figure 
2.11H; Hooft et al., 1996c). We assume that the growth of the average 
number of water molecules per PDB entry surpasses the effect of hydrogen 
bond validation. After all, any structure with a single water molecule that is 
flagged as having no hydrogen bonds, is used to calculate the percentages in 
Figure 2.11H.
In Figure 2.12A we show the development of a few structural 
normality Z-scores, over the last fifteen years. To avoid bias caused by a 
higher fraction of high resolution structures in the last few years, we have 
only taken in account X-ray structures with a resolution between 1.8 and 
2.2Ä.
Side-chain rotamer libraries, which are now commonly used in 
structure building, have had a large effect on the average X1- X2 distribution 
Z-score, whereas backbone libraries, which have also been available for a 
long time, have had a much smaller effect. The average residue packing 
quality, for which no such libraries exist, has stayed stable over the last 
fifteen years. The average quality of the Ramachandran plot has steadily 
increased, showing that the quality of structures in general has indeed risen. 
Figure 2.12B shows how these normality score are a function of resolution. 
This figure shows that there is a good correlation between validation scores 
and the real structure quality, strengthening the conclusions drawn from 
figure 2.12A.
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Figure 2.11: The development of errors over the years. All PDB entries were grouped by year 
of deposition and evaluated by WHAT_CHECK (Hooft et al., 1996a) for eight different dead 
checks. A) Atoms too close to the symmetry axis. B) Chain names not unique. C) Chirality 
deviations. D) Side-chain planarity problems. E) High bond angle deviation. F) Unusual bond 
angles. G) Unusual bond lengths. H) Water molecules without hydrogen bonds. The year of 
deposition is given on the horizontal axis, the percentage of entries with that particular error 
on the vertical axis.
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Figure 2.12: A) The development of four structure quality indicators over the last fifteen 
years for structures with resolution between 1.8 and 2.2Ä. There is a clear improvement of 
quality over time. All structures had at least 100 residues and a maximum of 1000 residues. 
Datasets for were truncated at 100 structures per year. B) The resolution dependence of the 
same four quality indicators. This dependence shows that high-resolution structures perform 
better than low-resolution structures. All structures had at least 100 residues and a maximum 
of 1000 residues. Datasets for every 0.1Ä resolution bin were truncated at 50 structures.
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2.3.4. The future of validation
Over the years we have written software to find errors, funnies, and 
anomalies in PDB files, and we made a website that lists all these 
observations (Hooft et al., 1996a). The previous section shows that these 
validation efforts, and those of several other groups (e.g. Vila et al., 1991; 
Ohlendorf, 1994; Schultze & Feigon, 1997; Hendlich et al., 1990; Gregoret & 
Cohen, 1990; Holm & Sander, 1992; Novotny et al., 1984; Morris et al., 1992; 
Miyazawa & Jernigan, 1996; Bohm & Jaenicke, 1992; Delarue & Koehl, 1995; 
Allain & Varani, 1997; Chung & Subbiah, 1999), combined with all efforts by 
the X-ray and NMR communities to improve the structure determination 
process, are paying off. Structures have been getting better over the last ten 
years. But where should structure validation go from here? We see several 
major validation topics that will help continue the observed trend of getting 
better structures with the progress of time.
The first topic is simply making the existing checks more accurate. 
We warn, for example, for missing C-terminal oxygen atoms. This is an 
important topic for drug design because a C-terminus normally is charged 
and thus influences electrostatic calculations. C-termini are seldom located 
near the active site, but if they are, missing atoms will mean missing 
interactions with the studied ligand. But what if the last residue in the chain 
is not the C-terminus because the real C-terminal residue(s) are too mobile to 
be observed in the electron density map? In that case we issue a warning that 
is not relevant. It will require harmonization of the PDB with UniProt 
(Apweiler et al., 2004) and a lot of artificial intelligence to read the PDB file­
header to resolve this problem. If one day we succeed in doing so, we can 
issue error messages for missing C-terminal oxygen atoms rather than the 
warnings we issue today. The second topic is designing new checks for errors 
that hitherto remained unnoticed.
Alternate atom positions are often observable in high-resolution X- 
ray structures. Information about alternate atom positions is important for 
rational drug design because their presence is a strong indicator for local 
mobility that could modify the shape of the ligand-binding pocket. However, 
a very large number of alternate atom positions are administratively fouled 
up beyond all recognition. Figure 2.13 shows two examples.
The third topic is a better understanding of the physicochemical 
properties of proteins. If we want to call something wrong, we first must 
know what is right. For example, loops often can adjust their conformation to 
accommodate crystal packing. What can we say about these loops? In an 
attempt to better understand this flexibility, we studied inter-molecular 
contacts in covalently identical proteins related by non-crystallographic
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symmetry (NCS). NCS related loops, by definition, have a different structural 
environment but are guaranteed to be crystallized under the same 
conditions.
J i á i
Figure 2.13: Examples of problems with alternate atom administration. A) Asparagine 143 in 
PDB entry 1hj8 has two alternate conformations, labelled A, and B. Due to an administrative 
error, the Osi atoms in the two conformation have been swapped. This results in two 
malformed side chains. B) The same PDB entry but now with the Osi atoms swapped back to 
form two good side chain conformations. C) The sulfate and water molecules in PDB entry 
1gvk occupy the same space as the peptide in D), they are therefore alternates. However, they 
are not administrated as such in the coordinates. Instead, a very thorough explanation is given 
in the entry header which makes human interpretation straightforward. Unfortunately, 
automated processing of this PDB entry is problematic.
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Nobody will be surprised by the observation that residues in loops are more 
often involved in inter-molecular contacts than one would expect from their 
frequency in the protein. It is also not surprising that loops that are involved 
in inter-molecular contacts show on average the largest backbone 
displacements (for penta-peptides in loops, strands and helices the average 
Ca-displacements are 0.42, 0.27, and 0.25Ä respectively). In a data set of 270 
crystal structures with NCS (all solved at better than 2.0Ä resolution) we 
could find only few examples of loops that made contacts in one monomer 
but not in the NCS related one. We looked at all loops in the first monomer of 
the PDB file and compared the contact patterns with the NCS related loops in 
the second monomer. Table 2.5 shows that there is a strong tendency for 
these pairs of loops to both be involved in contacts or to both not be 
involved. Part of this observed relation is caused by the fact that dimers in 
the asymmetric unit prefer to pack in such a way that they are related by an 
internal pseudo two-fold axis. However, table 2.5B, which is based on the 
same data as table2.5A but with the intra asymmetric unit contacts and the 
contacts with ligands neglected shows a similar tendency.
Table 2.5: Comparison of NCS related penta-peptides in loops3____________________________
A: including intra-asymmetric unit contacts
Pep1 makes contacts________Pep2 makes contacts______ Preference parameter
No No 1.75
No Yes -0.83
Yes No -0.83
Yes Yes 0.07
B: not using intra-asymmetric unit contacts
Pep1 makes contacts Pep2 makes contacts Preference parameter
No No 0.73
No Yes -0.88
Yes No -0.90
Yes Yes 0.28
a The dataset contained 8289 penta-peptide pairs. The preference parameters are relative to a 
model in which all peptides have an equal chance of making a contact. Pep1 and Pep2 are NCS 
related penta-peptide pairs. In the top table all contacts are counted, in the bottom table 
contacts with ligands and contacts within the asymmetric unit are excluded. Similar trends are 
observed if only helical, strand, or loop penta-peptides are studied.
There probably exist many possible explanations for this phenomenon. We 
like to think that “certain loops seem predestined to make contacts”, but that 
is not an explanation. The most likely explanation for this predestination is 
the capability to alter their structure, a capability we think is essential for the
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formation of crystals. After all, how big is the chance that any given protein 
would crystallize if it could not adjust its structure to fit well in the crystal? 
We could, however, find no correlation between the RMS deviation between 
pairs of NCS related loops and parameters such as the number of glycines in 
the loop, the end-to-end distance, the internally buried hydrophobic surface, 
the number of salt bridges or hydrogen bonds, or a whole series of other 
parameters.
We went one step further and analyzed the number of contacts made 
by penta-peptides in loops that are involved in crystal contacts. Figure 2.14 
shows on the x-axis the number of contacts made by a penta-peptide, on the 
y-axis the number of contacts made by the NCS related peptide and the 
height of the bars indicates the frequency of occurrence of that event in the 
set of 270 proteins. In this figure we only show those pairs of penta-peptides 
for which the sets of contacted residues overlap for less than 33%. That is, at 
least 2/3 of the contact partners of the one peptide are different from the 
contact partner of the NCS related peptide (contact partners that are related 
by NCS or crystallographic symmetry are considered the same). Figure 2.14 
shows that on top of the already concluded “predestination to make 
contacts” there is an even more mysterious predestination to make roughly 
equally many contacts even when the residues contacted are radically 
different.
If we want to make progress in rational drug design, we must not 
only increase the quality of the protein structures we work with, but we must 
also increase our understanding of those protein structures. What can move, 
and what cannot. Which interactions are favourable and which are not. The 
story about contacts between NCS related molecules is highly confusing, but 
we must figure out what is going on before we can start validating loops that 
make NCS contacts, or any crystallographic contact at all for that matter.
2.4. Conclusion
In macromolecular structures, as in science in general, anything that can go 
wrong will go wrong. Fortunately most problems are intercepted in time. The 
PDB contains a wealth of data for (structural) biologists, biochemists and 
drug designers but there are many pitfalls in using 3D coordinates.
Structure validation is indispensable for the identification of errors in 
protein structures. We have showed a variety of errors and discussed their 
implication for those who use the PDB entries that contain them. Many 
problems can be resolved and even those that cannot are a smaller threat 
when they are identified in time.
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Figure 2.14: Frequency of occurrence versus number of contacts made in pairs of NCS related 
penta-peptides. Every inter-atomic contact is counted, so a pair of large, tightly packed 
residues can easily make 100 contacts. Each bin represents 20 atomic contacts. The bar 
representing 0-20 contacts for both peptides is 677 high and has been truncated for clarity.
The methods used to obtain 3D protein models are still improving. Together 
with validation they have resulted in better structures over the years. 
Unfortunately, several problems are now more common than they used to be. 
A constant effort from all parties in this process is required to maintain this 
overall trend of improving structural data. With the ever increasing thirst for 
protein and nucleic acid structures and the pressure to publish before the 
competitor, the risk of a trade-off between speed and quality exists. We 
believe that the use of validation software throughout the process of 
structure determination can help avoiding this trade-off (Kleywegt & Jones,
1997). By intercepting errors before they can cause problems in the next 
refinement round structures can be solved faster and at the same time more 
reliably.
Validators continue to develop newer and better tools to recognize 
problems in structures, both known errors and newly discovered types of 
errors. Because of the increasing size of the PDB more statistical data is
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available to help this development. We are far away from perfect structures 
but we try to move closer one step at a time. The future will point out how 
big these steps are.
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3.1. Introduction
A small software flaw recently the retraction of a series of high-profile X-ray 
structures (Ma & Chang, 2007; Chang, 2007). Although in this case, the 
inaccurate protein structures were wrong and were promptly retracted, the 
Protein Data Bank (PDB; Berman et al., 2000) still holds other structures that 
either are entirely wrong or are not correct enough to be used for the design 
or explanation of biological experiments.
Hooft et al. (1996) reported one million anomalies in the PDB, and we 
recently detected 10 times as many anomalies in a PDB that is 10 times as 
large. Most of these anomalies are of minor importance, and a small fraction 
are genuine discoveries that warrant further studies. However, a substantial 
number are serious errors.
3.2. Methods
Using today's tools, we can correct many of the erroneous structures, 
provided that the original experimental X-ray data are available. We re­
refined all 1195 PDB files that had a reported resolution of 2.0 Ä and that 
were deposited after 1992 with the use of an experimental data file that 
included an R-free set. The details of the re-refinement procedure, the 
original and re-refined coordinate sets, structure validation reports for the 
original and TLS-refined coordinates, and all R and R-free values are 
available online (PDB_REDO; http://www.cmbi.ru.nl/pdb_redo).
3.3. Results and discussion
The crystallographic community has long been advocating the deposition of 
experimental data. This has resulted in a clear policy by the International 
Union of Crystallography (IUCr; Baker & Saenger, 2000) and many scientific 
journals that the deposition of these data is required before publication. 
Unfortunately, 11% of the macromolecular X-ray structures released in 2006 
lacked the experimental data, and another 4% did not have a properly 
defined R-free set.
The re-refinement results (http://www.cmbi.ru.nl/pdb_redo) show 
that today's software can clearly improve the quality of most structures 
solved in the past. The vast majority of our test set clearly improved in terms 
of R-free and in terms of protein geometry.
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3.4. Conclusion
These results show the benefits of storing experimental x-ray data; these 
data allowed us to keep old protein structures relevant by means of re­
refinement with the use of the latest insights and technologies. In 
anticipation of future improvements in refinement tools, we strongly urge 
journals and scientists to ever more rigorously strive for the deposition of all 
the original experimental X-ray data.
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Abstract
Structural biology, homology modelling, and rational drug design require 
accurate three dimensional macromolecular coordinates. However, the 
coordinates in the Protein Data Bank (PDB) have not all been obtained using 
the latest experimental and computational methods. In this study we present 
a method for automated re-refining existing structure models in the PDB. A 
large scale benchmark with 16807 PDB entries showed that they can be 
improved in terms of fit to the deposited experimental X-ray data as well as 
in terms of geometric quality. Our re-refinement protocol uses TLS models to 
describe concerted atom movement. The resulting structure models are 
made available through the PDB_REDO databank 
(http://www.cmbi.ru.nl/pdb_redo/). Grid computing techniques were used 
to overcome the computational requirements of this endeavour.
4.1. Introduction
The availability of three dimensional macromolecular coordinates is a 
prerequisite for many types of studies, such as engineering protein function 
and stability, understanding the molecular origin of genetic disorders, 
studying intermolecular interactions, etc. For some research fields the 
accuracy of the coordinates is more important than for others. To understand 
whether a single nucleotide polymorphism (SNP) causes an effect that leads 
to a disease, one often only needs to know its location in the protein, while 
the precise rotameric state of the amino acid side chain is of lesser 
importance. In structure based drug design, on the other hand, even small 
inaccuracies in atomic coordinates can have detrimental effects on 
predictions of intermolecular contacts.
Many methods in macromolecular structural bioinformatics are 
parameterized based on known protein structures. For example, if the 
structures that were used to design a force-field are not very accurate, the 
force-field will not be very accurate either. Macromolecular crystallography 
methods have improved a lot in recent years (Kleywegt & Jones, 2002; 
Joosten et al., 2007). The availability of rapidly increasing numbers of 
increasingly accurate protein structures is aiding the method development in 
fields such as drug docking (Nabuurs et al., 2007), molecular dynamics (Hub 
et al., 2007), and homology modelling (Krieger et al., 2004).
Macromolecular structure models are stored and maintained by the 
worldwide Protein Data Bank (wwPDB; Berman et al., 2003). The recent
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remediation of the existing PDB entries by the wwPDB has greatly improved 
the uniformity (Berman et al., 2007). This has made it easier to extract data 
from the PDB in an automated fashion. Despite these efforts, the PDB suffers 
from problems of a fundamental nature (Hooft et al., 1996). It is important 
that users of the PDB realize that they cannot blindly trust the entries. PDB 
entries are structure models that are the result of many iterations of trying to 
optimally explain indirect measurements. Structure validation tools like 
PROCHECK (Laskowski et al., 1993), WHAT_CHECK (Hooft et al., 1996), pdb- 
care (Lütteke & von der Lieth, 2004) and the Electron Density Server (EDS; 
Kleywegt et al., 2004) have shown that the PDB contains many anomalies 
ranging from proteins with small deviations from normal geometry to 
structures that fit their submitted experimental data very poorly. A few 
obvious errors have lead to structure retractions, e.g. the ABC transporters 
(Chang et al., 2006), but the vast majority of structure anomalies remain in 
the databank. When anomalies in structure models are not recognized, this 
can have serious impact on the quality of homology modelling and drug 
design.
It seems that often protein crystallographers lose their interest in a 
structure once it is deposited. This means that the person best suited to 
improve structure coordinates after an error was detected, or after better 
software has become available, is not very likely to actually work on the 
improvement. Therefore, an independent effort is required to try to apply 
new refinement techniques to the available structure models. This study 
shows that such an independent effort is possible. It is obvious that each PDB 
file has been refined with software that was at best state of the art at the 
moment it was published. Our previous studies in the field of NMR have 
shown that the re-refinement of existing PDB entries using methods that 
have improved over time can give significantly better structure models than 
the original ones (Nabuurs et al., 2004). This project has lead to an ongoing 
effort to re-refine all NMR structure models in the PDB for the RECOORD 
database (Nederveen et al., 2005).
We describe here the re-refinement of all X-ray structure models in 
the PDB with resolution higher than 2.70Ä for which suitable experimental 
data is available. The goal of this massive re-refinement project is to develop 
a re-refinement protocol to obtain a better match between the experimental 
data and the atomic parameters (coordinates, temperature factors) in the 
structure models. We use R-free (Brünger, 1992) as a measure of refinement 
progress and WHAT_CHECK as a tool to verify the quality of the coordinates. 
Because one single refinement protocol is used in this study, all the resulting 
structure models form a uniform dataset in terms of refinement. A key 
feature of this protocol is the application of TLS models (Schomaker &
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Trueblood, 1968) that represent the translation, libration, and screw 
displacement of groups of atoms that behave as (quasi) rigid bodies. 
Employing TLS models in the refinement process (Winn et al., 2001) gives 
the benefit of anisotropic B-factor refinement without serious implications 
for the data/parameter ratio of the structure model. Care is taken to respect 
as much of the interpretation of the experimental data by the depositor as 
possible. In other words, alternate atoms are kept, ligands remain unaltered, 
residue types unmodified, etc.
The re-refinement of such a vast number of structure models 
requires enormous amounts of computing power. Grid technology and large 
computer clusters are at present the best ways to get rapid access to vast 
numbers of CPUs for a relatively short period of time. Grid infrastructures 
are collaborative environment sharing large numbers of often heterogeneous 
computing and storage resources distributed geographically. Their objective 
is to provide at any time readily accessible production quality resources. 
Because of the large number of CPUs available, they are ideally suitable for 
so-called 'embarrassingly parallel' applications where computations can be 
easily split into fully independent tasks (Stockinger et al., 2006). The re­
refinement of 16807 PDB files with 16807 independent jobs each requiring 
from 1 to 24 hours of CPU is a very good example of an embarrassingly 
parallel project. The EMBRACE (European Model for Bioinformatics Research 
And Community Education; http://www.embracegrid.info) Virtual 
Organization of the EGEE infrastructure (Enabling Grids for E-sciencE; 
http://public.eu-egee.org) provides European bioinformaticians with 
computers, Grid technology, and the support in terms of software and human 
expertise, needed to perform massive computational projects such as the one 
we describe here.
4.2. Methods
4.2.1. Dataset selection
All X-ray entries in the PDB for which experimental data of 2.70Ä resolution 
or higher was available before February 2007 were considered for re­
refinement (Table 4.1). However, 4082 entries had incomplete experimental 
data files: the '_refln.status' column was either missing or contained no useful 
information (all values were the same). Therefore the original R-free set for 
these entries could not be reproduced, which means that R-free cannot 
readily be used as an independent measure of model quality for these files. 
These incomplete entries were removed from the dataset to avoid bias in the 
results. The resulting dataset consisted of 16807 PDB entries.
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Table 4.1: Dataset selection and re-refinement
PDB entries (January 2007) 41277
X-ray structure models 35003
X-ray + 2.70Ä resolution 29541
X-ray + Experimental data (SF) 20889
X-ray + SF + R-Free set 16877
X-ray + SF + Usable R-free set 16807
Re-refined structure models 15034
Improved structure models 10046
4.2.2. Re-refinement protocol
The re-refinement procedure consists of three steps: data preparation, re­
refinement, and validation of the results. The procedure uses the CCP4 suite 
(Collaborative Computational Project number 4, 1994); most notably Refmac 
(Winn et al., 2001), WHAT_CHECK, and a few dedicated programs. These 
dedicated programs as well as the re-refinement script described below are 
available for download at http://www.cmbi.ru.nl/pdb_redo.
4.2.2.1. Data preparation. We observed many inconsistencies in the 
reflection data files from the PDB that make automated use troublesome. For 
instance, there are several status flag schemes that separate R-free 
reflections from the working set (Table 4.2). In some cases, it was impossible 
to figure out the status flag scheme, e.g. in 1au9 (Pantoliano et al., 1989) 
which was originally refined without R-free. Data columns in reflection files 
do not always contain what is reported, for instance the reflection data file 
for 1gq3 (Beernink et al., to be published) reports phases in the '_refln.status' 
column and 1twi (Rajashankar et al., 2002) has the reported intensities and 
amplitudes swapped. Estimated standard uncertainties for reflections are 
not always reported, or sometimes all the values are the same, e.g. 101m 
(Smith, 1999).
Table 4.2: Status flag schemes for R-free set selection encountered in deposited reflection 
files at the wwPDB
Scheme_________ Working set___________ R-free set___________ Example PDB entry*
1 o f 1aa6 (1dzi)
2 0 1 101m (1a4i)
3 1 -1 1a8d
4 Positive integer 0 1b7d
5 Positive real number 0.00 1c3c
6 1.0 0.0 1a27
* PDB identifiers in parentheses are examples of reversed usage of the scheme
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A program, Cif2cif, was written to reformat the reflection data to a consistent 
format, in which only the essential information was kept. The Cif2cif output 
contains reflection indices (h,k,l), amplitudes (F), estimated standard 
uncertainties values ( g F ) ,  and the R-free flag. When necessary, intensities 
and their sigma values are converted to amplitudes. For consistency reasons, 
the same method as described for the EDS (Kleywegt et al., 2004) was used: 
F = Vi and g F  = g I /  2F. If g F  values are missing from the input file or when 
all values are zero, all sigma values are set to 0.01 to avoid technical 
problems in Refmac.
A second program, Extractor, was written to combine relevant 
information from the experimental reflection data file and the coordinate file. 
These data included reported resolution and R-factors, the resolution range 
of the experimental data, cell dimensions, and the TLS groups used in the 
original refinement. In cases where TLS was not used in refinement or where 
the TLS groups were not reported, they were defined as one single group per 
protein or nucleic acid chain.
The structure factor files were converted to MTZ format (a standard 
used in the CCP4 suite) and used to recalculate R and R-free with Refmac 
using default settings. When needed, ligand topologies were automatically 
created by Refmac.
4.2.2.2. Re-refinement. Three types of re-refinement of increasing 
sophistication were used consecutively. Unless mentioned otherwise, default 
Refmac parameters as used in the CCP4 graphical user interface CCP4i, were 
applied. Two key exceptions were made: carbohydrate links were only used 
if they were described in the PDB file and anisotropic temperature factors 
were refined if ANISOU records were provided.
First, the structure models were subjected to 10 cycles of rigid-body 
refinement. This was needed for a small number of structures that gave large 
deviations between the recalculated R-free and the value from the PDB 
header due to a rotation or translation of the coordinates with respect to the 
electron density, for instance PDB entry 1akv (McCarthy et al., 2002). As a 
side-effect of rigid-body refinement, Refmac removed all explicit hydrogen 
atoms.
The rigid-body refined structures were subjected to 20 cycles of 
restrained refinement, changing only the weight of the X-ray terms with 
respect to the geometric and temperature factor restraints. Seven different 
weights were used: 1.00, 0.70, 0.50, 0.30, 0.10, 0.05, and 0.01. No non- 
crystallographic symmetry (NCS) restraints were used (see the 'Results and 
discussion' section).
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TLS refinement was performed on the rigid-body refined structures. Ten 
cycles of TLS refinement were performed followed by 20 cycles of restrained 
refinement, changing only the weight of the X-ray terms.
The re-refinement resulted in 15 models for each PDB entry: one 
rigid-body refined structure model, seven structure models that were 
obtained through restrained refinement with TLS and seven models through 
restrained refinement without TLS.
4.2.2.3. Selection and validation. For both the set of re-refined structure 
models with TLS and the set without TLS, the best out of seven structure 
models was selected. The following criteria were used:
1. All models with a root mean-square deviation from ideal in the bond 
angles over 3.0o were rejected.
2. Models with a difference between R and R-free over 0.05, i.e. 5 
percentage points, were rejected. This rule was relaxed in cases 
where the difference between the recalculated R and R-free prior to 
re-refinement was also greater than 0.05. In those cases the 
requirement was that the difference was less than or equal to the 
initial difference.
3. The model with the lowest R-free was selected from the remaining 
candidates. In the few cases with two or more models with the same 
R-free (up to three decimal places), the one with the smallest 
difference between R and R-free was selected.
4. In case the R-free of the optimal model was higher than that of the 
rigid-body refined model, that is, when the structure model became 
worse as a result of re-refinement, all re-refined models were 
rejected and the rigid-body refined structure model was kept.
The best TLS refined structure model was analyzed with WHAT_CHECK. The 
structural Z-scores were compared with the values reported in the 
PDBREPORT databank for the original structure model. To ensure that all Z- 
scores were calculated with the same version of WHAT_CHECK, the entire 
PDBREPORT databank was recalculated for this project.
4.2.3. Grid implementation
The re-refinements of the structure models were done on hybrid computing 
environment consisting of two Virtual Organisations (Biomed and 
EMBRACE) of the EGEE Grid infrastructure and several clusters of EMBRACE- 
associated bioinformatics institutes in Europe. The infrastructure and 
especially the EMBRACE and biomed virtual organisations provided Grid
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computing resources while SIB (www.isb-sib.ch), IBCP (gbio-pbil.ibcp.fr), 
and UPPMAX/SNIC (www2.uppmax.uu.se) provided additional computing 
resources on clusters. Each Grid job consisted of 20 proteins that would run 
for approximately 20 hours and were managed using the WISDOM 
production environment (Lee et al., 2006; Jacq et al., 2007). The maximum 
allowed runtime was 72 for each job.
4.3. Results and discussion
4.3.1. Re-refined structure models
On a single CPU, the entire calculations would have taken about 17 years. 
With our Grid and cluster computing approach more than 90% of the total 
calculation was finished in only two months - this shows the clear time 
advantage due to the usage of modern computing technology. All 16807 re­
refinements were complete after 4 months; the vast majority was already 
done after three weeks. The time delays were caused by problems at two of 
the Grid nodes. As this was just as much a proof of concept for Grid 
computing as for re-refinement, we decided not to use one of the available 
supercomputers to finish the whole job quickly.
After filtering for obvious outliers, 15034 sets of re-refined structure models 
were obtained (Table 4.1). The majority of entries that could not be re­
refined had problems with atom names in non-protein and non-nucleic acid 
compounds. Some of these compounds suffered from a lack of uniformity 
that made it impossible to use the existing topology files supplied with the 
CCP4 package. Most of these problems have been solved by the remediation 
of the PDB (Henrick et al., 2008), which was completed six months after the 
start of our project. The affected PDB entries will be redone in future re­
refinements. Some other problems in the re-refinement were caused by size 
constraints in Refmac and time constraints on certain Grid nodes.
4.3.2. Improved structure models
4.3.2.1. Change in R-factors. In the majority of cases, recalculation of R(- 
free) resulted in slightly higher values than the values extracted from the 
PDB header (Figure 4.1). High resolution structure models are affected more 
than low resolution structure models. Many reasons for these deviations 
have been discussed previously by Kleywegt et al. (2004). Higher than
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expected values for R(-free) can, for example, occur because all experimental 
data were used in this study without resolution or signal-to-noise cut-offs, 
whereas the depositor may not have used all the high and low resolution 
reflections. Some extra complications were introduced by the R-free set. 
Deposition of experimental data with the wrong R-free set will cause a 
recalculated R-free value that is too low. The same happens when the R-free 
set was included in the final rounds of refinement before the structure model 
was deposited.
(Recalculated) R-free vs. resolution
30% ---------------------------------------------------------
23% -
26% --------------------------------------------------
24%
14% --
1.0 1.5 2.0 2.5
Resolution (A)
Figure 4.1: R-free values extracted from the PDB header (diamonds) and values recalculated 
with Refmac (Winn et al., 2001) using the deposited experimental data (squares) plotted 
against the experimental data resolution. The values are averages for all structure models in 
0.1Ä bins. The recalculated R values (not shown) follow the same pattern.
Subtle differences in the recalculated R(-free) can also be caused by the 
conversion of reflection intensities to amplitudes. Several methods exist, but 
the method in the CCP4 program Truncate (French & Wilson, 1978) is used 
most frequently. This method will be implemented in the re-refinement 
protocol.
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Different solvent models may be used in refinement, resulting in different 
R(-free) values. Especially at high resolution more sophisticated solvent 
models than the default model in Refmac may be used. Unfortunately, the 
applied solvent model cannot always be extracted from the PDB header. We 
are working on a method to circumvent this issue in the next refinement run.
The different ways in which the results of refinement with TLS 
models are deposited is more problematic. TLS tensors may be stored in the 
PDB header, but can also be added to individual (anisotropic) temperature 
factors. Lack of uniformity in the PDB means that no single method can be 
used to reliably recalculate R(-free) when a deposited structure was refined 
with TLS models. For future calculations, we have adapted our re-refinement 
protocol to include several approaches for dealing with TLS and anisotropic 
temperature factors.
Because the TLS tensors and the temperature factors are recalculated 
in the re-refinement, the final structure models are not affected by this issue.
The largest deviations in the recalculated R(-free) values are the 
result of rotations and translations of the structure model with respect to the 
electron density. Rigid-body refinement was used to correct this. In total 106 
structure models with very large deviations (well over 10% in R-free) 
benefited from this approach, other structures had small change in R(-free) 
or remained unaffected. Because only a small set of all evaluated PDB entries 
benefitted from this rigid-body refinement, the re-refinement protocol was 
adapted to, in future calculations, only perform rigid-body refinement when 
R-(free) cannot be reproduced to within 5% from the value extracted from 
the PDB header.
Restrained refinement with TLS models gave a substantial 
improvement in terms of R-free (Figure 4.2). A total of 10046 structure 
models (67%) had a lower R-free than reported in the PDB header (Table 
4.1). Restrained refinement without TLS had less effect: only 8012 structure 
models (53%) had a lower R-free than reported in the PDB header and the 
improvement was typically very small (Figure 4.2).
4.3.2.2. Structure quality validation. The results in the previous section 
could lead to the conclusion that the R(-free) improvement is mostly the 
result of the TLS parameterization and no significant change of the atomic 
coordinates occurred. To exclude this possibility, we performed a full 
structure validation with WHAT_CHECK of the original PDB entry and the 
optimal TLS-refined structure model to see the effect the re-refinement had 
on the coordinates. Validation is also needed to ensure that the observed 
improvements in R(-free) did not come at the cost of poorer geometry.
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R-free vs. resolution
30% ----
28%
14% ---------------------------------------------------
1.0 1.5 2.0 2.5
Resolution (Â)
Figure 4.2: R-free values extracted from the PDB header (diamonds) and values obtained 
after re-refinement in Refmac (Winn et al., 2001) with TLS models (squares) plotted against 
the experimental data resolution. The values are averages for all structure models in 0.1Ä bins. 
The effect of the TLS parameterization is clearly shown by the results of the re-refinement 
without TLS models (dotted line). For all but the highest resolution bins, refinement with TLS 
gives lower average R-free values.
The WHAT_CHECK software provides a series of quality scores based on 
comparison with a set of about 500 PDB entries with a resolution of 1.4Ä or 
better. A comparison gives rise to a so-called Z-score. This score expresses 
the difference between the structure model and the test set as the number of 
standard deviations from the mean. A positive Z-score means that a structure 
model is better than the average of the test set. Among the different values 
that are calculated, the Ramachandran Z-score has often proven to be the 
best estimator of the geometric quality of a protein structure model 
(Laskowski et al., 1993; Hooft et al., 1997).
In Figure 4.3, the Ramachandran Z-score before and after re­
refinement is plotted against the resolution. There is a clear improvement of 
this quality score over the entire resolution range which shows that the 
improvement in terms of R(-free) are backed by improved coordinates.
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WHAT_CHECK Z-scores for packing, side chain rotamer normality, and 
backbone normality were also evaluated but showed no significant 
improvement as a result of re-refinement. This can be expected since these 
scores are looking at atom arrangements in the medium resolution range (1 
to 5 Angstrom); changes to the structure model of this magnitude are 
unlikely with our current automated re-refinement protocol. Typical atomic 
shifts are in the order of tenths of Angstroms.
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Figure 4.3: WHAT_CHECK Ramachandran plot appearance Z-scores (Hooft et al., 1997) for 
original (diamonds) and TLS refined structure models (squares) as function of resolution. The 
values are averages for all structure models in 0.1Ä bins.
Another quality estimator is the average number of atomic overlaps or 
bumps. Like the Ramachandran Z-score, this estimator is sensitive to small 
changes in the atomic coordinates. Figure 4.4 shows that re-refinement 
reduces the number of bumps for structure models over a wide resolution 
range.
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The WHAT_CHECK validation reports showed many anomalies in the 
structure models both before and after re-refinement. Interpreting and, 
where possible, resolving these anomalies in an automated fashion will be 
subject of further studies (Joosten et al., 2009).
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Figure 4.4: Atomic overlaps (bumps) per structure model as detected by WHAT_CHECK for 
original (diamonds) and TLS refined structure models (squares) as function of resolution. The 
values are averages for all structure models in 0.1Ä bins.
4.3.2.3. The use of geometric restraints. In X-ray refinement one of the
important parameters is the relative weight of experimental X-ray terms and 
geometric restraints. T oo much weight on the restraints results in structure 
models that sub-optimally describe the 'real' structure of a protein by hiding 
real bond length (and angle) deviations at important parts of the protein, e.g. 
the active site. Too little weight may result in structure models in distorted 
geometry. In effect, restraints should be kept as tight as necessary, but as 
loose as possible (Kleywegt & Jones, 1995).
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This implies that the optimal restraint weight is resolution dependent: the 
higher the resolution, the weaker the restraints. The variation of the optimal 
restraint weights we found for each of the structures supports this, but the 
correlation between resolution and restraint weight is very weak. As a result, 
it is not possible to predict the optimal restraint weight.
Because our re-refinement protocol is aimed at lowering R(-free) 
without strict bond length and bond angle rmsD targets (the 3.0o cut-off on 
bond angle rmsD is very liberal), the geometric deviations calculated from 
the re-refined structure models (Figure 4.5 and 4.6) are less biased than the 
values extracted from the original PDB entries. Here, the root mean square Z- 
scores (rmsZ) are used as a measure of deviation from ideal instead of the 
rmsD, because Z-scores reflect the different standard deviations for the ideal 
bond lengths and angles in the work of Engh & Huber (1991).
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Figure 4.5: Bond length root mean square Z-score per structure model as calculated by 
WHAT_CHECK for original (diamonds) and TLS refined structure models (squares) as function 
of resolution. The values are averages for all structure models in 0.1Ä bins.
For example, 0.01Ä deviations from ideal bond length between the Ca and Cß 
and the Côi and Csi of phenylalanine are treated the same with rmsD, 
whereas rmsZ acknowledges the difference between the two bond types. The 
latest version of Refmac, which was made available after we started our re­
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refinement, reports both rmsD and rmsZ. We have updated our protocol to 
use an rmsZ of 1.0 as a cut-off for the bond lengths and angles.
Bond angle rmsZ vs. resolution
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Figure 4.6: Bond angle root mean square Z-score per structure model as calculated by 
WHAT_CHECK for original (diamonds) and TLS refined structure models (squares) as function 
of resolution. The values are averages for all structure models in 0.1Ä bins.
An rmsZ value greater than unity means that the bond angle deviation is 
larger than what can be expected based on the standard deviations in the 
restraint dictionary.
For re-refined structure models with a resolution of 1.7Ä or lower, 
there is clear resolution dependence for the average bond length rmsZ: lower 
resolution structures typically have a lower rmsZ (Figure 4.5). The rmsZ 
value is expected to fall to zero at around 3Ä (about twice the average bond 
length, i.e. about 1.5Ä), because data of resolution d cannot contain 
information about interatomic distances less than d/2 (Tronrud, 2008). This 
is not observed here because only one important parameter for refinement, 
the relative weight of experimental X-ray terms and geometric restraints, 
was optimized in this study. Another key parameter for refinement, the 
relative weight of the temperature factors and the X-ray terms, will be 
subject of future experiments. The original PDB files do not show a clear 
decrease of rmsZ with decreasing resolution, but a constant value for
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structure models of 1.8Ä resolution or lower. This implies that a specific 
rmsD (or rmsZ) target was used with little attention to the X-ray resolution. 
The bond angle rmsZ values follow the same pattern, but the difference 
between the re-refined and original structure models is much smaller.
At resolutions higher than 1.7Ä the rmsZ goes up with increasing 
resolution for both bond lengths and angles in the original PDB entries. The 
re-refined structures do not follow this pattern. This is caused by the 
restraint settings used in our protocol: the highest setting (1.00) was still too 
low for some of the high resolution structure models. This resulted in fewer 
structures that improved in terms of R(-free) than possible and unexpected 
geometric rmsZ values. Our protocol was adapted to allow looser restraints 
at high resolution.
On average, atomic resolution structure models, 1.2Ä or higher 
(Sheldrick, 1990), in the PDB have bond angle rmsZ values greater than 1.0. 
This is surprising because this means that the bond angle deviations are 
larger than what is to be expected based on the Engh and Huber parameters. 
This may be caused by the implementation of bond angle restraints in 
ShelX(L) (Sheldrick & Schneider, 1997) which is commonly used at atomic 
resolution. The bond angles are restrained as 1-3 distances instead of actual 
angles. This approach is valid when the bond lengths are close to ideal, but 
this is not necessarily the case for refinement at high resolution. A different 
reason for these deviations to appear at atomic resolution structures should 
also be considered: there is some context dependent variation in main chain 
bond angles (Karplus, 1996). This variation may be underestimated by the 
Engh and Huber parameters because they are based on monomer and dimer 
small molecule models that do not contain a macromolecular context. Only at 
atomic resolution is it possible to trust the experimental data enough to let 
such large deviations from the Engh and Huber parameters appear during 
refinement.
4.3.2.4. Resolution dependence. Figure 4.2 shows that R-free for the 
TLS refined structure models of 1.3Ä resolution or higher is higher than the 
value extracted from the PDB header. This is caused by the problems with 
reproducing the R-free value extracted from the PDB header (Figure 4.1). 
When the recalculated R-free values are compared with values obtained for 
the TLS refined structure models, it becomes clear that our re-refinement 
protocol works over the entire resolution range up to 2.7Ä. Notwithstanding, 
the method is indeed less successful at (near) atomic resolution than at lower 
resolutions. As discussed in the previous subsection, the restraint weights 
are probably the most important refinement parameter involved. The solvent
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model and the refinement of anisotropic temperature factors may also 
improve the success rate of the refinement protocol.
Geometric quality in terms of Ramachandran Z-score or atomic 
overlaps (Figures 4.3 and 4.4) shows greater improvements with decreasing 
resolution. This is not surprising because the lower resolution structure 
models have more room for improvement. Real-space intervention is needed 
to improve these results.
PDB entries with resolutions lower than 2.7Ä were not considered in 
this study. At this resolution non-crystallographic symmetry (NCS) restraints 
become invaluable (Morris et al., 2007). Unfortunately, NCS group definitions 
used in the original cannot be extracted from the PDB reliably. The relative 
weights of the NCS restraints are even harder to obtain. Redefining NCS 
groups and finding appropriate restraint weights based on the coordinates 
deposited in the PDB is not reliable: in the original refinement NCS may have 
been severely over- or underrestrained, which biases any NCS 
parameterization. The only alternative is a full NCS parameter optimization 
during the re-refinement. This was, at the start of our study, a very 
computationally intensive and lengthy process because it would involve a 
trial-and-error process. Fortunately, new automated methods have arisen 
that will greatly speed up the parameterization process (Smart et al., 2008). 
Integration of this autoNCS method in the re-refinement protocol will allow 
for reliable re-refinement of structure models with NCS at resolutions lower 
than 2.7Ä. Preliminary test with structure models without NCS show 
promising re-refinement results. Of course, at very low resolution our 
current method with refinement in cartesian space becomes unsuitable and a 
method with torsion space refinement must be implemented.
4.3.2.5. Old PDB entries versus new. Structure model quality, in terms 
of fit to the experimental data and in terms of geometry, has increased over 
time as new refinement methods arose (Kleywegt & Jones, 2002; Joosten et 
al., 2007). It is to be expected that older structure models benefit more from 
re-refinement than newer structure models. The percentage of improved 
structure models plotted against the year of deposition supports this (Figure 
4.7). About 90% of the structure models deposited in 1995 to 1997 could be 
improved in terms of R-free. This percentage drops to just over 60% for 
structure models deposited in 2004 to 2006. These results show that the 
benefit of re-refinement is not limited to older structure models. Even 60% of 
recently deposited structure models can be improved upon re-refinement. It 
must be noted however that the average improvement in terms of R(-free) is 
smaller for recent structures than for structures deposited 10 years ago.
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The improvement of structure models previously refined with TLS show no 
clear trend over the years (Figure 4.7). TLS refinement may be too new to 
provide proper statistics at this point: for 2006, only 27% of all structure 
models were refined with TLS. The fraction of improved structure models 
varies between a fifth and a third. This success rate may be lower, but it 
remains clear that re-refinement is worthwhile for a large number of 
structure models. The success rate may be increased by re-evaluation of TLS 
group definitions.
Figure 4.7: Percentage of structure models that improve in terms of R-free after TLS 
refinement plotted as a function of the year of deposition. The percentage of all evaluated 
structures (diamonds) decreases from 90% for 1995 to 62% for 2006. The percentage of 
structures previously refined with TLS (squares) varies between 21% and 32%.
4.4. Website
The re-refinement protocol and the re-refined structure models are available 
from http://www.cmbi.ru.nl/pdb_redo/. Each entry has a web page with a 
summary of the R-factors after consecutive steps of re-refinement, a 
comparison between the WHAT_CHECK Z-scores before and after re-
88
refinement, and information about the unit cell and structure factors. A 
compressed file with the structure models for each re-refinement step is 
provided. This file also contains an MTZ file for each structure model that can 
be used to generate electron density maps. Links to the full WHAT_CHECK 
validation reports as well as links to relevant external databases, like EDS 
and PDBsum (Laskowski et al., 2005), are provided. Entries that are missing 
because our re-refinement procedure can (currently) not deal with the 
original PDB files are annotated in our new WHY_NOT server: 
http://www.cmbi.ru.nl/whynot/.
It should be noted that over the course of this project we encountered 
numerous problematic cases. One example is structure models for which the 
amplitudes in the submitted experimental data are inconsistent with the 
intensities in the same experimental data file. In such cases, both amplitudes 
and intensities have to be evaluated to see which set is correct. We are 
presently evaluating all files and validation reports to find ways to 
circumvent these problems, but the number of things that can go wrong is 
large, so this will be very time consuming.
4.5. Applications
Re-refined structure models can, like the original ones, be used for drug 
design, molecular dynamics, structural biology, and homology modeling. 
However, the structure model is not the only product of the re-refinement. 
An improved X-ray model gives rise to improved electron density maps. 
These can be used to (manually) inspect and solve problems recognized by 
validation software like WHAT_CHECK. This can lead to further improvement 
of both geometric quality and fit to the experimental data. The results of this 
validation and real-space intervention effort are discussed elsewhere 
(Joosten et al., 2009).
Re-refinement itself is a valuable means of testing refinement 
software. This does not only apply to Refmac: the development teams behind 
Phenix and BUSTER-TNT also regularly re-refine existing PDB entries to test 
their software and to understand the refinement problems that may occur 
(Adams 2009; Joosten et al., 2009).
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4.6. Future work
In this first complete re-refinement of the all PDB files of 2.7Ä resolution or 
higher, the interpretation of the original depositors regarding amino acid 
sequence, alternate atoms, atomic occupancies, hetero compounds, water 
molecules, etc., were left unaltered. We have started working on re­
refinement protocol without these constraints. Refitting of atoms to the 
electron density maps and error fixing based on WHAT_CHECK reports will 
be included. This will be an even larger effort that will require some new 
concepts, a lot of artificial intelligence and probably more than twice as much 
CPU time.
In our current work we have only evaluated PDB entries for which 
complete experimental data was available. Entries without a deposited R- 
free set were left out because any newly selected R-free set is not an 
independent measure of model quality. Eventually, these will be added too 
using an adapted re-refinement procedure to (partially) compensate for the 
bias introduced by the newly selected R-free sets.
The TLS group assignments used in this work were very effective 
already but can be improved. Preliminary tests have shown that some 
structures that cannot be improved with our current TLS model can be 
improved using more sophisticated TLS group assignments like the ones 
from TLSMD (Painter & Merritt, 2006). At the moment, creating TLSMD 
groups is still computationally too expensive; we are working on a faster 
method.
There are, of course, many other issues to be resolved for fully 
automated re-refinement, both in the selection of the optimal result and in 
the parameterization of the refinement. The selection of the optimal re­
refined structure model in this work was based on R-free. New versions of 
Refmac report the (log) free likelihood which is a more appropriate target for 
optimization (Bricogne, 1997; Tickle, 2007). The refinement protocol has 
been updated to reflect this. The difference between R and R-free was used 
as a measure for overrefinement. The applied cut-off of 0.05 as maximum 
allowed difference is, although frequently used, rather arbitrary. A better 
method to check for overrefinement, which uses the ratio R-free/R, was 
described by Tickle et al. (1998). An adapted version of this method that uses 
R-free Z-scores has been added to the model selection step of our refinement 
method.
As mentioned before, optimizing the temperature factor restraint 
weights in the re-refinement may lead to better results. The Refmac setting 
for these weights are by default not shown in the CCP4 graphical user 
interface and good results can be obtained with the default settings. It is
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therefore likely that these settings are not always optimized. It has been 
shown that optimizing the Refmac temperature factor restraints can lead to 
improved refinement results (Tickle, 2007).
Also, refinement software continuously improves. For example, 
automatic NCS group optimization was recently made available and the latest 
version of Refmac can deal with twinned datasets without user interaction. 
These and other software improvements may not solve all problems, but 
they can make automated (re-)refinement methods a little better. We will 
continue to update our protocol to benefit from newly developed methods. 
The re-refinement protocol used here must therefore be seen as a starting 
point for further development, not as an attempt to build an alternative PDB.
4.7. Conclusion
We have presented and thoroughly tested a re-refinement protocol for X-ray 
structure models that works at a wide resolution range. By employing 
methods like TLS refinement, 10046 out of 15034 structure models (67%) 
are improved in terms of R-free. The geometric quality of the structure 
models, expressed as WHAT_CHECK's Ramachandran Z-score, also increases. 
Both old and recently deposited PDB files can benefit from re-refinement.
These results show that re-refinement of existing PDB entries is 
worthwhile and because the method is fully automated, little time 
investment needed to re-refine a single structure model. We now routinely 
re-refine PDB entries before they are used for molecular dynamics, homology 
modeling or drug design.
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Chapter 4.A
New protein structures replace the
old
Katherine Sanderson
Nature (2009), 459:1038-1039 
A Nature news article in recognition o f the success of the PDB_REDO project
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Dutch software to weed out errors in Protein Data
Bank
Protein structures are getting regular makeovers with the help of 're­
refinement' software developed by Dutch structural biologists.
The Protein Data Bank (PDB) holds nearly 53,000 three-dimensional 
structures of protein molecules and nucleic acids that have mainly been 
deciphered through X-ray crystallography. Most journals, including Nature, 
require such data to be deposited in the PDB if a paper with a protein 
structure is to be published.
But some structures are not as accurate as they could be. The data 
bank began in 1971, and the ability to analyse crystallographic data has 
improved dramatically since then.
"There are definitely errors in the PDB," says crystallographer Nenad 
Ban at the Swiss Federal Institute of Technology Zurich.
This has consequences for 
scientists who want to use the 
PDB to look for sites on proteins 
to target with small-molecule 
drugs, or to feed the data into 
molecular dynamics simulations. 
More profoundly, a wrong 
structure in the data bank could 
also trigger wrong ideas about 
how the protein works.
Figure 4.a1: Human papilloma virus protein.
To help, Gert Vriend at Radboud University Medical Centre in Nijmegen, the 
Netherlands, and his colleagues are writing software that they hope will 
eventually automatically re-refine, at the click of a mouse, all the data 
deposited in the PDB.
So far, Vriend has gone through 38,000 data files with his PDB_REDO 
program. Earlier this year, he published the initial results of work on 16,807 
files (R. P. Joosten et al. J. Appl. Crystallogr. 42, 376-384; 2009); for each he
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produced a new structure based on the old data. Roughly 67% of those new 
structures were better than the original structure as measured by a quantity 
known as R-free, used by crystallographers to determine structure quality. 
The automated program could also decipher other problems caused by 
human error: data deposited with the wrong labels, for example, in which 
intensity of a signal is labelled as amplitude. "If the intensity and amplitude 
are swapped, the structure doesn't make sense," says collaborator Robbie 
Joosten.
Vriend runs his program on all new entries in the PDB every two 
weeks and sends the PDB a monthly report flagging problems. 
Administrators can correct small problems like names of labels being 
swapped; bigger problems are added to an ongoing list of things to fix.
Maintenance for the PDB is spread over three sites: the Research 
Collaboratory for Structural Bioinformatics based at Rutgers University in 
Piscataway, New Jersey; the European Bioinformatics Institute (EBI), in 
Hinxton, UK; and the Japan Science and Technology Agency in Tokyo.
Helen Berman of Rutgers, who runs the US part of the PDB, says that 
the data bank welcomes efforts to improve deposited data. "This is exactly 
the vision we had when we started," she says. Staff at the data bank run a 
standard set of quality checks before depositing a structure and flag any 
problems to the researcher who submitted it, but "we're not the data police". 
The data bank doesn't reject an entry even if its advice on improving a 
structure is ignored.
Vriend occasionally contacts the scientists who deposited data that he 
has refined, with mixed reactions. "Sometimes people are very grateful, and 
sometimes they are insulted," he says.
Occasionally, the program can cause researchers to change 
interpretations of their data. Annalisa Pastore, a molecular biologist at the 
National Institute for Medical Research, London, UK, recalls asking Vriend to 
validate a protein structure she had worked out from her nuclear magnetic 
resonance (NMR) data. Vriend told her she had got it wrong, and she took a 
closer look. It turned out that she wasn't wrong, but that she had uncovered a 
histidine residue that was unusually buried within the protein. "Gert 
correctly focused our attention to this residue," she says. "In the end we 
could definitely say the structure was right."
Pastore says researchers might be more careful about submitting 
their structures to the data bank if they think re-refinement software might 
be checking up on it.
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Vriend is not the only one looking at data-bank quality. At the Lawrence 
Berkeley National Laboratory in California, computational biologist Paul 
Adams is testing the PHENIX crystallography software he develops on PDB 
data before sharing the software with other academics or licensing it to 
companies. "We [want to] make sure the software we are giving to people 
can do the right thing," he says. Adams doesn't make his results public, but 
says he has noticed that his software often improves an original structure 
assignment.
Vriend hopes his re-refinement software will eventually be linked to the PDB 
so that a user could click through from the data bank to obtain the most up- 
to-date protein structure. Gerard Kleywegt, who took over the European PDB 
operations at the EBI late last month, says that this will probably be 
implemented at some point.
Even so, the software is not sophisticated enough to automatically fix 
problems that are more than cosmetic, Kleywegt says. More serious 
problems, such as amino-acid side chains that have been assigned to the 
wrong location, require manual intervention. "I see this as a first step," he 
says.
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Chapter 5
Re-refinement from deposited X- 
ray data can deliver improved 
models for most PDB entries
Robbie P. Joosten, Thomas Womack, Gert Vriend, Gérard
Bricogne
Acta crystallographica (2009), D65:176-185
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Abstract
The deposition of X-ray data along with the customary structural models 
defining PDB entries makes it possible to apply large-scale re-refinement 
protocols to those entries, thus giving users the benefit of improvements in 
X-ray methods that have occurred since each structure was deposited. 
Automated gradient refinement is an effective method to achieve this goal, 
but real-space intervention is most often required to adequately address 
problems detected by structure validation software. In order to improve our 
existing protocol, we combined automated re-refinement with structure 
validation and difference-density peak analysis to produce a catalog of 
problems in PDB entries that are amenable to automatic correction. We show 
that re-refinement can be effective in producing improvements - often 
associated with the systematic use of the TLS parameterization of B-factors - 
even for relatively new and high-resolution PDB entries; while the 
accompanying manual or semi-manual map analysis and fitting steps show 
good prospects for eventual automation. We propose that the potential for 
simultaneous improvements in methods and in re-refinement results be 
further encouraged by broadening the scope of depositions to include 
refinement meta-data and, ultimately, primary rather than reduced X-ray 
data.
5.1. Introduction
The availability of three-dimensional macromolecular coordinates is a 
prerequisite for many types of studies, such as engineering protein function 
and stability, understanding the molecular origin of genetic disorders, 
studying intermolecular interactions, and designing new drugs, to name only 
a few. For some of these research fields the accuracy of the coordinates is 
more important than for others. For example, understanding whether a 
single nucleotide polymorphism (SNP) causes an effect that leads to a disease 
often only requires the knowledge of its location in the protein. On the other 
hand, even small inaccuracies in atomic coordinates can have detrimental 
effects on predictions of intermolecular contacts in structure-based drug 
design and on numerous other methods in macromolecular structural 
bioinformatics that are parameterized on the basis of known protein 
structures. For example, if the structures that are used to design a docking 
force-field are not very accurate, the force-field will not be very accurate, and 
thus docking calculations based on it will be of limited usefulness.
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The methods of macromolecular crystallography have improved a great deal 
in recent years e.g. Kleywegt & Jones (2002). The rapidly growing numbers of 
increasingly accurate protein structures are aiding methods development in 
such fields as drug docking (Nabuurs et al., 2007), molecular dynamics (Hub 
et al., 2007), and homology modelling (Krieger et al., 2004).
It is a truism that every deposited structure has been refined with 
software that was, at best, state of the art at the time of deposition, and that 
the software itself may not have been used in an optimal manner. It was 
therefore no big surprise when previous studies in the field of NMR showed 
that the re-refinement of existing protein structures using methods that have 
improved since their deposition can give significantly better structure 
models than the original ones (Nabuurs et al., 2004). We have developed a 
fully automated re-refinement protocol to achieve similar results with 
structures solved by macromolecular X-ray crystallography (Joosten & 
Vriend, 2007). Although this automated re-refinement gives useful results, 
we continue in this paper to seek further improvements and propose 
enlarging the scope of what should ideally be deposited.
Validation software used at the Protein Data Bank (Berman e t al., 
2000) reports numerous outliers in protein geometry and backbone torsion 
angles. Other potential problems are recorded in external validation sites like 
PDBREPORT (Hooft et al., 1996) or the Electron Density Server (Kleywegt et 
al., 2004). Re-refinement of PDB entries may reduce the number of outliers 
and improve the fit to the experimental data in terms of R and R-free, but 
large problems cannot be fixed by automated gradient refinement alone. 
Fortunately, such re-refinement procedures also produce new electron- 
density and difference-density maps that can be used to manually (and in the 
future, hopefully, also automatically) identify and remedy the remaining 
problems.
In this study we combined automated re-refinement with validation 
methods in order to make a catalog of problems in PDB entries that are 
amenable to automatic correction. For this purpose we have applied to five 
selected PDB entries the PDB-redo protocol (Joosten & Vriend, 2007) (with 
which we had previously performed a re-refinement of 1195 PDB files for 
which adequate experimental X-ray data to a resolution of 2.00Ä were 
available) followed by manual real-space intervention based on the results of 
structure validation routines in WHAT_CHECK (Hooft et al., 1996), Coot 
(Emsley & Cowtan, 2004), and pdb-care (Lütteke & von der Lieth, 2004). An 
overview of an independent and complementary activity of monitoring most 
new PDB depositions since July 2007 for possible model improvements on 
the basis of electron-density maps and difference maps, using the 
autoBUSTER software suite (Bricogne et al., 2008), is presented in §5.6.
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The results of both studies show that there is great potential for 
improvement of X-ray structures, especially with the continuously improving 
software tools available. As long as crystallographers keep faithfully 
depositing their experimental data and critical details of their refinement 
procedures, the PDB files of X-ray structures can be improved from year to 
year, thereby strengthening the basis of structural biology and 
bioinformatics research.
5.2. Methods
5.2.1. T est case selection
Five PDB entries were selected because they were important in our current 
homology modelling projects, have medium to high resolution reflection data 
(ranging from 1.45Ä - 1.94Ä) that includes an R-free test set, and were 
recent additions to the PDB. These were: 1lf2 (Asojo et al., 2002), 1zcs 
(Thapper et al., 2007), 2ete (Opaleye et al., 2006), 2qc1 (Dellisanti et al., 
2007), and 2vno (Gregg et al., 2008).
It must be stated strongly at the outset that these five files were by no 
means singled out because they were particularly good or bad. They are just 
examples from a very large group of PDB entries that triggered one of the 
'this can be improved' diagnostics in one of the validation programs and that 
we recently needed as templates for in-house projects.
5.2.2. Automated re-refinement
5.2.2.1. Software. The automated re-refinement procedure uses the CCP4 
suite (Collaborative Computational Project, number 4, 1994), most notably 
Refmac (Murshudov at al., 1997), WHAT_CHECK, and a few dedicated 
programs (Cif2cif and Extractor, described below). These programs as well 
as the re-refinement script are available at http://www.cmbi.ru.nl/pdb_redo.
5.2.2.2. Reflection data preparation. When we re-refined all 
crystallographic structures in the PDB for which X-ray data to a resolution of 
exactly 2.00Ä had been deposited, we observed a series of inconsistencies in 
the reflection data files from the PDB that made automated use troublesome. 
Some typical examples were: measured reflections reported as amplitudes, 
intensities or both; missing estimated standard uncertainties; R-free flags in 
different formats, etc.
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The program Cif2cif was written to reformat the reflection data to a 
consistent format keeping only the essential information. The Cif2cif output 
contains reflection indices (h,k,l), amplitudes (F), estimated standard 
uncertainty values ( g F ) ,  and the R-free flag. When necessary, intensities and 
their sigma values are converted to amplitudes using F = Vi and g F  = g I /  2F 
(Kleywegt et al., 2004). If g F  values are missing from the input file or when 
all values present are zero, they are all set to 0.01 to avoid technical 
problems in Refmac.
The program Extractor was written to combine relevant information 
from the experimental reflection data file and the coordinate file. These data 
included reported resolution, R(-free), the resolution range of the data, cell 
dimensions, and the TLS (Schomaker & Trueblood, 1968) groups used in the 
original refinement. In cases where TLS was not used in the original 
refinement or where the TLS groups were not reported, they were defined as 
one single group per protein chain.
The structure factor files were converted to MTZ format (a standard 
used in the CCP4 suite) and used to recalculate R and R-free with Refmac 
using default settings. When needed, ligand restraint dictionaries were 
automatically created by Refmac.
5.2.2.3. Re-refinement. Default Refmac parameters, as specified in the 
CCP4 Graphical User Interface (CCP4i), were applied, with two exceptions: 
carbohydrate links were only used if they were described in the PDB file; and 
anisotropic B-factors were refined if ANISOU records were provided. The 
structure models were first subjected to 10 cycles of rigid-body refinement. 
In our previous study this was needed for a small number of structures that 
gave large deviations between the recalculated R-free and the value from the 
PDB header because of a rotation or translation of the coordinates with 
respect to the electron density which may follow from a slight mismatch in 
cell parameters. We retained this non-invasive step to provide a fall-back 
structure in case further re-refinement was unsuccessful.
TLS refinement was then performed on the rigid-body refined 
structures. Ten cycles of TLS refinement were performed, followed by 20 
cycles of restrained refinement in which only the weight of the X-ray terms 
with respect to the geometric and B-factor restraints was changed. Seven 
different weights were used: 1.00, 0.70, 0.50, 0.30, 0.10, 0.05, and 0.01. This 
re-refinement resulted in 8 models for each structure: one rigid-body refined 
structure model and seven structure models that were obtained through 
restrained refinement with TLS.
The best of the seven TLS refined structure models was selected 
using the following criteria, in which AR is used to denote the difference in R-
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values (all expressed in units of percentage points or % - see below in 
§5.3.1), Rfree-R:
1. All models with a root mean-square deviation from ideal values in the 
bond angles over 3.0o were rejected
2. Models with AR greater than 5%, were rejected. This rule was relaxed 
in cases where AR0, the value of AR prior to re-refinement, was also 
greater than 5%. In those cases, the requirement was that AR did not 
increase above AR0 .
3. The model with the lowest R-free was selected from the remaining 
candidates. In cases when two or more models had the same R-free 
(within 0.1%), the one with the smallest AR was selected.
4. In case the R-free of the optimal model was higher than that of the 
rigid-body refined model - that is, when the structure model actually 
became worse as a result of re-refinement - all re-refined models 
were rejected and the rigid-body refined structure model was kept as 
the final re-refinement result.
5.2.3. Validation and manual real-space intervention
After automated re-refinement had proceeded as described, the resulting 
structure models were analyzed with WHAT_CHECK to search for features 
that required manual optimization. Special attention was paid to tests for 
bond lengths, bond angles, missing side-chain atoms, atomic occupancies, 
alternate side-chain conformations, atomic overlap (bumps), residue 
packing, and hydrogen bonding. These tests were based on the atomic 
parameters only and can therefore be used on any structure model, with or 
without experimental data.
Coot was used to evaluate anomalies detected by WHAT_CHECK in 
the context of the experimental data. The 'Check/Delete waters' routine and 
peaks in the mFo-DFc difference electron density maps were used to detect 
additional problem areas in the re-refinement results. When necessary, these 
anomalies were resolved by side-chain refitting and addition or removal of 
waters, alternate side-chain conformations, or hetero compounds. The 
resulting structure models were refined in Refmac using 5 cycles of TLS 
refinement followed by 5 cycles of restrained refinement with default 
settings for Refmac in CCP4i and with the optimal geometric restraint weight 
found during the previous automated re-refinement stage. This cycle of 
rebuilding and refinement was performed three times. The final structures 
were validated with WHAT_CHECK and pdb-care.
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5.3. Results
5.3.1. Overall re-refinement results
The process of automated re-refinement followed by manual rebuilding 
resulted in five structure models with similar or improved R-free values. 
Table 5.1 shows the validation scores for the original, re-refined, and 
manually optimized structures.
In order to avoid all misunderstandings in the forthcoming 
comparisons of R-values, that are traditionally expressed in terms of 
percentage points (%), we wish to state explicitly that the changes 
mentioned in the text are absolute changes in percentage point (%) units 
rather than relative changes as a percentage of a reference value. For 
instance, a 5% improvement to an R-value of 20% would produce R=15% 
(i.e. a decrease of 5 percentage points from  the initial value), and not R=19% 
(i.e. a decrease of 5% of the initial value). The same applies to the outline of 
the re-refinement logic presented in §5.2.2.3.
Table 5.1: Validation scores for original, re-refined, and manually optimized structure
models____________________________________________________________________________________
PDB identifier 1lf2 1zcs 2ete 2qc1 2vno
Resolution (A)
R(%)
- Original3
- Re-refined
- Manually optimized 
R-free (%)
- Originala
- Re-refined
- Manually optimized 
Non-water atoms
- Original
- Re-refined
- Manually optimized 
Waters
- Original
- Re-refined
- Manually optimized
Atomic overlapsb
- Original
- Re-refined
- Manually optimized
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1.80
24.0 (19.5)
17.6
17.4
27.8 (25.8)
22.2
21.3
2658
2644
2663
338
338
254
59
64
53
1.45
18.0 (15.8) 
17.3
15.2
19.8 (18.0) 
19.5
17.3
6955
6955
6981
1002
1002
1005
72
72
87
1.75
18.2 (18.1) 
15.9
14.8
18.3 (19.4)
17.9 
16.6
3020
3020
3057
308
308
378
23
31
23
1.94
22.7 (21.4) 
19.2
18.6
24.8 (23.3)
23.9 
23.4
2426
2426
2434
187
187
193
145
143
87
1.45
19.5 (18.0)
19.5 
18.7
24.1 (22.6)
24.1 
22.0
2753
2753
2781
574
574
532
58
58
42
Packing qualityc
- Original -1.94 -1.51 -1.97 -1.87 -2.38
- Re-refined -1.96 -1.53 -1.98 -1.79 -2.38
- Manually optimized
Ramachandranc
-1.83 -1.50 -1.97 -1.79 -2.30
- Original -1.86 0.07 0.05 -0.62 0.24
- Re-refined -1.43 0.05 -0.23 -0.26 0.24
- Manually optimized 
Rotamer normalityc
-1.44 0.06 -0.16 -0.17 0.39
- Original -2.38 0.51 0.26 -0.26 -0.11
- Re-refined -1.83 0.42 0.28 -0.37 -0.11
- Manually optimized 
BB conformation^
-1.24 0.63 0.67 -0.39 0.28
- Original -3.87 -1.90 -2.31 -1.44 -2.18
- Re-refined -3.61 -1.95 -2.56 -1.31 -2.18
- Manually optimized 
Bond rmsZ
-3.37 -1.82 -2.57 -1.29 -2.04
- Original 0.74 0.46 0.43 0.38 1.40
- Re-refined 0.96 0.49 0.95 0.96 1.40
- Manually optimized 
Angle rmsZ
0.61 0.40 0.80 0.70 0.60
- Original 0.94 0.69 0.60 0.75 0.87
- Re-refined 1.00 0.68 0.83 0.93 0.87
- Manually optimized 
SC planarity rmsZd
0.80 0.65 0.76 0.81 0.87
- Original 0.83 0.59 0.38 0.26 2.01
- Re-refined 1.23 0.66 1.04 1.15 2.01
- Manually optimized 0.71 0.55 0.86 0.80 0.90
a Calculated from experimental data, PDB header values in parentheses 
b Van der Waals overlap greater than 0.40Ä 
c WHAT_CHECK Z-scores 
d BB = back bone; SC = side chain
5.3.2. PDB entry 1lf2
The automated re-refinement of PDB entry 1lf2 resulted in an R-free 
improvement of 5.6% and an improvement of the Ramachandran and 
rotamer normality scores. However the side-chains were distorted, with 
planarity deviations much larger than the standard uncertainties in the 
WHAT_CHECK geometry library. 14 hydrogen atoms (all glutamine Hs atoms 
with a B-factor of exactly 20.00) were observed in the original PDB entry. 
The arbitrary nature of the presence of only these 14 protons and the fact 
that there is no mention of these protons in the associated article led us to 
believe that they were most likely a remnant of an experiment during the
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refinement procedure. We therefore believe that the automatic removal of 
these protons is not a problem.
WHAT_CHECK detected a range of atoms in residues 237A to 244A 
with 0.50 occupancies but without alternate positions. The difference map 
showed positive density up to 6.0 o at these atoms. Resetting the atomic 
occupancies to 1.00 removed nearly all these difference density peaks.
Evaluation of the hydrogen bond network showed 28 waters without 
hydrogen bonds; these 28 waters were removed. Additional validation of 
waters in Coot resulted in 56 more waters being removed during manual 
optimization of the structure.
The second and fifth highest peaks in the difference map, one on a 
two-fold symmetry axis and the other near Lys238A, were nearly 
tetrahedral. They were assumed to be sulfates because the original 
publication of the 1lf2 structure mentions the use of ammonium sulfate in 
the crystallization medium.
After one cycle of manual optimization and refinement the third 
largest difference-map peak was located near the side-chain of Lys238A, 
indicating a post-translation modification or a possible sequence error. 
Modeling Lys238A as an Arginine gave an improved fit to the electron 
density map and removed the difference-map peak (Figure 5.1).
Figure 5.1: Detail of PDB entry 1lf2 after one round of manual optimization (A) and the final 
model (B) in 2mFo-DFc electron density maps (contoured at 2.0o) and mFo-DFc difference 
density (contoured at 4.0o). Based on the crystallization conditions described in Asojo et al. 
(2002) the tetrahedral difference map peak in (A) was modelled as a sulfate. Lys238A was 
modelled as an arginine based on the (difference) density map contours. The He of this 
arginine in (B) makes a hydrogen bond with the backbone carbonyl of Leu242A.
Figures created with Coot (Emsley & Cowtan, 2004) and Raster3D (Merritt & Bacon, 2007).
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The final refinement resulted in an R-free improvement of 6.5% compared to 
the original PDB entry. All WHAT_CHECK quality scores were also improved, 
most notably the side-chain rotamer normality score and the side-chain 
planarity.
5.3.3. PDB entry 1zcs
The automated re-refinement of 1zcs resulted in a small improvement of R- 
free by 0.3%. Geometric quality scores did not show large changes either.
WHAT_CHECK reported 52 residues that had atoms with partial 
occupancies. Most of these were side-chain atoms with occupancies of 0.50 
and poor electron density. No alternate conformers were supplied for these 
side-chains. The carbonyl atoms of residue 20A also had occupancies of 0.50, 
whereas a positive difference-map peak near these atoms suggested that the 
site was fully occupied (Figure 5.2). All these occupancies were resetto 1.00.
Figure 5.2: Detail of PDB entry 1zcs after automated re-refinement. The carbonyl atoms of 
Glu20A were modelled with 50% occupancy, but without any alternate atom positions by 
Thapper et al. (2007). This results in a positive mFo-DFc difference map peak on that carbonyl 
group, contoured here at 3.0o. The difference map peak disappeared after setting the atomic 
occupancies to 1 .00.
The difference map showed high positive peaks on the iron atoms of two 
iron-sulfur clusters. Due to a software problem in the re-refinement, they had 
been refined as nitrogen atoms. These peaks disappeared after subsequent
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refinement with a corrected version of Refmac. TLS groups were added for 
the (molybdopterin-cytosine dinucleotide-S,S)-dioxo-aqua-molybdenum(V) 
ligand and the two iron-sulfur clusters.
The final refinement resulted in an R-free improvement of 2.5%. 
Overall, re-refinement caused little change in the WHAT_CHECK quality 
scores apart from a small increase in the number of atomic overlaps and a 
slight improvement of the rotamer normality.
5.3.4. PDB entry 2ete
Prior to any re-refinement, the calculated R-free was found to be 1.1% lower 
than the value from the PDB header, whereas R was nearly equal to the value 
from the header. Additionally, the calculated values of R and R-free differed 
by only 0.1%. This indicated that there was something wrong with the R-free 
set specified in the experimental data file. As a result, the calculated R and R- 
free could not be used as reference values to assess the result of the re­
refinement. The values extracted from the PDB header were used instead.
The automated re-refinement of 2ete resulted in a 1.5% 
improvement of R-free at the expense of the geometric quality of the 
structure. The bond lengths and angles deviated much more from ideal 
values than they did before the re-refinement. The side-chain planarity rmsZ 
score of 1.04 was poor.
Closer inspection of the WHAT_CHECK validation report showed that 
many geometric outliers could be traced to residues B94 and B166, two 
threonines with inverted Cß chirality. Inspection of the electron-density 
maps showed that both side-chains were poorly fitted in the original PDB 
entry, with X1 torsion angles deviating by 180 degrees from optimal values. 
They had been forced into their awkward conformation by the automated 
refinement. Apart from these outliers, a cell scaling problem was diagnosed 
as the possible reason why bond lengths that were systematically slightly 
longer than ideal.
The difference map showed a large number of peaks, six of them over 10.0o. 
The two largest peaks in the difference map were interpreted as waters 
coordinating two manganese ions (Figure 5.3). Other large difference map 
peaks were caused by poorly fitted side-chains and by a large number of 
unassigned water peaks. Seventy waters could be unambiguously assigned 
on the basis of those peaks.
The final refinement round resulted in an R-free improvement of 
2.8%. The side-chain rotamer score increased, but backbone and 
Ramachandran scores decreased. The geometric deviations from ideality
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were still larger than in the original PDB entry, but as all rmsZ scores were 
well below 1.00 we saw no need for using tighter geometric restraints.
Figure 5.3: Manganese atoms in PDB entry 2ete after automated re-refinement in 2mFo-DFc 
electron density maps (contoured at 2.5o). Both chain A and chain B show a clear positive 
difference density peak (contoured at 5.0o) at a manganese coordination site. Placing waters 
at these peaks removed the difference density.
5.3.5. PDB entry 2qc1
The automated re-refinement of 2qc1 resulted in an R-free improvement of 
0.9%. The validation report showed small improvements in the quality Z- 
scores except for the side-chain rotamers. The side-chain planarity was 
distorted.
The most striking validation result was the large number of 
problematic atomic overlaps, the worst one being a 2.21Ä overlap between 
two mannose oxygen atoms that were part of a large N-linked glycan. A 
development version of pdb-care showed many more problems in this 
carbohydrate structure. The oxygen atoms that are eliminated when a 
carbohydrate link is formed had been left in the original PDB entry. Ten such 
superfluous oxygens were detected, each of them associated with a strong 
negative difference map peak (Figure 5.4). Furthermore, residue B304, a ß-D- 
mannose, was named MAN instead of BMA.
Apart from removing the superfluous oxygen atoms and refitting one poorly 
fitted tryptophan (residue B176), little real-space intervention was needed. 
The final R-free was 1.4% lower than before re-refinement. Most quality 
scores improved, and the number of atomic overlaps was reduced by 40%.
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Figure 5.4: The first four carbohydrates of the N-linked glycan in PDB entry 2qc1 with four 
negative mFo-DFc difference density peaks at their O1 atoms. The difference density map is 
contoured at -3.0a and waters were not shown for clarity.
The O1 atom in NAG302B was placed in an axial conformation in the original PDB entry, but 
should have been removed completely before deposition. This superfluous oxygen hampers 
the detection of the link with Asn141B in Coot. The other O1 atoms are were left on top of 
other oxygen atoms when creating links between the carbohydrates, which resulted in 
difference density peaks and numerous atomic overlap warnings in WHAT_CHECK (Hooft et 
al., 1996). Additionally, MAN304B is a ß-D-mannose and must be named BMA instead of MAN.
5.3.6. PDB entry 2vno
The R and R-free values from the PDB header (18.0% and 22.6%) could not 
be reproduced, the recalculated values coming out at 19.5% and 24.1% 
respectively. Automated re-refinement did not improve these values. The 
first manual optimization cycle was therefore based on the rigid-body 
refined structure.
WHAT_CHECK validation of this structure showed some large geometry 
outliers which resulted in a bond length rmsZ of 1.40 and a side-chain 
planarity rmsZ of 2.01. A number of residues also had missing atoms in the 
middle of side-chains. For instance, residue A176 was a glutamate with 
missing Cy and Cô atoms, even though the Os atoms were present.
Analysis of waters using Coot showed a number of questionable 
waters near the N-terminus of chain A. In the non-crystallographic symmetry 
related chain B, these positions were occupied by a glutamate residue. The 
waters near chain A were replaced by a glutamate residue (Figure 5.5). A 
total of 42 waters were removed.
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Figure 5.5: N-terminus of chain A in PDB entry 2vno after automated re-refinement (A) and 
manual optimization (B). The waters near the N-terminus of chain A occupied electron density 
that was occupied by a glutamate in the NCS-related chain B, the electron density (contoured 
at 1.0a) was not fully connected. The waters were removed and replaced by an N-terminal 
Glutamate. After further refinement connected electron density was obtained for the Glutamate 
backbone.
Refinement of the anisotropic B-factors in combination with the TLS models 
led to over-parameterization, and subsequent refinement steps were 
successful only after the ANISOU records were removed. The final R-free was 
0.6% lower than the value from the PDB header, and all quality indicators 
had improved. Based on validation with pdb-care, residues 1210A and 1211B 
were renamed from GAL to GLA in accordance with the remediated PDB 
format (Henrick et al., 2008).
5.4. Discussion
In a previous experiment (Joosten & Vriend, 2007) we had shown that a 
simple automated re-refinement protocol could improve the R-free values of 
78% of 1195 PDB entries (all with 2.00Ä resolution) for which the X-ray 
reflection data and the R-free set could be reconstructed from the deposited 
data (Figure 5.6). It is obviously our goal to get the best possible atomic 
coordinates out of the available data. We therefore decided to manually 
optimize five structure models in order to see how the refinement affected 
the electron density maps and to search for improvements that are simple 
enough to be automated in the next re-refinement round.
We encountered several problems in the automated and manual re­
refinement, the most important being the lack of information about the 
original refinement protocol. This causes problems when trying to reproduce
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Figure 5.6: Distributions of AR-free for 1195 X-ray structures from the PDB with a reported 
resolution of 2.00Ä. AR-free = R-freeorg - R-freerecalc where R-freeorg values were taken from 
the PDB file headers and R-freerecalc are recalculated after subsequent refinement steps: 1) 
Simple recalculation of R-free without any additional refinement; 2) rigid body refinement to 
compensate for any accidental translation or rotation of the coordinates before deposition; 
and 3) refinement with TLS models for atomic displacement.
TLS models in PDB headers were kept if available; in all other cases one group per chain was 
used. The Gaussian fits through these histograms are for visual reference only. The average R- 
free values reported in the PDB are 24.2%. We recalculated these values without additional 
refinement and obtained an average of 24.5%. After rigid body refinement and TLS refinement 
the average R-free values were 24.3% and 23.0%, respectively.
the refinement results, as shown with the calculated R-free value of 2ete. 
Because the calculated R-free deviated from the PDB header values, but the 
calculated R did not, it is likely that the wrong set of reflections was flagged 
as the R-free set. This has implications for the re-refinement results: because 
the R-free reflections have been used in the model building process, the R- 
free values after re-refinement are biased.
The general lack of sufficient “meta-data” about the original 
refinement makes it difficult to set up regular large-scale re-refinements for 
new PDB entries using given versions of refinement and rebuilding software,
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or, conversely, large-scale benchmarks for new versions of the software 
against the same set of entries. The differences between the calculated R and 
R-free and the values from the PDB header are small for the five PDB entries 
discussed here. In the case of 1zcs a small deviation was caused by applying 
the wrong solvent model. Applying Refmac's bulk solvent model removed 
this deviation. For 1zcs, the solvent model should have been recognized by 
the re-refinement protocol, because it is described in the PDB header. This 
error has been corrected in our scripts. In contrast, no information about the 
solvent model was reported for 2qc1. Therefore, other sources of R-factor 
deviations should be considered. Kleywegt et al. (2004) have discussed many 
possible causes for such discrepancies. Here, typical issues are resolution and 
F/gF cut-offs that were applied when selecting reflections used in the 
original refinement and subsequent calculations of R and R-free. As the PDB- 
redo protocol always uses all available reflections, slightly different sets of 
reflections may be used in the original vs. our current calculation of R and R- 
free.
Much larger differences between calculated R values and values from 
the PDB header occur than we found in this study. Such deviations do not 
necessarily mean that the atomic coordinates are poor, but may rather 
indicate that there is something wrong with the deposited reflection data. 
One such instance, PDB entry 3d0b (Barta et al., 2008), will be mentioned 
below in §5.5.
Hetero compounds are troublesome entities for re-refinement and 
structure validation. Their geometric restraints are not deposited in the PDB, 
which means that refinement programs have to generate restraints for all 
compounds not described in their restraints library. This typically requires 
interpretation of atomic coordinates in a PDB file to assign bond types, 
protonation states, possible charges, and to detect other features like 
aromatic ring systems. This can lead to different geometric restraints being 
used by different refinement programs, and thus to different (re-)refinement 
results. Validation software suffers from the same problems. These issues 
may be addressed by creating a standard repository of geometric restraints 
for hetero compounds, similar to what Engh and Huber (1991) did for 
proteins and others for nucleic acids (Parkinson et al., 1996). However new 
compounds are added to the PDB every week, which makes it problematic to 
keep such a repository up to date.
Carbohydrates have their own problems, some of which have 
recently been resolved in the PDB remediation. Compounds that only differ 
in the chirality of one atom now have unique names. For instance a-D- 
mannose (MAN) and ß-D-mannose (BMA) differ only in the chirality of the C1 
atom. Before the remediation, the single hetero compound name MAN was
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used for both compounds, even though the compound BMA was already 
described in the PDB ligand dictionary. Unfortunately, compounds that were 
previously refined with the wrong chirality have now been renamed to make 
the compound name match the coordinates, thereby perhaps casting in stone 
a certain number of errors. We are working on a pdb-care based method that 
can detect such problems and give suggestions for (automated) correction. 
After updating the compound name, the coordinates can be refined with the 
correct chirality.
A number of the real-space interventions applied to the five 
evaluated PDB entries can be automated. In fact, several tools already exist 
for side-chain refitting (DePristo et al., 2005) and density fitting of water 
molecules (Perrakis et al., 1997). However, these tools should be applied 
with great care. For example, some of the “free atoms” placed into density 
during the automatic model building with ARP/wARP (Perrakis et al., 1999) 
of PDB entry 2vno, were placed at positions that should have been assigned 
to protein side-chain atoms; however the automated interpretation process 
failed to identify them as such, and they were left as “waters” while 
distributed differently from true waters. On the other hand, too few waters 
were fitted in the case of 2ete. These examples show that a careful re­
evaluation of waters in structure models is necessary in the automated re­
refinement protocol. Implementing this is not trivial, automated water fitting 
requiring sensitive parameter optimization and thorough validation of the 
putative waters.
The two missing waters that appeared at manganese coordination 
sites in 2ete revealed another difficulty: waters in ion coordination sites 
behave differently from other waters, their B-factors being markedly lower, 
and coordination distances being much shorter than regular hydrogen 
bonding distances. This can erroneously trigger distance cut-offs in water 
fitting routines and bump detection routines in validation software.
Less invasive real-space interventions, such as small geometry fixes, 
occupancy fixes, and side-chain flips to optimize the hydrogen bonding 
network, can be applied automatically with little risk of introducing new 
problems. Of course, these will have little effect on quality estimators like R 
and R free, but that does not mean that they are unimportant.
Filling positive difference-map peaks with compounds other than 
water, as shown here in 1lf2, requires knowledge of the crystallization 
conditions and of the cryoprotectants used. This information can be stored in 
'REMARK 280' records in the PDB header, as was done for three of the five 
PDB entries in this study. Even though this record is not ideal for automatic 
interpretation, it may prove invaluable in future automated re-refinement
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efforts, and the PDB might consider designing an appropriate ontology for 
these REMARKs.
The mutation in plasmepsin-2 in 1lf2 is an example of real-space 
intervention that cannot be automated, yet. Sequence retrieval in UniProt 
(Leinonen et al., 2004) showed only distant homologs of plasmepsin-2 with 
an arginine instead of a lysine residue at position 238 in the sequence. 
However, this change can be caused by a point-mutation in the plasmepsin-2 
expression system. To safely fix this possible sequence error, help from the 
original depositor is required to verify the proposed sequence. It is therefore 
important that issues like this be recognized by validation software before 
deposition of the structure model. Of course, this is not limited to possible 
sequence errors; structure validation before deposition is always more 
effective than after deposition. For example, shortly before WHAT_CHECK 
became available to automatically flag space-group related problems, 
Kleywegt et al. (1996) discovered a space-group problem in the PDB entry 
1chr (Hoier et al., 1994). They corrected the problem and the improved 
structure was submitted as 2chr. The correction of this type of error is still 
beyond automation. Had WHAT_CHECK already been available in 1994, and 
had it been used by the original crystallographers, the present situation of 
having the incorrect 1chr sit in the PDB database next to the much better 
2chr could have been avoided.
5.5. An alternative approach to detecting problem 
regions in deposited models
In parallel with the investigations reported above on deposited structures 
that were flagged by structure validation programs, one of the authors (TW) 
has been carrying out since July 2007 a regular process of refining on a 
weekly basis, as they are received, most new PDB depositions with the 
autoBUSTER software (Bricogne et al., 2008). The selection of structures for 
re-examination is made by analysing the post-refinement difference map 
rather than the geometry of the deposited model; this shows up different 
kinds of modelling issues. The five PDB entries examined above were also 
analyzed with autoBUSTER, with essentially identical conclusions; although 
the final R-values achieved were adversely affected by the fact that 
autoBUSTER does not yet allow TLS refinement. The two entries with NCS 
(2ete and 2vno) were refined with the autoNCS option based on Local 
Structure Similarity Restraints (LSSR) described in Smart et al. (2008).
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Looking at the structures with the highest peaks in their difference maps 
tends to select for high-resolution structures containing unmodelled ions, 
which can often be recognized by considering their observed coordination 
and the crystallization conditions. These may be deemed biologically 
irrelevant, but in 2qae (Werner et al., to be published) an unmodelled sodium 
appears to mediate a contact between the main chain and an FAD; and there 
is a loop in 3czk (Kim et al., 2008) that has been built into density where a 
caesium ion clearly ought to be. It also shows up a plethora of unmodelled 
waters. Even high-resolution structures often show large numbers of 
unambiguous, and even NCS-conserved, unmodelled waters; often, such a 
peak due to water indicates the correct orientation of a nearby histidine 
through the implied hydrogen bonding.
Dipoles of difference density along the axis of the C=O bond, which 
can be detected automatically, are a good diagnostic for flipped peptides. 
Looking for difference-map peaks in the vicinity of ligands shows up both 
incorrectly-modelled buffer molecules (2q5b; Bukhman-DeRuyter et al., to be 
published.), at 1.45A, has a glycerol modelled as acetate) and the occasional 
situation where the ligand is not as claimed. The deposited structure factors 
for 3d0b appear to be from a crystal in which a ligand significantly different 
from the one modelled is bound. The reported R is 20.0%, whereas we 
calculated an R of 28.7%. Review of the electron density maps of 3d0b 
showed an unmistakable 3,4,5-trimethoxybenzyl group, which was not part 
of the chemical structure of the purported ligand, indicating that the 
reflection data belonged to the correct protein but crystallized with a 
different ligand than that described in the coordinate file. This is just one 
example of the problems that can be encountered with liganded protein 
structures. A recent review by Davis et al. (2008) discusses more examples.
For lower-resolution structures, more substantial interpretation 
errors or insufficiencies are often pointed out by this process, such as 
register errors, unmodelled density at the termini, or extra copies of ligands. 
This independent monitoring of incoming PDB depositions supports the 
conclusion that there is a strong case for extending the scope of depositions 
so that they specify all the relevant information required to reproduce the 
refinement steps that led to the deposited results, and to subsequently repeat 
them with later versions of the software that may bring better results out of 
the deposited X-ray data. Such a database of reproducible refinements would 
be a great asset to software developers, in that it would simplify the large- 
scale benchmarking of progress in refinement algorithms. In small molecule 
crystallography it has become common practice to no longer even look at 
electron density and only a few problematic structures still require the 
attention of experienced crystallographers. We can imagine that our results
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might provide a small step towards achieving that same situation in the 
future of macromolecular crystallography.
5.6. Outlook
This proposal of extended depositions leads naturally to the consideration of 
X-ray data themselves. In the same way that deposited coordinates are only 
the best results that could be obtained from the deposited X-ray data by the 
refinement protocols available at the time, and are therefore improvable as 
these protocols become more sophisticated, those deposited X-ray data are 
only the best summary of sets of diffraction images according to the data 
reduction programs and practices available at the time they were processed.
Just like refinement software, those programs and practices are 
subject to continuing developments and improvements, especially in view of 
the current interest and efforts towards better understanding radiation 
damage during data collection and in taking it into account in the subsequent 
processing steps. It is therefore natural that the deposition of X-ray data 
should go beyond its present form, and endeavour to collect the diffraction 
images themselves, together with sufficient information to enable any 
investigator to retrace the steps of the entire structure determination 
process. The Joint Center for Structural Genomics archive 
(http://www.jcsg.org) is an excellent prototype of what can be achieved in 
this respect, and its often acknowledged value to software developers is a 
clear indication of the potential benefits of such an extended deposition 
scheme, through the dual improvements it would enable in both the results 
for structures already solved and in the ability to solve new, more difficult 
ones in the future thanks to better tested and better validated software 
advances.
5.7. Conclusion
Ongoing improvements in crystallography software and validation tools, 
combined with the deposition of X-ray data into the PDB, have enabled the 
development of automated re-refinement protocols, like the one described 
here, that can improve most structure models compared to their initially 
deposited form. We have shown examples of real-space interventions that 
must be incorporated into this protocol to increase its effectiveness.
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The rate at which greater sophistication can be achieved in these re­
refinement and validation methods will depend greatly on the success of 
eliciting more information, or “meta-data”, from the depositors about the 
protocols they followed - ultimately, from the raw X-ray data to their 
refinement results. We are aware that this will make the deposition process 
more time-consuming; however, users of the PDB and software developers 
will greatly benefit from this extra effort, as it will turn what was previously 
a static archive of frozen models into a repository of self-improving results 
through the steady progress in methods developments it will catalyse. 
Depositors will also benefit from such a paradigm shift, because it will make 
their structural results more 'future-proof', leading to more citations and to 
higher visibility of their work.
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Abstract
Homology modelling is normally the technique of choice when experimental 
structure data are not available but three-dimensional coordinates are 
needed, for example, to aid with detailed interpretation of results of 
spectroscopic studies. Herein, the state of the art of homology modelling will 
be described in the light of a series of recent developments, and an overview 
will be given of the problems and opportunities encountered in this field. The 
major topic, the accuracy and precision of homology models, will be 
discussed extensively due to its influence on the reliability of conclusions 
drawn from the combination of homology models and spectroscopic data. 
Three real-world examples will illustrate how both homology modelling and 
spectroscopy can be beneficial for (bio)medical research.
6.1. Introduction
Knowledge of the three-dimensional structure of proteins is a prerequisite 
for much research in fields as diverse as protein engineering, human genetics 
and drug design. Only two spectroscopic techniques, nuclear magnetic 
resonance (NMR) and X-ray, can produce high-resolution three-dimensional 
coordinates of macromolecules. Most other spectroscopic techniques either 
add information to such three dimensional coordinates, or require these 
coordinates for the detailed interpretation of their results. NMR and X-ray 
are very elaborate techniques, and worldwide only about 30 protein 
structures are solved per day. In the time needed to read the above abstract, 
on the other hand, about 50 sequences were determined (worldwide) and 
deposited in international, freely and easily accessible sequence databases. 
Consequently, the necessity for homology modelling is only increasing.
In its most elementary form, homology modelling involves calculating 
the structure of a protein for which only the sequence is known using its 
alignment with a homologous protein for which the structure is known.
The first homology modelling articles were published as early as the 
late 1970s (Greer, 1980), and since then we have kept using and improving 
the same concepts described in those ground-breaking articles. The process 
starts with the detection of a suitable template; an alignment is produced; 
insertions, deletions and residue substitutions are performed; the model is 
optimized; and since the late 1990s there is consensus that structure 
validation is needed to detect the unavoidable errors in the final model.
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In the early 1990s many homology models were built (and unfortunately also 
published; also in EBJ) just for the sake of modelling, but since the mid 1990s 
homology models are considered tools that can aid with the design of 
experiments and with the interpretation of their results, although 
occasionally things can still go very wrong in the literature.
G-protein-coupled receptors (GPCRs) are by far the most important target for 
the pharmaceutical industry, and due to the scarcity of GPCR structure data 
these are also the most frequently modelled molecules. Until August 2000 
GPCR models were either built ab initio, or using the non-homologous 
bacteriorhodopsin as a homology modelling template. In August 2000 the 
structure of bovine opsin became available (Palczewski et al., 2000), and 
since then GPCR homology modelling has been a serious possibility. GPCR 
models built before that historical moment are better forgotten (Oliveira et 
al., 2004). Unfortunately, people kept building, using and publishing ab initio 
models even after the bovine opsin structure became available (Orry & 
Wallace, 2000). Today, four GPCR structures are available that can be used as 
template; Figure 6.1 shows the principal differences between the bovine 
opsin structure and the structure of the beta-2 adrenergic receptor 
(Cherezov et al., 2007), one of the recently resolved GPCR crystal structures. 
Long before August 2000 the importance of GPCR structure models for drug 
design triggered a very large number of spectroscopic experiments, focussed 
on a variety of aspects.
The following series of short paragraphs illustrate the mutual 
relation between spectroscopy and homology modelling. Most examples are 
drawn from the GPCR research field. These examples are just illustrations 
and neither imply a judgment nor pretend completeness.
6.1.1 Exposed residue labelling
In two studies, Davison and Findlay (1986a, 1986b) identified residues that 
were exposed to the membrane environment or the retinal binding site, 
respectively, by labeling opsin with photoactivated L-azido-4- 
[125]iodobenzene. This study was carried out long before the first crystal 
structure of any GPCR became available, and determining which residues 
were labelled allowed Davison and Findlay to get a more complete picture of 
the three-dimensional organization of the opsin molecule.
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Figure 6.1: The most striking difference between the crystal structures of rhodopsin (PDBid 
1f88; Palczewksi et al., 2000) and the beta-2 adrenergic receptor (PDBid 2rh1; Cherezov et al., 
2007) concerns the structure and location of the extracellular loop between helix IV and V. 
The loop IV-V in rhodopsin forms a ß-sheet that folds into the binding pocket (yellow), 
whereas loop IV-V in the beta-2 adrenergic receptor forms an a-helix and extends towards the 
extracellular environment (purple).
6.1.2. Site-directed spin labelling
The group of Khorana used site-directed spin labelling to analyse the 
structure and light-dependent changes of part of GPCRs. The electron 
paramagnetic resonance (EPR) spectrum of each spin-labelled mutant was 
analysed in terms of residue accessibility and mobility. In the article where 
they describe the region extending from helix VII to the palmitoylation sites 
in the rhodopsin molecule (Altenbach et al., 1999; Cai et al., 1999) they 
concluded that this region had extensive tertiary interactions. After Oliveira 
et al. (1999) -correctly- modelled this region as a helix that runs parallel to 
the membrane, the interpretation of the EPR data could be extended 
significantly, indicating how modelling can help interpret spectroscopic 
measurements.
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6.1.3. Fluorescence resonance energy transfer
Turcatti et al. (1996) studied ligand-receptor interactions in the neurokinin- 
2 receptor (NK2) using fluorescence resonance energy transfer (FRET). A 
fluorescent unnatural amino acid was introduced at known sites into NK2. 
Inter-molecular distances were determined by measuring the fluorescence 
resonance energy transfer between the fluorescent unnatural amino acids 
and a fluorescently labelled NK2 heptapeptide antagonist. A similar approach 
was used to measure distances between the cholecystokinin receptor and a 
natural agonist (Harikumar et al., 2002) and between the secretin receptor 
and secretin analogues (Harikumar et al., 2007). Distances obtained were 
used as constraints to improve models for ligand-receptor interactions. The 
NK2 results were interpreted in terms of an obviously very poor 
bacteriorhodopsin structure. Looking at their results more than 10 years 
later, and with four GPCR structures at hand, we can see that they located the 
NK2 ligand largely at the correct place. This tells us how to trust or distrust 
the secretin FRET results and illustrates how spectroscopy can help improve 
modelling.
6.1.4. Fourier-transform infrared spectroscopy
Molecular models of rhodopsin based upon electron density projection maps 
that were constructed before the first crystal structure became available 
proposed a specific interaction between transmembrane (TM) helices III and 
V, which appeared to be mediated by amino acid residues Glu122 and His211 
on TM helices III and V, respectively. Beck et al. (1998) used a combination of 
site-directed mutagenesis and Fourier-transform infrared spectroscopy 
(FTIR) to validate this hypothesis.
6.1.5. Small-angle scattering
Small-angle scattering has occasionally been used to assist with homology 
modelling of water-soluble proteins. Mascarenhas et al. (1992) studied 
crotoxin. The sequence identity with a template structure was generally high 
enough to build a good homology model, but the structure of one large loop 
remained highly ambiguous. Small-angle neutron scattering data 
corresponded much better with one of the two models made, thus solving 
this problem. Comoletti et al. (2007) studied the structure of the neuroligins
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and their complex with neurexin using small-angle neutron scattering and 
small-angle X-ray scattering. A high-resolution structure of the neurexin was 
available, but no structure was available for the neuroligins. However, the 
neuroligins have significant sequence similarity with acetylcholine esterase, 
making it possible to build a homology model. Scattering from neuroligin 
constructs was similar to that previously obtained from acetylcholine 
esterase structures (Marchot et al., 1996) indicating that the homology 
model was valid.
6.1.6. Fluorescent ligands
Turcatti et al. (1995) studied the NK2 receptor using a number of fluorescent 
ligands, differing only in the length of the spacer between the fluorescent 
probe and the peptide ligand. By analyzing the different levels of 
fluorescence related to the spacer lengths they found that the binding pocket 
of the NK2 receptor was buried at a depth of 5-10 Ä.
6.1.7. Modelling and spectroscopy of the M13 protein
The final example to illustrate the never-ending love story of modelling and 
spectroscopy was recently reviewed by the Hemminga group. In a beautiful 
review (Vos et al., 2009) entitled "From 'I' to 'L' and back again: the odyssey 
of membrane-bound M13 protein" they illustrate how a large series of 
spectroscopic techniques have been employed worldwide over a period of 
more than 20 years to continuously update the structure model of the M13 
protein in its membrane-bound form. The (mainly spectroscopic) techniques 
used during this whole odyssey include NMR, site-specific and other solid- 
state NMR, X-ray fibre diffraction, cryo-electron microscopy, site-directed 
spin labelling and site-directed introduction of fluorescence probes, similar 
to that described above for the GPCR studies, fluorescence energy transfer, 
site specific infrared dichroism etc. Throughout this odyssey of Hemminga 
and others, homology modelling and spectroscopy were both applied. This 
example nicely illustrates the importance of homology modelling for 
spectroscopy, and vice versa. In some cases the spectroscopic results 
triggered the need to analyse the model, while in other cases the model 
suggested the spectroscopic experiments, and in some cases both went hand 
in hand. Throughout this odyssey the model improved and the spectroscopy 
became more sophisticated.
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The M13 odyssey also shows that spectroscopic techniques developed over 
the years, allowing for continuously more precise and more accurate 
measurements. At this same time homology modelling improved too. In the 
next paragraphs we will discuss the latest developments in homology 
modelling and its remaining unsolved problems. We will also illustrate the 
usefulness of homology models, sometimes in combination with 
spectroscopic techniques, with a few real-world examples.
6.2. Method overview: the eight steps of homology 
modelling
Homology modelling is usually described as a multi-step process in which the 
number of steps typically varies from X to Y. Here we use an eight-step plan 
(Figure 6.2). Over the years each of these eight steps has undergone 
extensive scrutiny and has been the topic of much research. Consequently, 
models built today with a fully automatic web server are considerably more 
accurate than the first modelling approach used four decades ago by Browne 
et al. using wire and plastic models of bonds and atoms (Browne et al. 1969). 
Here, we will discuss the latest innovations and developments in each of the 
eight homology modelling steps.
6.2.1. Step 1: Template recognition and initial alignment
Traditionally, the modelling template is found by performing a BLAST 
(Altschul et al., 1990) search against the Protein Data Bank (PDB; Berman et 
al., 2003). This approach is often successful when the query is highly similar 
to structures in the database. In contrast, templates that are close to the 
possible homology modelling threshold are harder to find or may even 
remain undetected (Sander & Schneider, 1991). The development of PSI- 
BLAST (Altschul et al., 1997) and fold-recognition methods (e.g. Jones, 1999) 
improved the detection of those difficult-to-find templates because these 
methods use a profile instead of a single sequence to search the database. 
Furthermore, the growing number of structures collected in the PDB makes it 
every year easier to find a homologous one.
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Figure 6.2: The eight steps of homology modelling. The first step involves finding a suitable 
homologous protein whose structure can be used as a modelling template, and generating the 
initial alignment between that template and the model sequence. In step 2 this alignment is 
refined using, for example, knowledge obtained from the template structure. In step 3 the 
backbone is generated and deletions are performed so that, temporarily forgetting insertions, 
the backbone of the template looks like that of the model as much as possible. In step 4 gaps in 
the model are closed, and optionally loops are constructed ab initio. In step 5 the side-chains 
are added using rotamer libraries to find the best rotamer for that local backbone 
conformation. Step 6 consists of molecular-dynamics simulation of the complete model in 
order to remove (the majority of) the introduced errors. In step 7 the model is checked for 
remaining errors using validation software. Depending on the outcome of the validation step 
we either approve the model or iterate the modelling process (step 8) starting from steps 1 -6 .
Finding the best possible template is not limited to searching the PDB with 
(PSI-)BLAST. There may be several candidate templates with similar 
sequence identities to the query. In that case, the optimal template must be 
selected based on other criteria. The X-ray resolution is, although frequently 
used as such, only a limited measure of structure quality because it says 
something about the experimental data, not about the quality of the structure 
model. I.e. with 1.8Ä data one can typically make a better structure model 
than with 2.2Ä data, but whether or not this better structure model is 
actually made depends on the crystallographer and the software used.
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The crystallographic residual, the so-called R-factor, says something about 
the correlation of the structure model with the experimental data and 
therefore seems more indicative than the X-ray resolution alone. 
Unfortunately, acceptable and even seemingly encouraging R-factors can be 
attained by adding more parameters to the structure models, effectively 
over-fitting/over-refining the model (Brândén & Jones, 1990). This problem 
was solved by the introduction of the free R-factor (Brünger, 1992), which is 
much more robust against over-fitting because the value is calculated only 
with the fraction of the X-ray data that was not used to build the structure 
model. Therefore, R-free can be seen as a description of how well the 
structure model predicts an 'independent' measurement.
While very robust, the free R-factor is a global indicator: it describes 
the structure model as a whole, but not a particular part of the protein that 
may interest us. A local measure of fit with the experimental data is needed, 
for instance, the real-space R-factor (Jones et al., 1991). For PDB entries 
these values can be obtained from the Electron Density Server (EDS; 
Kleywegt et al., 2004).
So, with the X-ray resolution, the (free) R-factor and the real-space 
R-factor, one can select a proper template from the (PSI-)BLAST results. That 
is, one can select a template that corresponds well with the X-ray experiment. 
A more in-depth analysis of the template structure is needed to see whether 
it also corresponds to our current knowledge of protein structures. Structure 
validation scores such as the Ramachandran Z-score (Hooft et al., 1997), the 
fraction of Ramachandran plot outliers (Laskowski et al., 1993), side-chain 
rotamer normality scores (Hooft et al., 1996a), residue packing scores 
(Vriend & Sander, 1993), hydrogen-bond network quality (Hooft e t al., 
1996b), and many others are used to obtain insight into the geometric 
quality of the template structure. Most of these validation scores, both global 
and local, can be obtained via the PDB and the linked databanks.
Another possible step in template selection is optimisation of the 
template before the actual modelling. We have recently shown that 
validation scores such as the Ramachandran Z-score and the number of 
atomic clashes (bumps) can be improved by a fully automated re-refinement 
of the PDB entry with its original experimental data (Joosten et al., 2009). In 
addition, the crystallographic R-factor, or rather the free R-factor, is also 
improved by this re-refinement. This optimisation is particularly useful for 
templates that will be used for drug docking studies because their success 
often depends critically on the quality of the atomic model. The benefit of re­
refinement is tightly correlated with sequence identity between the template 
and the model sequence. That is, any improvement of the atomic coordinates 
of a residue is lost when this residue (or just its side-chain) has to be rebuilt.
129
Fortunately, even with low sequence identity, there may be regions of the 
template that are not changed in the modelling process and thus can be 
improved by re-refinement.
Of course, when sufficient central processing unit (CPU) time is 
available to the modeller, it may be beneficial to use a number of (re-refined) 
PDB entries as templates, instead of a single one.
6.2.2. Step 2: Alignment correction
Having identified one or more possible modelling templates using the initial 
screening described above, more sophisticated methods are needed to arrive 
at a better alignment. Molecular class-specific information systems (MCSISs) 
can be a great asset in the homology modelling process. MCSISs contain a 
large amount of heterogeneous data on one particular class of proteins. The 
GPCRDB at www.gpcr.org/7tm/ (Horn et al., 2003) is a good example of 
such a system. It contains sequences, structures, mutation data, ligand 
binding data and much more. All of this information is used (directly or 
indirectly) for creating sequence profiles for GPCR (sub-)families. Profile- 
based alignments (Oliveira et al., 1993) are used to generate alignments that 
are of a significantly higher quality than alignments generated by automatic 
methods based solely on sequence data. Currently, MCSISs are available for 
only a small number of protein families and therefore in most cases other 
sequence alignment tools are needed.
Many programs are available to align a number of related sequences, 
for example, CLUSTALW (Thompson et al., 1994). The resulting multiple 
sequence alignment implicitly contains a lot of additional information. For 
example, if at a certain position only exchanges between hydrophobic 
residues are observed, it is highly likely that this residue is buried. Multiple 
sequence alignments are also useful to place deletions or insertions in areas 
where the sequences are strongly divergent. To consider this knowledge 
during the alignment, one uses the multiple sequence alignment to derive 
position-specific scoring matrices, which are also called "profiles" (e.g. 
Taylor, 1986; Dodge et al., 1998). In recent years, new programs such as 
MUSCLE and T-Coffee have been developed that use these profiles to 
generate and refine the multiple sequence alignments (Edgar, 2004; 
Notredame et al., 2000).
When building a homology model, we are in the fortunate situation of 
having an almost perfect profile: the known structure of the template. We 
simply know that a certain alanine sits in the protein core and must therefore
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not be aligned with a glutamate. Alignment techniques such as SSALN make 
use of this structural knowledge found in the template (Qiu & Elber, 2006).
6.2.3. Step 3: Backbone generation
Aligned residues occupy the same position in the template and model. 
Coordinates can thus simply be copied over to create the initial model 
backbone. In practice, there are many ways to improve this crude recipe. 
First, the template is likely to be present more than once in the PDB (e.g. a 
bundle of NMR structures, multiple copies in the crystal, or solved multiple 
times under different conditions). Here, one can use structure validation 
tools (Hooft et al., 1996a; Laskowski et al., 1993), such as the PDBREPORT 
databank at www.cmbi.ru.nl/gv/pdbreport/ to pick the best one, 
correcting errors where possible. Second, one can combine multiple 
templates, because residues missing in one template can sometimes be found 
in the other, or because the alignment covers more than one template, which 
is common for multi-domain targets. The well-known SwissModel server 
(http://swissmodel.expasy.org/; Arnold et al., 2006) selects fragments 
from different PDB files that locally are most similar to the corresponding 
model fragment.
The Zhang (http://zhang.bioinformatics.ku.edu/I-TASSER/) and 
Robetta (http://robetta.bakerlab.org/; Chivian et al., 2003) modelling 
servers have successfully extended on this concept and are today among the 
best homology modelling servers available online. Some methods do not 
even create a single backbone at all; instead they use the alignment to derive 
restraints (hydrogen bonds, backbone torsion angles etc.), and only later 
build the model, while trying to satisfy the restraints (Sali & Blundell, 1993).
6.2.4. Step 4: Loop modelling
Any insertion or deletion in the alignment implies a structural change of the 
backbone, and can thus not be modelled in the previous step. Since these 
changes usually take place outside regular secondary structure elements, 
their prediction is referred to as "loop modelling". There are two major 
approaches to the problem: first knowledge-based methods (Michalsky et al., 
2003), which search the PDB for known loops with high sequence similarity 
to the target and endpoints that match the anchor residues between which 
the loop has to be inserted, and second energy-based methods, which sample
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random loop conformations while minimizing an energy function (Xiang & 
Honig, 2002). Since loops never fit the anchor points exactly, they have to be 
closed, using for example an algorithm borrowed from robotics (Canutescu et 
al., 2003a). In practice, a combination of both methods is common.
6.2.5. Step 5: Side-chain modelling
The most successful approaches to side-chain prediction are knowledge 
based. They use libraries of common side-chain rotamers extracted from 
high- resolution X-ray structures (Dunbrack & Karplus, 1993; Chinea et al., 
1995; Lovell et al., 2000). An essential feature of these libraries is backbone 
dependence, hence they store the distribution of the side-chain dihedral 
angles (X1, X2, etc.) as a function of the backbone dihedrals ^  and ^. This not 
only increases the accuracy, but also helps to shrink the search space (i.e. the 
possible combinations of interacting side-chain rotamers) to a size that can 
be handled, for example using dead-end elimination (Canutescu et al., 
2003b). The prediction accuracy is usually highest for residues in the 
hydrophobic core, where more than 90% of all predicted X1-angles fall within 
±20° of the experimental values, but significantly lower for residues on the 
surface where the percentage drops to 70%, and further down to 50% for the 
combined X1/X2 accuracy (Canutescu et al., 2003b). This is mainly caused by 
the electrostatic and hydrogen-bonding interactions, which are partly 
solvent mediated and much more difficult to get right than the simple 
repulsive Van der Waals interactions in the core, but also partly due to the 
fact that flexible side-chains on the surface tend to adopt multiple 
conformations, which are additionally influenced by crystal contacts, so there 
simply may not be a single correct conformation at all. Nevertheless, the 
surface residues are among the most important ones to get right; they 
mediate all the interactions, and applications such as drug design or protein 
docking thus critically depend on them.
6.2.6. Step 6: Model optimisation
Once all these steps are completed, one obtains the initial homology model, 
which hopefully looks broadly similar to the (usually unknown) target 
structure. The minor details however, such as the precise backbone 
conformation, hydrogen-bonding networks or certain side-chain rotamers, 
are often wrong. While this deficiency keeps scientists working on 
experimental structure determination busy, predictors strive to bridge the
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gap between model and target (the 'last mile' of the protein folding problem) 
using various optimisation and refinement techniques, the most prominent 
ones being molecular dynamics (Krieger et al., 2004) and Monte Carlo 
simulations (Misura, 2006). For a given model, there are unfortunately many 
more paths leading away from the target than towards it, and combined with 
the limited accuracy of empirical force fields, this makes it very easy to 
reduce the model accuracy during the refinement. Consequently, the best 
optimisation was often no optimisation. We did well in the early Critical 
Assessment of Structure Prediction (CASP) homology modelling 
competitions simply by not performing MD simulations on the models 
(except for 25 energy-minimization steps with CNS (Brünger et al., 1998) to 
introduce the same local geometric features that CNS put into the real 
structure against which our prediction would be compared). Nevertheless, 
steady progress over the past years has changed this rule of thumb (see 
"Results").
6.2.7. Step 7: Model validation
Protein structures were error free until the landmark article on Procheck by 
the Thornton group (Laskowski et al., 1993). This article can be seen as the 
beginning of the realisation that crystallographers and NMR spectroscopists 
actually use experimental techniques to determine their coordinates. With 
the release of the first WHAT_CHECK (Hooft et al., 1996a) structure 
validation became a common household technique for most scientists and, 
although not at the speed we hoped, errors in protein structures are 
becoming less frequent. The two main bottlenecks are the introduction of 
improved technologies in all structure solution software used all over the 
world, and the fact that the detection of an error does not implicitly mean 
that the error can be removed.
6.2.8. Step 8: Iteration
If the model is not good enough, (part of) the modelling process has to be 
repeated. For instance, wrong side-chain conformations can be improved by 
iterating the process from step 5 onwards. Sometimes, this iteration step 
means that one has to start the modelling process all over again using 
another template or alignment. Alternatively, one can start several modelling 
processes using different templates. The resulting models can be combined
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in the end to produce a hybrid model that consists of the strongest points of 
each separate model.
6.3. Unsolved problems and future directions in 
homology modelling
While many scientific disciplines face huge difficulties when trying to 
experimentally validate theoretical predictions, protein modelling is in a 
fortunate situation: since 1994, the biennial Critical Assessment of Structure 
Prediction (CASP) contests (Moult et al., 2007) have provided an ideal 
opportunity to evaluate the accuracy of today's many protein structure 
prediction methods. During each CASP season (lasting about 4 months once 
every 2 years), about 200 research groups try to predict the structures of 
~100 proteins, the CASP targets. The target sequences are provided to CASP 
by structural biology laboratories just before the corresponding structures 
are solved. The predictions are thus true blind predictions, allowing 
performance to be measured on realistic test cases, locating areas of progress 
as well as still unsolved problems.
CASP regularly shows that the eight homology modelling steps 
summarized above allow reliable models to be built in many cases, from 
which a lot of structural and functional insights can be derived. However, 
these eight steps are unfortunately not sufficient to actually solve the protein 
structure prediction problem via homology modelling as soon as enough 
templates become available. Figure 6.3 shows CASP8 targets T0498 and 
T0499: both proteins are 56 amino acids long, 53 of which are conserved 
(95% sequence identity). Still, the two structures are entirely different; just 
three point mutations completely change the fold. While this is an extreme 
example of human protein engineering art (He et al., 2008), also naturally 
occurring proteins with similar sequences often show surprising structural 
diversity (Kosloff & Kolodny, 2008), leading classic homology modelling to 
fail miserably. The prion protein (Prusiner, 1998) and other amyloid-forming 
proteins provide an even more dramatic case; here 100% identical 
sequences can exist in two totally different structures. Obviously, the 
homology modelling problem is tightly intertwined with the more general 
protein folding problem itself. Even if a close template is available, there can 
always be structurally divergent regions, which are either expected from the 
poor local alignment, or unexpectedly caused by critical point mutations, or 
widely differing crystal packing contacts.
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Figure 6.3; Comparison of CASP8 targets T0498 and T0499. The sequences of both proteins 
are 95% (53 of 56) identical (only residues 20, 30 and 45 differ), yet the structures are totally 
different. Classic homology modelling predicted T0499 correctly (which looks like the related 
homology modelling templates in the PDB), but failed completely for T0498. Since the 
structures of T0498 and T0499 have not been released yet, this figure is based on a closely 
related pair with PDB IDs 2jws and 2jwu from the same authors, who showed by NMR 
spectroscopy that these two structures look essentially the same as T0498 and T0499 (He et 
al., 2008).
The only way to handle these difficult cases is to apply more general ab initio 
folding algorithms, which do not depend on template structures, but try to 
simulate the complete folding process from the stretched-out conformation. 
As it turns out, this 'one-algorithm-fits-all' approach is currently the most 
successful one at CASP (Chivian et al., 2003; Pandit et al., 2006): if available, 
it uses known templates (or fragments thereof) only to guide the search, but 
does not depend on them. As a side-effect, this allows hybrid-models to be 
built, combining the best parts from multiple templates.
Despite these encouraging developments, the protein folding 
problem is far from solved. The best models are still built by those who got 
the alignment right in the first place, which unfortunately implies that 
structural diversity is often missed: one cannot yet ignore the difficult-to- 
align regions and simply predict them with ab initio folding instead. The
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sequence alignment problem will thus remain an active research field for 
years to come.
Noteworthy progress has been made with model optimisation to 
bridge the structural gap between initial model and target. While in the early 
days of CASP, predictors were well advised to keep the backbone of their 
model fixed (the 'frozen-core approach'), simply because the danger of 
messing up the model was too large, the situation is quite different today: 
force field accuracy (Krieger et al., 2004) and sampling efficiency (Misura et 
al., 2006) have improved to a level that allows well-performing methods like 
Modeller-CSA (Joo et al., 2008), Rosetta (Chivian et al., 2003), undertaker 
(Vriend, 1990), and YASARA (Krieger et al., 2009) to free all atoms during the 
refinement, often moving models considerably closer to the target.
While homology modelling currently focusses on the protein in a 
model, other entities, i.e. carbohydrates, small molecules and ions, also make 
up important parts of certain proteins and protein complexes; for instance, 
zinc atoms in so-called zinc fingers are important for the stability of the 
protein, and the common protein haemoglobin would be useless without its 
haem groups and the iron atoms therein. Carbohydrates in glycoproteins 
perform numerous functions, ranging from providing stability to signalling 
and labelling for intracellular transport (Lütteke, 2009). The many roles of 
non-protein entities make it obvious that homology modelling should look 
beyond the protein. A complete model should thus be more than a three­
dimensional (3D) representation of an amino acid sequence. One major 
challenge for homology modelling is recognising binding sites for non­
protein entities.
Drug docking software (e.g. Rarey et al., 1996; Nabuurs et al., 2007) 
can be used to detect the binding sites of compounds such as haem groups or 
coenzymes. However, relevant biological information is needed to select 
compounds that may be bound to the protein. Copying the binding site from 
the template structure is the simplest method, but does not work for ab initio 
folding models. For such models, spectroscopic analysis of the protein can 
provide insight into which compounds are bound. This approach is not 
limited to homology modelling; X-ray crystallography can also benefit from 
spectroscopic analysis of a protein to identify a bound compound (Chen et al., 
2002).
Incorporating ions can be an additional step of the modelling process. 
Nayal & Di Cera (1996) have suggested a method to detect sodium binding 
sites in protein structures which can be extended to detect various other ion 
binding sites. Of course, any additional experimental data can guide this ion­
site detection process. Especially tightly bound functional ions that co-purify 
with the protein can be detected by means of spectroscopic analysis. A
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significant number of PDB files have bound ions or water molecules that 
were erroneously assigned. We have observed H2 0 , and Na+, K+, Mg2+, Ca2+, 
and NH4+ ions that should actually be one of the others in this list. This is the 
result of X-ray crystallography having difficulties distinguishing between 
H2O, NH4+, Na+ and Mg2+ because these entities have equally many electrons, 
as do K+ and Ca2+.
The power of force-field-based model optimisation methods can be 
significantly reduced when such problems include a difference in the ionic 
charge. It is therefore very important to (experimentally) validate the ions in 
template structures when these are important for the final homology model.
Carbohydrates can be modelled at the final stage of the homology 
modelling process, but this does not always reflect the protein folding 
process. Carbohydrates are not only added in post-translational modification 
(that is, when the protein is 'done'), but also during the protein expression by 
the ribosome. They are important in the protein folding process and the 
detection of misfolded proteins (Parodi, 2002). It may therefore prove 
interesting to add the necessary carbohydrates to the unfolded protein 
before ab initio folding. Apart from their role in protein folding, 
carbohydrates are sometimes important in oligomerisation of proteins; for 
instance, the neuraminidase protein from influenza shows different 
glycosylation states in its monomeric, dimeric and tetrameric states. The 
carbohydrates in tetrameric state provide extra stability (Figure 6.4) and, in 
the case of the Spanish flu influenza virus, resistance to trypsin digestion 
leads to increased virulence (Wu et al., 2009). This shows the vital (and 
sometimes lethal) importance of considering carbohydrates in homology 
models.
6.4. Results and discussion: other roles for homology 
modelling
In the 1990s most articles that included homology modelling described just 
how the model of one protein was constructed, and ended with the ominous 
sentence "...this model will help us perform our research on this intriguing 
protein", after which the group would start working on something else. Here, 
we will illustrate the importance of homology modelling for the study of 
inheritable diseases, but the value of models has been amply illustrated in 
fields ranging from drug design to laundry powder enzyme engineering, from 
validating experimental structures to the design of humanized antibodies,
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and from mutation analysis to intelligent experimental design in many 
spectroscopic research projects.
In the following examples building the homology model was not the 
ultimate goal but one of the tools used to gain more information about a 
mutation, a disease or a process in the human body. These examples prove 
that homology models can be of great use in the (bio)medical field.
Figure 6.4: Tetrameric form of whale influenza neuraminidase (PDBid 2r8h; Smith et al., 
2006), coloured by monomer. Protein chains are displayed in ribbon representation, 
carbohydrate atoms in ball representation. The carbohydrates of one monomer interact with 
the adjacent monomer, thus stabilising the tetramer.
6.4.1. Modelling of the LRTOMT-COMT domain
In a study of non-syndromic deafness four pathogenic mutations were found 
in an as-yet uncharacterized gene which codes for two different proteins, 
called LRTOMT1 and LRTOMT2 (Ahmed et al., 2008). Three of these 
mutations were mis-sense mutations located in the catechol-O- 
methyltransferase (COMT; EC 2.1.1.6) domain of LRTOMT2; one introduced a 
stop codon causing the loss of a large fraction of the protein. The COMT 
domain catalyses the transfer of a methyl group from S-adenosyl-L- 
methionine (Ado-Met) to a hydroxyl group of catechol. No structure for
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LRTOMT2 was known, so we needed a homology model to study the mis- 
sense mutations in more detail.
Using the crystal structure of rat COMT (39% identity to LRTOMT2 
over 212 amino acids (PDBid 1h1d; Bonifacio et al., 2002)) we were able to 
model the COMT domain of human LRTOMT2. The three mutated residues 
are located in helix 1 (p.R81Q), helix 2 (p.W105R) and the loop that follows 
helix 2 (p.E110K), and thus not in the hypothetical substrate-binding 
pockets. However, the loop is predicted to be important for the groove that 
binds the putative methyl acceptor. The Arg81 and Glu110 residues are 
predicted to form a hydrogen-bonded salt bridge between helix 1 and the 
loop, and Trp105 is predicted to make hydrophobic interactions in the core 
between these helices (Figure 6.5). These residues may therefore be 
important for local protein stability and can affect the substrate binding 
region.
6.4.2. Modelling of the ligand-binding domain of ESRRB
Sequence analysis revealed four mis-sense mutations of the ESRRB gene 
leading to autosomal-recessive non-syndromic hearing impairment (Collin, 
2008). Experimental results indicated that ESRRB is essential for inner-ear 
development and function. ESRRB encodes the estrogen-related receptor 
protein beta, a member of the nuclear hormone receptor (NHR) family. In 
general, members of this family share a zinc finger C4 DNA-binding domain 
at their N-terminus and a ligand-binding domain that is located near the C- 
terminus. The ligand-binding domain of nuclear hormone receptors is a well- 
conserved and highly organized structure containing 12 alpha-helices. Three 
mutations (p.L320P, p.V342L and p.L347P) were located within this ligand- 
binding domain. The fourth mutation was located in the DNA binding domain 
and will not be discussed here.
To study the three mutations in the ligand binding domain in more 
detail we built a homology model of this domain using the structure of the 
ESRRG receptor (PDBid 1kv6; Greschik et al., 2002) as a template. It had 79% 
sequence identity over 229 amino acids. The molecular model showed that 
the three mis-sense mutations in the ligand binding domain are likely to 
affect the structure and stability (Figure 6.6). Two of the mutations involved 
a leucine-to-proline mutation, L320P in helix 7 and L347P in helix 8. In 
general, the introduction of proline residues within helices reduces the 
stability of the helix, and therefore these mutations will disturb the structure 
of the helices and probably the complete ligand-binding domain. In addition, 
the loss of the leucine side-chain abrogates a number of hydrophobic 
interactions.
139
Figure 6.5: A) Molecular model of the catechol-0-methyltransferase domain of LRTOMT2, 
residues 79-290. The affected residues are depicted in blue. The predicted ligands are 
coloured yellow, and the tyrosine residue (Tyr111) that lines the hydrophobic groove of the 
ligand binding site is shown in cyan. The boxed region containing residues affected by mis- 
sense mutations of LRTOMT2 is enlarged in panels b-d. The helices 1 (H1) and 2 (H2) are 
shown with wild-type residues Arg81, Trp105 and Glu110 depicted in blue and mutated 
residues in green. Hydrogen bonds are represented by yellow dotted lines. B) The Arg81 and 
Glu110 residues form a salt bridge between helix 1 and the loop following helix 2. The Gln81 
residue cannot form this salt bridge as it is not positively charged. Also, the formation of 
hydrogen bonds is impaired because of the smaller size of glutamine as compared with 
arginine. c) The Trp105 residue is predicted to make hydrophobic interactions as a result of 
its large side-chain. Most of these interactions would be lost by the W105R substitution. d) 
Substitution E110K is predicted to lead to the loss of hydrogen bonds and a salt bridge. There 
would likely be repulsion between the side-chains Lys110 and Arg81 as both are positively 
charged.
The other mutation in this domain (V342L) substitutes a leucine for a valine 
residue resulting in the occurrence of a somewhat larger side-chain that 
bumps into the molecular surface of helix one. This substitution is predicted 
to reduce the strength of the interaction between helix 1 and 8.
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In summary, the molecular modelling data predicts that mutations of ESRRB 
will result in conformational changes near the substituted amino acids or 
decreased helix stability and are therefore likely to affect the stability and 
function of the complete ligand-binding domain.
L347P
Figure 6 .6 : A) Molecular modelling of the ligand-binding domain of the human ESRRB protein. 
The structure was deduced from the known ESRRB structure. The various helices are 
represented by cylinders. The three amino acids that are affected by the mis-sense mutations 
are indicated in green. Detailed views of the three mutations are shown in panels B, C and D. 
The wild-type residue is depicted in green, whereas the side-chain of mutant residue is 
presented in red. B) L320 makes hydrophobic contacts in the core between two helices, the 
mutation to P causes loss of many hydrophobic interactions. Additionally, the P will disturb 
the structure of the helix. C) V342 is tightly packed in the core between two helices. This core 
will be disturbed by the V342L mutation because L has a larger side-chain. D) L347P will 
cause loss of hydrophobic interactions between the helices, and the introduction of P will 
disturb the structure of the helix
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6.4.3. Functional states of alcohol oxidase
Van der Klei and co-workers studied four different conformational states of 
the flavoenzyme alcohol oxidase (AO) from the methylotrophic yeasts 
Hansenula polymorpha and Pichia pastoris, including assembly intermediates 
(Boteva et al., 1999). These proteins had to be homology modelled from the 
enzyme glucose oxidase that shows only 25% sequence identity with the 
AOs. With so little similarity, homology modelling is very difficult and large 
modelling errors are to be expected. An additional problem is that glucose 
oxidase is a dimer while AO is an octamer. The low quality of the model 
certainly precluded any form of protein-protein docking to construct an 
octamer from the dimer. The model fortunately revealed a series of 
hydrophobic surface patches, some of which have tryptophan residues at the 
surface. As there were also tryptophans observed in the model near the FAD 
group, the suggestion to apply spectroscopic techniques to extend the 
modelling study came shouting from Figure 6.7. A series of spectroscopic 
techniques, including time-resolved fluorescence, fluorescence anisotropy 
decay, steady-state fluorescence, and visible and near-ultraviolet (UV) 
circular dichroism, was used to characterize native AO and several putative 
assembly intermediates. A good working hypothesis for the AO folding 
pathway could be derived. The study also triggered the search for 
chaperones that seemed necessary to allow FAD to bind to AO in vivo.
6.5. Conclusion
Homology modelling will always be needed because it is impossible to solve 
the three-dimensional structure for each determined sequence. An 
increasing number of scientists are now using protein structures for 
mutational analysis and experimental design. The process of homology 
modelling has improved dramatically over the years, but there are still many 
problems to solve. It is reassuring for homology modellers that modelling 
problems can often be solved using spectroscopic techniques. 
Spectroscopists, on the other hand, normally need homology models to fully 
harvest the results from their spectroscopic studies. This interplay brings us 
back to the title of this article: homology modelling and spectroscopy are 
indeed a never-ending love story.
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Figure 6.7: Model of one monomer of AO shown as ribbon; helix in blue, strand in red, loop 
and turn in shades of green. All tryptophan side chains are shown in yellow, the FAD group is 
shown in purple.
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Samenvatting
Eiwitten zijn betrokken bij (bijna) alle processen in levende wezens. Ze 
vormen zo de kleine tandwielen in de machinerie van het leven. Het is dan 
ook niet verbazingwekkend dat onderzoeksvragen in de moleculaire 
biologie, genetica en de medische wetenschap vaak teruggebracht kunnen 
worden tot een aantal vragen over de chemie van een bepaald eiwit. Een 
actuele onderzoeksvraag is bijvoorbeeld: “Waarom werkt Oseltamivir 
(Tamiflu) niet tegen een nieuwe griepvariant en hoe moet het medicijn 
worden aangepast om het weer bruikbaar te maken?”. Om een dergelijke 
vraag te beantwoorden, is een correcte beschrijving van de structuur van het 
onderzochte eiwit nodig.
De structuur van eiwitten wordt op verschillende niveaus 
beschreven. Deze niveaus lopen van de volgorde (sequentie) van de 
bouwstenen, de aminozuren, in het eiwit, tot een beschrijving waarin ieder 
atoom van het eiwit zijn eigen driedimensionale (3D) coördinaten heeft. In 
Hoofdstuk 1 worden de verschillende niveaus van eiwitstructuren besproken 
en wordt ook aandacht besteed aan de methoden om de structuur van een 
eiwit experimenteel te bepalen.
De 3D structuur van een eiwit, die meestal wordt bepaald met behulp 
van röntgenkristallografie (X-ray crystallography), is meestal veel 
informatiever dan de sequentie. Helaas is die structuur ook een stuk 
moeilijker te bepalen. Hierdoor kennen we ruim 100 keer zoveel sequenties 
als 3D structuren. Ondanks zware inspanningen van alle kristallografen 
wereldwijd, zal dit gebrek aan 3D structuren niet snel verholpen worden. Om 
onze kennis over eiwitten te vergroten, moeten we dus werken met het 
beperkte aantal 3D structuren die nu voor wetenschappers beschikbaar zijn 
via de Protein Data Bank (PDB). Bioinformatica, het gebruik van computers 
om biologische en biomedische problemen op te lossen, kan helpen om de 
best mogelijke wetenschappelijke resultaten te krijgen met de huidige 
collectie van 3D eiwitstructuren. In dit proefschrift worden drie 
verschillende benaderingen behandeld.
In Hoofdstuk 2 wordt de eerste benadering uitgebreid behandeld: 
structuurvalidatie. Eiwitstructuren worden experimenteel bepaald en bij 
ieder experiment horen ruis en experimentele (menselijke) fouten. 
Structuurvalidatie maakt gebruik van bestaande wetenschappelijke kennis 
over de chemie van eiwitten en kleine moleculen om de goede, de slechte en 
de lelijke stukken van eiwitstructuren te onderscheiden. Ook statistische 
kennis over eiwitstructuren wordt toegepast om te kijken of een 
eiwitstructuur 'normaal' is. Structuurvalidatie helpt dus om de beste 
eiwitstructuur te selecteren voor het beantwoorden van onze
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onderzoeksvragen. Het helpt ook de betrouwbaarheid van de conclusies die 
we trekken op basis van (delen van) eiwitstructuren te bepalen. Conclusies 
gebaseerd op een goed stuk eiwitstructuur zijn immers betrouwbaarder dan 
conclusies gebaseerd om slechte stukken van de een eiwitstructuur. 
Structuurvalidatie geeft ons de mogelijkheid om de kwaliteit van een 
eiwitstructuur te bepalen. Het is een logische vervolgstap om te proberen die 
kwaliteit te verbeteren. Deze tweede benadering om het beste resultaat met 
de bestaande 3D structuren te krijgen is gebaseerd op de volgende 
redenering: Een 3D structuur is een (indirect) model van een 
röntgenkristallografie-experiment. De methoden om dergelijke modellen te 
maken worden voortdurend verbeterd. Het is daarom waarschijnlijk dat we 
nu betere modellen kunnen maken dan, bijvoorbeeld, tien jaar gelden.
Het volledig opnieuw uitvoeren van de röntgenkristallografie- 
experimenten van alle bestaande eiwitstructuren (de vruchten van tientallen 
jaren hard werken door een enorme groep wetenschappers) is natuurlijk 
onmogelijk. Gelukkig hebben de kristallografen de vooruitziende blik gehad 
om de originele experimentele data voor een meerderheid van de bestaande 
3D structuren te bewaren. We kunnen dus “Oude data combineren met 
nieuwe methoden" (de eerste helft van de ondertitel van dit proefschrift) om 
betere structuren te krijgen. In Hoofdstuk 3 laten we zien dat dit ook echt 
mogelijk is. In dit eerste PDB_REDO experiment hebben we een beperkte 
testset van bijna 1200 eiwitstructuren herverfijnd met behulp van de 
originele experimentele data. Dat wil zeggen, we hebben een van de laatste 
stappen van het kristallografie-experiment, het verfijnen van het model, 
herhaald (zie Hoofdstuk 1) met een methode die volledig geautomatiseerd is.
In Hoofdstuk 4 wordt de herverfijning van een veel grotere set 
eiwitstructuren behandeld. Het ging hier om alle eiwitstructuren waarvoor 
de complete experimentele data (inclusief de zogenaamde R-free set) 
beschikbaar waren. Vanwege het enorme aantal (bijna 17000 structuren) 
hebben we een nieuw soort computersysteem gebruikt: het GRID. Met 
behulp van de structuurvalidatiemethoden uit Hoofdstuk 2 hebben we 
bewezen dat bestaande eiwitstructuren volledig automatisch verbeterd 
kunnen worden door de originele kristallografiedata te gebruiken. In 
Hoofdstuk 4.A, komen enkele reacties op onze resultaten en het PDB_REDO 
project aan bod van de gebruikers van 3D eiwitstructuren.
Met de herverfijning wordt het model verbeterd door middel van 
parameteroptimalisatie; we 'sleutelen' aan het model. In Hoofdstuk 5 is 
gekeken naar de mogelijkheden om PDB_REDO uit te breiden zodat ook 
fouten uit het model gehaald kunnen worden (zo wordt nog een stap van het 
kristallografie-experiment toegevoegd). Vijf eiwit structuren zijn eerst 
automatisch herverfijnd en daarna met de hand verder verbeterd om
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verschillende types fouten te vinden die automatisch verbeterd kunnen 
worden.
Met structuurvalidatie en structuurverbetering ontstaat een solide 
fundament voor de meest constructieve benadering in de bioinformatica om 
veel kennis te halen uit het beperkte aantal 3D structuren: het maken van 
nieuwe 3D structuren op basis van bestaande eiwitstructuren. In het Engels 
heet dit homology modelling. In het laatste hoofdstuk wordt ingegaan op 
deze methode. Enerzijds wordt gekeken naar het belang van het van 
eiwitstudies in het lab voor homology modelling-experimenten, anderzijds 
kijken we naar het belang van eiwitstudies in de computer. Bestaande 
eiwitstructuren worden gebruikt als startpunt voor homology modelling en 
daarom is het van belangrijk dat deze van zo hoog mogelijke kwaliteit zijn. 
Dit benadrukt het belang van de herverfijning die in dit proefschrift wordt 
behandeld. Hierin herkennen we de tweede helft van de ondertitel van dit 
proefschrift: “Oude data combineren m et nieuwe methoden voor be tere  
structuurbioinform atica . "
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gevonden. Je zorgt dat werk en privé in evenwicht blijven en ik altijd iemand 
heb bij wie ik echt thuis kan zijn. Stan, je hebt nu weer een nieuw boekje om 
in te bladeren en om mee te spelen. Ik hoop dat je het met plezier leest als je 
wat ouder bent en dan kunt zeggen: “dat heeft papa gemaakt en ik heb 
geholpen”.
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